{
    "items": "251",
    "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
    "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
    "feed": [
        {
            "title": "After a 90% Gain, Is It Too Late to Buy Eli Lilly?",
            "url": "https://www.fool.com/investing/2024/02/04/after-a-90-gain-is-it-too-late-to-buy-eli-lilly/",
            "time_published": "20240204T090500",
            "authors": [
                "Adria Cimino"
            ],
            "summary": "Its drug tirzepatide showed top efficacy as a weight-loss treatment according to the latest real-world data.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F763686%2Fgettyimages-903626078.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.961735"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.236494,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.055236",
                    "ticker_sentiment_score": "0.04908",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.554014",
                    "ticker_sentiment_score": "0.356177",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.164656",
                    "ticker_sentiment_score": "0.052794",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Interested in the new weight loss drugs? Here are 5 things to know",
            "url": "https://www.cnn.com/2024/02/03/health/weight-loss-drugs-wellness/index.html",
            "time_published": "20240203T080000",
            "authors": [
                "Andrea Kane"
            ],
            "summary": "Editor's note: Season 9 of the podcast Chasing Life With Dr. Sanjay Gupta explores the intersection between body weight and health. We'll delve into a wide range of topics, including how to talk to kids about weight and the myths surrounding menopause and weight gain. You can listen to the season ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/1678332595136.jpg?q=w_1110,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.064541,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.095644",
                    "ticker_sentiment_score": "0.064916",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.031949",
                    "ticker_sentiment_score": "0.237899",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "3 Reasons Growth Investors Will Love Novo Nordisk  ( NVO ) ",
            "url": "https://www.zacks.com/stock/news/2220495/3-reasons-growth-investors-will-love-novo-nordisk-nvo",
            "time_published": "20240202T174504",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) could produce exceptional returns because of its solid growth attributes.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default72.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.983783"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.87644"
                }
            ],
            "overall_sentiment_score": 0.456102,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.579393",
                    "ticker_sentiment_score": "0.530521",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Bristol-Myers  ( BMY )  Q4 Earnings & Sales Beat, Stock Gains",
            "url": "https://www.zacks.com/stock/news/2220491/bristol-myers-bmy-q4-earnings-sales-beat-stock-gains",
            "time_published": "20240202T174000",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Bristol-Myers' (BMY) fourth-quarter 2023 earnings and sales surpass estimates as Reblozyl and Revlimid outperform. Shares rise on the same.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b7/2106.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999998"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.142674,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "SRPT",
                    "relevance_score": "0.104988",
                    "ticker_sentiment_score": "0.055906",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.139669",
                    "ticker_sentiment_score": "0.12798",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KRTX",
                    "relevance_score": "0.035086",
                    "ticker_sentiment_score": "0.143066",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RYZB",
                    "relevance_score": "0.035086",
                    "ticker_sentiment_score": "0.1973",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MRTX",
                    "relevance_score": "0.035086",
                    "ticker_sentiment_score": "0.056473",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.104988",
                    "ticker_sentiment_score": "0.170629",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.339978",
                    "ticker_sentiment_score": "0.345425",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "A Closer Look At The Disruption Of Medifast",
            "url": "https://www.forbes.com/sites/gurufocus/2024/02/02/a-closer-look-at-the-disruption-of-medifast/",
            "time_published": "20240202T173126",
            "authors": [
                "GuruFocus"
            ],
            "summary": "The weight loss and nutrition product company is coping with the GLP-1 drug tsunami • The new diabetes and diet drugs appear to have disrupted the company's extremely profitable business model. Weight loss and wellness product company Medifast Inc. ( MED, Financial ) has experienced a significant ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65bd2469f0bee498c099bcba/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.967645"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.098847,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.069294",
                    "ticker_sentiment_score": "-0.170101",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "LFMD",
                    "relevance_score": "0.03468",
                    "ticker_sentiment_score": "-0.012375",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VALU",
                    "relevance_score": "0.03468",
                    "ticker_sentiment_score": "-0.163211",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "MED",
                    "relevance_score": "0.33628",
                    "ticker_sentiment_score": "0.10894",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.069294",
                    "ticker_sentiment_score": "-0.170101",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Stocks Handle Huge Earnings, Fed, Jobs Report: Weekly Review",
            "url": "https://www.investors.com/news/stock-market-handles-huge-earnings-week-fed-powell-jobs-report-weekly-review/",
            "time_published": "20240202T171500",
            "authors": [
                "IBD STAFF",
                "Investor's Business Daily"
            ],
            "summary": "Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2016/04/SSA-040816-shutterstock.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.99977"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.142857"
                }
            ],
            "overall_sentiment_score": 0.029434,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MXL",
                    "relevance_score": "0.033236",
                    "ticker_sentiment_score": "0.01579",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.099476",
                    "ticker_sentiment_score": "0.026313",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CVX",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "-0.145994",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.066414",
                    "ticker_sentiment_score": "0.045467",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AWON",
                    "relevance_score": "0.016621",
                    "ticker_sentiment_score": "-0.013684",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NYCB",
                    "relevance_score": "0.082963",
                    "ticker_sentiment_score": "-0.121209",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "-0.136008",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALGM",
                    "relevance_score": "0.033236",
                    "ticker_sentiment_score": "0.01579",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.099476",
                    "ticker_sentiment_score": "0.050168",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SHOP",
                    "relevance_score": "0.033236",
                    "ticker_sentiment_score": "-0.154811",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.033236",
                    "ticker_sentiment_score": "0.007675",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MA",
                    "relevance_score": "0.016621",
                    "ticker_sentiment_score": "0.113074",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "QCOM",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.016017",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.033236",
                    "ticker_sentiment_score": "-0.109096",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMD",
                    "relevance_score": "0.099476",
                    "ticker_sentiment_score": "0.005554",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NXT(EXP20091224)",
                    "relevance_score": "0.016621",
                    "ticker_sentiment_score": "0.155736",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.066414",
                    "ticker_sentiment_score": "-0.024213",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.082963",
                    "ticker_sentiment_score": "0.120391",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SYK",
                    "relevance_score": "0.033236",
                    "ticker_sentiment_score": "0.158384",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BSX",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.161989",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GM",
                    "relevance_score": "0.099476",
                    "ticker_sentiment_score": "0.036073",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LSTR",
                    "relevance_score": "0.033236",
                    "ticker_sentiment_score": "-0.014716",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SMCI",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.16469",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "-0.069943",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "-0.136008",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MANH",
                    "relevance_score": "0.033236",
                    "ticker_sentiment_score": "-0.154811",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.033236",
                    "ticker_sentiment_score": "-0.133526",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "POWL",
                    "relevance_score": "0.033236",
                    "ticker_sentiment_score": "0.053581",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DECK",
                    "relevance_score": "0.033236",
                    "ticker_sentiment_score": "0.092797",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.033236",
                    "ticker_sentiment_score": "-0.142727",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SOFI",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.010999",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RCL",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "-0.059814",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WOLF",
                    "relevance_score": "0.033236",
                    "ticker_sentiment_score": "0.01579",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.033236",
                    "ticker_sentiment_score": "-0.133526",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SBNY",
                    "relevance_score": "0.016621",
                    "ticker_sentiment_score": "-0.102369",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.028998",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.066414",
                    "ticker_sentiment_score": "0.004048",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ODFL",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "-0.015004",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:NXT",
                    "relevance_score": "0.016621",
                    "ticker_sentiment_score": "0.155736",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Pharma Stock Roundup: PFE, MRK, NVO & SNY's Q4 Earnings, FDA Updates",
            "url": "https://www.zacks.com/stock/news/2220214/pharma-stock-roundup-pfe-mrk-nvo-snys-q4-earnings-fda-updates",
            "time_published": "20240202T142100",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "Pfizer (PFE), Merck (MRK), Novartis (NVS), Novo Nordisk (NVO) and Sanofi (SNY) announce fourth-quarter and full-year 2023 results.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999682"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.076936,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.121241",
                    "ticker_sentiment_score": "0.03191",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.200688",
                    "ticker_sentiment_score": "0.114304",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.121241",
                    "ticker_sentiment_score": "0.03563",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.121241",
                    "ticker_sentiment_score": "0.071481",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "4 Large Drug Stocks Trying to Survive the Industry Challenges",
            "url": "https://www.zacks.com/commentary/2220023/4-large-drug-stocks-trying-to-survive-the-industry-challenges",
            "time_published": "20240202T134700",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), AbbVie (ABBV) and Novartis (NVS) are worth retaining in one's portfolio.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/906.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.976913"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.938238"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.215569,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.235366",
                    "ticker_sentiment_score": "0.15857",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.023885",
                    "ticker_sentiment_score": "0.065458",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.189298",
                    "ticker_sentiment_score": "0.236489",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.118999",
                    "ticker_sentiment_score": "0.140653",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.023885",
                    "ticker_sentiment_score": "0.065458",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DICE",
                    "relevance_score": "0.023885",
                    "ticker_sentiment_score": "0.031019",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Daily: Earnings Show Meta's Turnaround And Apple's Tepid Growth",
            "url": "https://www.forbes.com/sites/forbesdaily/2024/02/02/forbes-daily-earnings-show-metas-turnaround-and-apples-tepid-growth/",
            "time_published": "20240202T125833",
            "authors": [
                "Danielle Chemtob"
            ],
            "summary": "This is a published version of the Forbes Daily newsletter, you can sign-up to get Forbes Daily in your inbox here. Tax season kicked off this week, but a looming question mark as taxpayers begin filing is whether Congress will expand the child tax credit in the coming weeks.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65bce56ce9686add8c01fef8/0x0.jpg?format=jpg&crop=4571,2570,x0,y232,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.95493"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.070277,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.024053",
                    "ticker_sentiment_score": "0.041601",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.048084",
                    "ticker_sentiment_score": "0.055997",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPOT",
                    "relevance_score": "0.024053",
                    "ticker_sentiment_score": "0.064262",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.024053",
                    "ticker_sentiment_score": "0.059694",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TCTZF",
                    "relevance_score": "0.024053",
                    "ticker_sentiment_score": "-0.156505",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Could Abbott Labs Be the Next Big Winner in the Billion-Dollar Weight Loss Market?",
            "url": "https://www.fool.com/investing/2024/02/02/could-abbott-be-big-winner-weight-loss-market/",
            "time_published": "20240202T100300",
            "authors": [
                "Adria Cimino"
            ],
            "summary": "Abbott Labs is using its well-established strengths to make gains in the weight loss market.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F763499%2Fgettyimages-1139704348.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.057745,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.056407",
                    "ticker_sentiment_score": "0.22549",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.112532",
                    "ticker_sentiment_score": "0.083808",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.112532",
                    "ticker_sentiment_score": "0.101063",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk to increase supply of weight-loss drug Wegovy",
            "url": "https://www.cnn.com/2024/02/01/health/novo-nordisk-wegovy-weight-loss-drug/index.html",
            "time_published": "20240201T211100",
            "authors": [],
            "summary": "Novo Nordisk to increase supply of weight-loss drug ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/240116085159-01-wegovy-cartridges-file.jpg?c=16x9&q=h_144,w_256,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.113143,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.172919",
                    "ticker_sentiment_score": "0.094842",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.2842",
                    "ticker_sentiment_score": "0.188717",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons",
            "url": "https://www.globenewswire.com/news-release/2024/02/01/2822403/0/en/Novo-Nordisk-A-S-Trading-in-Novo-Nordisk-shares-by-board-members-executives-and-associated-persons.html",
            "time_published": "20240201T195100",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 1 February 2024 - This company announcement discloses the data of the transaction ( s ) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.100301,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.186738",
                    "ticker_sentiment_score": "0.058933",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.186738",
                    "ticker_sentiment_score": "0.058933",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.94121",
                    "ticker_sentiment_score": "0.177803",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Roche  ( RHHBY )  2023 Earnings Miss, COVID-19 Product Sales Down",
            "url": "https://www.zacks.com/stock/news/2219814/roche-rhhby-2023-earnings-miss-covid-19-product-sales-down",
            "time_published": "20240201T193300",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Roche (RHHBY) misses earnings and sales estimates in 2023 due to a significant decline in COVID-19-test sales. Currency rate fluctuations also impact results.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d7/2114.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972193"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.0,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "SRPT",
                    "relevance_score": "0.107495",
                    "ticker_sentiment_score": "0.056329",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.142989",
                    "ticker_sentiment_score": "0.12965",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:CHF",
                    "relevance_score": "0.792785",
                    "ticker_sentiment_score": "-0.188144",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Novo Nordisk Stock Just Earned A 92 RS Rating; Gapped Up On Earnings",
            "url": "https://www.investors.com/news/stocks-showing-market-leadership-novo-nordisk-adr-earns-92-rs-rating-2/",
            "time_published": "20240201T191000",
            "authors": [
                "Investor's Business Daily",
                "GLENN LARKIN",
                "INVESTOR'S BUSINESS DAILY"
            ],
            "summary": "Novo Nordisk Stock Just Earned A 92 RS Rating. Gapped Up On Earnings Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2017/05/IRU6.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.37797,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ZTS",
                    "relevance_score": "0.254307",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EOLS",
                    "relevance_score": "0.254307",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.254307",
                    "ticker_sentiment_score": "0.560025",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Merck  ( MRK )  Q4 Earnings Beat, Sales Miss, Upbeat '24 View",
            "url": "https://www.zacks.com/stock/news/2219776/merck-mrk-q4-earnings-beat-sales-miss-upbeat-24-view",
            "time_published": "20240201T173800",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Merck (MRK) beats Q4 estimates for earnings but misses the mark on sales. The company issues an encouraging 2024 guidance. Stock rises in pre-market.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ef/472.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999682"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.128144,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "SKXJF",
                    "relevance_score": "0.055173",
                    "ticker_sentiment_score": "-0.020978",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DSKYF",
                    "relevance_score": "0.055173",
                    "ticker_sentiment_score": "-0.020978",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.082677",
                    "ticker_sentiment_score": "0.046148",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ESALF",
                    "relevance_score": "0.027603",
                    "ticker_sentiment_score": "-0.001861",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HARP",
                    "relevance_score": "0.110082",
                    "ticker_sentiment_score": "0.129953",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.110082",
                    "ticker_sentiment_score": "0.124794",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Coupa Named a Leader in the Inaugural 2024 Gartner® Magic Quadrant™ for Source-to-Pay Suites",
            "url": "https://www.prnewswire.com/news-releases/coupa-named-a-leader-in-the-inaugural-2024-gartner-magic-quadrant-for-source-to-pay-suites-302050990.html",
            "time_published": "20240201T170000",
            "authors": [
                "Coupa Software"
            ],
            "summary": "Driving transformational operational efficiency and growth for customers large and small through the leading, AI-driven source-to-pay platform",
            "banner_image": "https://mma.prnewswire.com/media/818424/coupa_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.365422,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.08687",
                    "ticker_sentiment_score": "0.07457",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IT",
                    "relevance_score": "0.08687",
                    "ticker_sentiment_score": "0.052402",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Biden Administration Starts Negotiations Over Medicare Drug Prices-Here's How Prices May Be Affected",
            "url": "https://www.forbes.com/sites/tylerroush/2024/02/01/biden-administration-starts-negotiations-over-medicare-drug-prices-heres-how-prices-may-be-affected/",
            "time_published": "20240201T155916",
            "authors": [
                "Ty Roush"
            ],
            "summary": "The Biden Administration started negotiations on Thursday with the manufacturers of 10 drugs widely used by older Americans, as part of an effort to cut prescription prices for the costliest medications covered by Medicare, which federal officials estimate could save the health program an ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65bbbf6b3630d3d86b3603b7/0x0.jpg?format=jpg&crop=2510,1410,x0,y0,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": -0.040623,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.068896",
                    "ticker_sentiment_score": "-0.025316",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.068896",
                    "ticker_sentiment_score": "-0.025316",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.068896",
                    "ticker_sentiment_score": "-0.025316",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Sanofi  ( SNY )  Misses on Q4 Earnings and Sales, Stock Down",
            "url": "https://www.zacks.com/stock/news/2219619/sanofi-sny-misses-on-q4-earnings-and-sales-stock-down",
            "time_published": "20240201T150500",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Sanofi (SNY) misses fourth-quarter estimates for earnings and sales. It maintains 2024 earnings growth guidance.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/8d/2080.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.99989"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.109787,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.083444",
                    "ticker_sentiment_score": "0.068928",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.083444",
                    "ticker_sentiment_score": "0.044266",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.350183",
                    "ticker_sentiment_score": "0.186663",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "InnovationRx: Show Me The Healthcare Savings",
            "url": "https://www.forbes.com/sites/katiejennings/2024/02/01/innovationrx-welltheory-healthcare-savings/",
            "time_published": "20240201T150012",
            "authors": [
                "Katie Jennings"
            ],
            "summary": "InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. here were a whopping two healthtech startups that hit billion-dollar valuations in 2023, compared to 52 unicorns minted during the two years prior, according to a PitchBook analysis.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65bbabdc914b96812cb02bf8/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.152677,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SCI",
                    "relevance_score": "0.041323",
                    "ticker_sentiment_score": "0.118104",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.041323",
                    "ticker_sentiment_score": "0.11689",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HUM",
                    "relevance_score": "0.041323",
                    "ticker_sentiment_score": "-0.009886",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAH",
                    "relevance_score": "0.041323",
                    "ticker_sentiment_score": "0.197529",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.041323",
                    "ticker_sentiment_score": "0.124483",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.041323",
                    "ticker_sentiment_score": "0.233516",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Futures Rebound Ahead Of Jobless Claims",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-jobless-claims-amazon-apple-to-report/",
            "time_published": "20240201T143300",
            "authors": [
                "SCOTT LEHTONEN",
                "Investor's Business Daily"
            ],
            "summary": "Dow Jones Rises On Surprise Jobless Claims. Amazon, Apple To Report Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/10/stock-wall-street-flags-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.12074,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DKNG",
                    "relevance_score": "0.218423",
                    "ticker_sentiment_score": "0.023672",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.044222",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.175539",
                    "ticker_sentiment_score": "0.1099",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNOW",
                    "relevance_score": "0.175539",
                    "ticker_sentiment_score": "0.151815",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.132125",
                    "ticker_sentiment_score": "0.125522",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.044222",
                    "ticker_sentiment_score": "0.201665",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSCO",
                    "relevance_score": "0.044222",
                    "ticker_sentiment_score": "0.088953",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.175539",
                    "ticker_sentiment_score": "0.136375",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.044222",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "QCOM",
                    "relevance_score": "0.044222",
                    "ticker_sentiment_score": "0.088953",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RCL",
                    "relevance_score": "0.044222",
                    "ticker_sentiment_score": "0.088953",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.175539",
                    "ticker_sentiment_score": "0.1099",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NXT(EXP20091224)",
                    "relevance_score": "0.044222",
                    "ticker_sentiment_score": "0.088953",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.175539",
                    "ticker_sentiment_score": "0.092629",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Futures Rise After Powell Sell-Off; This Solar Play Surges",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-stocks-tumble-after-fed-powell-fuels-market-sell-off-solar-play-nextracker-surges/",
            "time_published": "20240201T124100",
            "authors": [
                "Investor's Business Daily",
                "ED CARSON"
            ],
            "summary": "Futures Rise After Powell Sell-Off. This Solar Play Surges Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2022/06/Stock-jeromepowell2022-04-gov.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.838487"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.996718"
                }
            ],
            "overall_sentiment_score": -0.039117,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.17824",
                    "ticker_sentiment_score": "-0.194614",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.119383",
                    "ticker_sentiment_score": "-0.146872",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.05986",
                    "ticker_sentiment_score": "-0.046997",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.05986",
                    "ticker_sentiment_score": "-0.046997",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "QCOM",
                    "relevance_score": "0.119383",
                    "ticker_sentiment_score": "0.008447",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.029951",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMD",
                    "relevance_score": "0.119383",
                    "ticker_sentiment_score": "-0.189889",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "RCL",
                    "relevance_score": "0.089685",
                    "ticker_sentiment_score": "0.087084",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALGN",
                    "relevance_score": "0.089685",
                    "ticker_sentiment_score": "0.14723",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.029951",
                    "ticker_sentiment_score": "0.026376",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NYCB",
                    "relevance_score": "0.089685",
                    "ticker_sentiment_score": "-0.133714",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NXT(EXP20091224)",
                    "relevance_score": "0.05986",
                    "ticker_sentiment_score": "0.139442",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:NXT",
                    "relevance_score": "0.05986",
                    "ticker_sentiment_score": "0.139442",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Weight loss medication shortage creates market for bogus drugs",
            "url": "https://www.foxbusiness.com/lifestyle/weight-loss-medication-shortage-creates-market-bogus-drugs",
            "time_published": "20240201T120000",
            "authors": [
                "Daniella Genovese"
            ],
            "summary": "Counterfeit versions of weight-loss related medications are \"detrimental to the field of obesity medicine\" and can pose severe risks to patient health, particularly to those who rely on them most, according to medical experts.",
            "banner_image": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/854081161001/daf39b6e-8ec1-4a4d-8f33-07a012f1364e/4c087976-f71c-402b-a088-f2a237d0132b/1280x720/match/image.jpg",
            "source": "Fox Business News",
            "category_within_source": "n/a",
            "source_domain": "www.foxbusiness.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.163306,
            "overall_sentiment_label": "Somewhat-Bearish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.043499",
                    "ticker_sentiment_score": "-0.094265",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Medicare drug price negotiations begin after Biden administration makes initial offers | Politics",
            "url": "https://www.cnn.com/2024/02/01/politics/medicare-drug-price-negotiations-initial-offers/index.html",
            "time_published": "20240201T110600",
            "authors": [
                "Tami Luhby"
            ],
            "summary": "Medicare drug price negotiations start after Biden administration makes initial offers ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230929184725-medicare-drug-price-negotiations-092923.jpg?c=16x9&q=w_800,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.104844,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.063763",
                    "ticker_sentiment_score": "-0.042288",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.127119",
                    "ticker_sentiment_score": "0.112589",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.063763",
                    "ticker_sentiment_score": "-0.042288",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Wegovy: Here's When Supply Of The Weight Loss Drug Could Improve This Year",
            "url": "https://www.forbes.com/sites/roberthart/2024/02/01/wegovy-supply-heres-when-supply-of-the-weight-loss-drug-could-improve-this-year/",
            "time_published": "20240201T102417",
            "authors": [
                "Robert Hart"
            ],
            "summary": "Wegovy Supply: Here's When Supply Of The Weight Loss Drug Could Improve This Year Forbes ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65bb70e98e33fc34c0979393/0x0.jpg?format=jpg&crop=3467,1950,x0,y1612,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.142616,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.43816",
                    "ticker_sentiment_score": "0.173958",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Why Eli Lilly Stock Topped the Market Today",
            "url": "https://www.fool.com/investing/2024/01/31/why-eli-lilly-stock-topped-the-market-today/",
            "time_published": "20240131T231600",
            "authors": [
                "Eric Volkman"
            ],
            "summary": "One of its more recently approved drugs will be launched into a white-hot market.",
            "banner_image": "https://g.foolcdn.com/editorial/images/763435/patient-and-physician-smiling-during-a-visit.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                }
            ],
            "overall_sentiment_score": 0.265184,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.614086",
                    "ticker_sentiment_score": "0.456209",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.512093",
                    "ticker_sentiment_score": "0.509193",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "What To Do After Powell-Led Market Sell-Off",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-stocks-tumble-as-fed-chief-powell-says-march-rate-cut-unlikely/",
            "time_published": "20240131T214300",
            "authors": [
                "Investor's Business Daily",
                "ED CARSON"
            ],
            "summary": "Stocks Tumble As Fed Chief Powell Says March Rate Cut Unlikely Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2022/06/Stock-jeromepowell2022-04-gov.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972476"
                }
            ],
            "overall_sentiment_score": -0.041559,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.185306",
                    "ticker_sentiment_score": "-0.20005",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.124164",
                    "ticker_sentiment_score": "-0.149651",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.062271",
                    "ticker_sentiment_score": "-0.047223",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.062271",
                    "ticker_sentiment_score": "-0.047223",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "QCOM",
                    "relevance_score": "0.124164",
                    "ticker_sentiment_score": "0.004927",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.031159",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMD",
                    "relevance_score": "0.124164",
                    "ticker_sentiment_score": "-0.193493",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "RCL",
                    "relevance_score": "0.093289",
                    "ticker_sentiment_score": "0.160199",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ALGN",
                    "relevance_score": "0.093289",
                    "ticker_sentiment_score": "0.146688",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.031159",
                    "ticker_sentiment_score": "0.026523",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NYCB",
                    "relevance_score": "0.093289",
                    "ticker_sentiment_score": "-0.135028",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NXT(EXP20091224)",
                    "relevance_score": "0.062271",
                    "ticker_sentiment_score": "0.137736",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:NXT",
                    "relevance_score": "0.062271",
                    "ticker_sentiment_score": "0.137736",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  Q4 2023 Earnings Call Transcript",
            "url": "https://www.fool.com/earnings/call-transcripts/2024/01/31/novo-nordisk-nvo-q4-2023-earnings-call-transcript/",
            "time_published": "20240131T170015",
            "authors": [
                "Motley Fool Transcribing"
            ],
            "summary": "NVO earnings call for the period ending December 31, 2023.",
            "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.955357"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.998663"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.310843"
                }
            ],
            "overall_sentiment_score": 0.313126,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BCS",
                    "relevance_score": "0.005144",
                    "ticker_sentiment_score": "0.2538",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.010288",
                    "ticker_sentiment_score": "0.164341",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.010288",
                    "ticker_sentiment_score": "0.055173",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.005144",
                    "ticker_sentiment_score": "0.203516",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.035998",
                    "ticker_sentiment_score": "0.123272",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "APG",
                    "relevance_score": "0.020575",
                    "ticker_sentiment_score": "0.06753",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AWON",
                    "relevance_score": "0.010288",
                    "ticker_sentiment_score": "0.008373",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Stocks Mixed To Start Day; Google Sinks After Earnings",
            "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-mixed-while-google-microsoft-drop/",
            "time_published": "20240131T160000",
            "authors": [
                "KIMBERLEY KOENIG",
                "Investor's Business Daily"
            ],
            "summary": "Stock Market Mixed While Google And Microsoft Drop Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/02/Stock-GoogleBard-01-shutt.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.988787"
                }
            ],
            "overall_sentiment_score": 0.106669,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.103554",
                    "ticker_sentiment_score": "-0.105911",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.103554",
                    "ticker_sentiment_score": "0.046173",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.103554",
                    "ticker_sentiment_score": "0.046173",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.154785",
                    "ticker_sentiment_score": "0.042486",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PARA",
                    "relevance_score": "0.154785",
                    "ticker_sentiment_score": "0.064474",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.154785",
                    "ticker_sentiment_score": "0.124158",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.051886",
                    "ticker_sentiment_score": "0.223627",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.154785",
                    "ticker_sentiment_score": "0.04596",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "POWL",
                    "relevance_score": "0.103554",
                    "ticker_sentiment_score": "0.127899",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.103554",
                    "ticker_sentiment_score": "0.046173",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SBUX",
                    "relevance_score": "0.154785",
                    "ticker_sentiment_score": "0.105972",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMD",
                    "relevance_score": "0.20537",
                    "ticker_sentiment_score": "0.124586",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.103554",
                    "ticker_sentiment_score": "0.034917",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.154785",
                    "ticker_sentiment_score": "-0.104673",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Private-Sector Payrolls Declined More Than Expected",
            "url": "https://www.zacks.com/stock/news/2218869/private-sector-payrolls-declined-more-than-expected",
            "time_published": "20240131T155200",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "January Jobs Week continues this morning, even as we're only just closing out the month today. Private-sector payrolls reported by Automatic Data Processing ( ( ADP Quick QuoteADP - ) came in below estimates: 107K versus 150K expected, and beneath the previous month's downwardly revised 158K.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/78/424.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.094228,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.136499",
                    "ticker_sentiment_score": "0.066689",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ADP",
                    "relevance_score": "0.269033",
                    "ticker_sentiment_score": "0.016126",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.136499",
                    "ticker_sentiment_score": "0.148231",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.2035",
                    "ticker_sentiment_score": "0.02959",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novartis  ( NVS )  Q4 Earnings Miss on Higher Costs, Sales Lag",
            "url": "https://www.zacks.com/stock/news/2218865/novartis-nvs-q4-earnings-miss-on-higher-costs-sales-lag",
            "time_published": "20240131T154800",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novartis' (NVS) earnings and sales miss estimates in the fourth quarter. The outlook for 2024 does not look promising as well.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b7/2350.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.967321"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.151664,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "REGN",
                    "relevance_score": "0.123315",
                    "ticker_sentiment_score": "0.059389",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.163909",
                    "ticker_sentiment_score": "0.140904",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVS",
                    "relevance_score": "0.204072",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "ADP Cools to 107K Private-Sector Jobs; BA, NVO Beat in Q4",
            "url": "https://www.zacks.com/stock/news/2218851/adp-cools-to-107k-private-sector-jobs-ba-nvo-beat-in-q4",
            "time_published": "20240131T152500",
            "authors": [
                "Mark Vickery"
            ],
            "summary": "We've now spent a full six months sub-200K private-sector job gains per month.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/55/60428.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.682689"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.091824,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.132733",
                    "ticker_sentiment_score": "0.066926",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ADP",
                    "relevance_score": "0.261818",
                    "ticker_sentiment_score": "0.015775",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.132733",
                    "ticker_sentiment_score": "0.137755",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.197951",
                    "ticker_sentiment_score": "0.028968",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick",
            "url": "https://www.zacks.com/stock/news/2218712/are-you-a-growth-investor-this-1-stock-could-be-the-perfect-pick",
            "time_published": "20240131T144507",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default62.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.838487"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.488422,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.531326",
                    "ticker_sentiment_score": "0.507266",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "AWON",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "0.016814",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  Q4 Earnings Top, GLP-1 Drugs Boost Sales",
            "url": "https://www.zacks.com/stock/news/2218660/novo-nordisk-nvo-q4-earnings-top-glp-1-drugs-boost-sales",
            "time_published": "20240131T142200",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) reports better-than-expected fourth-quarter results, beating both earnings and revenues, driven by strong sales of Diabetes and Obesity care products.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999965"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.227826,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ADMA",
                    "relevance_score": "0.217508",
                    "ticker_sentiment_score": "0.056736",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DERM",
                    "relevance_score": "0.146025",
                    "ticker_sentiment_score": "0.017942",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.387238",
                    "ticker_sentiment_score": "0.345136",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PBYI",
                    "relevance_score": "0.146025",
                    "ticker_sentiment_score": "0.064165",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Zacks Analyst Blog Highlights Apple, Visa, Novo Nordisk, PepsiCo and CrowdStrike Holdings",
            "url": "https://www.zacks.com/stock/news/2218659/the-zacks-analyst-blog-highlights-apple-visa-novo-nordisk-pepsico-and-crowdstrike-holdings",
            "time_published": "20240131T142100",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Apple, Visa, Novo Nordisk, PepsiCo and CrowdStrike Holdings are part of the Zacks Analyst Blog.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b0/524.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.318734,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.360752",
                    "ticker_sentiment_score": "0.172304",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PEP",
                    "relevance_score": "0.148731",
                    "ticker_sentiment_score": "0.038952",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRWD",
                    "relevance_score": "0.148731",
                    "ticker_sentiment_score": "0.038952",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.426225",
                    "ticker_sentiment_score": "0.281599",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "V",
                    "relevance_score": "0.360752",
                    "ticker_sentiment_score": "0.34599",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo's Ozempic Puts Up A Commanding Beat, But Weight-Loss Sales Miss",
            "url": "https://www.investors.com/news/technology/novo-nordisk-stock-novo-nordisk-earnings-q4-2023/",
            "time_published": "20240131T135800",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "Novo Nordisk Stock Rises On Ozempic's Commanding Beat Despite Light Weight-Loss Sales Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/Stock-NovoNordisk-Denmark-company.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.904684"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.972756"
                }
            ],
            "overall_sentiment_score": 0.185299,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.461699",
                    "ticker_sentiment_score": "-0.020837",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:DKK",
                    "relevance_score": "0.461699",
                    "ticker_sentiment_score": "-0.023844",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:NOK",
                    "relevance_score": "0.461699",
                    "ticker_sentiment_score": "-0.023844",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Take Your Ozempic: Why Late Entry Of Rival Weight-Loss Drugs Won't Floor Novo, Eli Shares - AstraZeneca  ( NASDAQ:AZN ) , Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36866023/take-your-ozempic-why-late-entry-of-rival-weight-loss-drugs-wont-floor-novo-eli-sha",
            "time_published": "20240131T134944",
            "authors": [
                "Neil Dennis"
            ],
            "summary": "Eli Lilly LLY reports its fourth quarter earnings next week and, as Novo Nordisk NVO did on Wednesday, is expected to wow investors with earnings and revenue beats thanks, in large part, to the overwhelming success of its diabetes treatments that have become popular weight-loss solutions.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/ozempic-shutter.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.928769"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.187068,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.211191",
                    "ticker_sentiment_score": "0.249005",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.141726",
                    "ticker_sentiment_score": "-0.039113",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PTAIF",
                    "relevance_score": "0.071145",
                    "ticker_sentiment_score": "0.119694",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.211191",
                    "ticker_sentiment_score": "0.289771",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.211191",
                    "ticker_sentiment_score": "0.262369",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.211191",
                    "ticker_sentiment_score": "0.092059",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here's How Much a $1000 Investment in Novo Nordisk Made 10 Years Ago Would Be Worth Today",
            "url": "https://www.zacks.com/stock/news/2218555/heres-how-much-a-1000-investment-in-novo-nordisk-made-10-years-ago-would-be-worth-today",
            "time_published": "20240131T133005",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Holding on to popular or trending stocks for the long-term can make your portfolio a winner.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default212.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.298868,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CURN",
                    "relevance_score": "0.05257",
                    "ticker_sentiment_score": "0.160943",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.571178",
                    "ticker_sentiment_score": "0.415498",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Futures Mixed Ahead Of Fed Decision, Powell",
            "url": "https://www.investors.com/market-trend/stock-market-today/tech-falls-dow-jones-futures-rise-ahead-of-fed-decision-amd-google-microsoft-tesla-slide/",
            "time_published": "20240131T132100",
            "authors": [
                "SCOTT LEHTONEN",
                "Investor's Business Daily"
            ],
            "summary": "Dow Jones Futures Rise Ahead Of Today's Fed Decision, Powell. Google, Microsoft, Tesla Slide Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2022/06/Stock-jeromepowell2022-05-gov.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                }
            ],
            "overall_sentiment_score": 0.067028,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DKNG",
                    "relevance_score": "0.216473",
                    "ticker_sentiment_score": "0.0821",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.043818",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNOW",
                    "relevance_score": "0.173958",
                    "ticker_sentiment_score": "0.119702",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.130926",
                    "ticker_sentiment_score": "0.136821",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.043818",
                    "ticker_sentiment_score": "0.034852",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.173958",
                    "ticker_sentiment_score": "0.12846",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.130926",
                    "ticker_sentiment_score": "0.15035",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.173958",
                    "ticker_sentiment_score": "-0.05982",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MA",
                    "relevance_score": "0.043818",
                    "ticker_sentiment_score": "-0.02796",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SBUX",
                    "relevance_score": "0.043818",
                    "ticker_sentiment_score": "-0.02796",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMD",
                    "relevance_score": "0.130926",
                    "ticker_sentiment_score": "0.012269",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.043818",
                    "ticker_sentiment_score": "-0.02796",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.173958",
                    "ticker_sentiment_score": "0.083352",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk files annual report with the SEC",
            "url": "https://www.globenewswire.com/news-release/2024/01/31/2821017/0/en/Novo-Nordisk-files-annual-report-with-the-SEC.html",
            "time_published": "20240131T123400",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 31 January 2024 - Novo Nordisk A/S has filed its Annual Report 2023 on Form 20-F for the financial year 2023 with the US Securities and Exchange Commission ( SEC ) , incorporating by reference parts of the Novo Nordisk A/S Annual Report 2022.",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.181454,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.245339",
                    "ticker_sentiment_score": "0.104822",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.245339",
                    "ticker_sentiment_score": "0.104822",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.7887",
                    "ticker_sentiment_score": "0.295425",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk Skyrockets To $506B Valuation Driven By 'Miracle' Drugs Ozempic, Wegovy - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/24/01/36862998/novo-nordisk-skyrockets-to-506b-valuation-driven-by-miracle-drugs-ozempic-wegovy",
            "time_published": "20240131T115705",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "Novo Nordisk NVO has reported a remarkable increase in its market value, reaching $500 billion, driven by a surge in demand for its key drugs. What Happened: The Danish pharmaceutical company's market value soared to $506 billion on Wednesday following the release of its 2023 earnings, CNBC ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/West-Bangal--India---April-20--2022--Nov.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.31634,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.29234",
                    "ticker_sentiment_score": "0.308009",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk hits $500 billion in market value as it flags soaring demand for Wegovy, Ozempic",
            "url": "https://www.cnbc.com/2024/01/31/novo-nordisk-beats-earnings-expectations-as-wegovy-ozempic-demand-soars.html",
            "time_published": "20240131T094956",
            "authors": [
                "Elliot Smith"
            ],
            "summary": "Novo Nordisk, Europe's largest company by market capitalization, on Wednesday reported better-than-expected 2023 earnings.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107366836-17066941841706694181-33131569394-1080pnbcnews.jpg?v=1706694183&w=750&h=422&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Earnings",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.172624,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.245339",
                    "ticker_sentiment_score": "0.040807",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Best Growth Stocks to Buy for January 31st",
            "url": "https://www.zacks.com/commentary/2218409/best-growth-stocks-to-buy-for-january-31st",
            "time_published": "20240131T092100",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "TX, POWL and NVO made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 31, 2024.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.167638,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "TX",
                    "relevance_score": "0.802374",
                    "ticker_sentiment_score": "0.157069",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "POWL",
                    "relevance_score": "0.730535",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.802374",
                    "ticker_sentiment_score": "0.141549",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ozempic maker Novo Nordisk reports 62% surge in profit",
            "url": "https://www.marketwatch.com/story/ozempic-maker-novo-nordisk-reports-62-surge-in-profit-584a5064",
            "time_published": "20240131T085200",
            "authors": [
                "Steve Goldstein"
            ],
            "summary": "Novo Nordisk on Wednesday said its fourth-quarter profit surged by nearly two-thirds, driven by the popularity of its weight-loss drugs that have made it Europe's largest company.",
            "banner_image": "https://images.mktw.net/im-809249/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.239467,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.224903",
                    "ticker_sentiment_score": "-0.059165",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.746902",
                    "ticker_sentiment_score": "0.417184",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.113597",
                    "ticker_sentiment_score": "-0.038291",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk Beats Profit Forecasts As Weight-Loss Sales Soar",
            "url": "https://www.forbes.com/sites/roberthart/2024/01/31/novo-nordisk-beats-profit-forecasts-as-weight-loss-sales-soar/",
            "time_published": "20240131T083945",
            "authors": [
                "Robert Hart"
            ],
            "summary": "Danish pharma giant Novo Nordisk on Wednesday reported better-than-expected earnings for 2023, propelled by a tsunami of demand for its blockbuster weight loss and diabetes drugs as new treatments emerge and compete for a slice of the growing market.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65ba06e3114e9d96266b396e/0x0.jpg?format=jpg&crop=5200,2923,x0,y271,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.29136,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.44622",
                    "ticker_sentiment_score": "0.325127",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NOK",
                    "relevance_score": "0.078611",
                    "ticker_sentiment_score": "0.136341",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk FY23 Profit Rises; Sales Up 36% At CER",
            "url": "https://markets.businessinsider.com/news/stocks/novo-nordisk-fy23-profit-rises-sales-up-36-at-cer-1033013390",
            "time_published": "20240131T070000",
            "authors": [
                "markets.businessinsider.com"
            ],
            "summary": "Novo Nordisk FY23 Profit Rises. Sales Up 36% At ...",
            "banner_image": "https://markets.businessinsider.com/Images/FacebookIcon.jpg",
            "source": "Business Insider",
            "category_within_source": "RSS",
            "source_domain": "markets.businessinsider.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.928139"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.384914,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.38588",
                    "ticker_sentiment_score": "0.483383",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk's sales increased by 31% in Danish kroner and by 36% at constant exchange rates to DKK 232.3 billion in 2023",
            "url": "https://www.globenewswire.com/news-release/2024/01/31/2820720/0/en/Novo-Nordisk-s-sales-increased-by-31-in-Danish-kroner-and-by-36-at-constant-exchange-rates-to-DKK-232-3-billion-in-2023.html",
            "time_published": "20240131T063000",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 31 January 2024 - Financial report for the period 1 January 2023 to 31 December ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.282213,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.079392",
                    "ticker_sentiment_score": "0.040378",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.079392",
                    "ticker_sentiment_score": "0.040378",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.309864",
                    "ticker_sentiment_score": "0.253674",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "FirstFT: France seeks UK loan guarantee for Hinkley Point C nuclear plant",
            "url": "https://www.ft.com/content/4dbfc3c2-39d5-464b-82a1-fb4c9975d569",
            "time_published": "20240131T053229",
            "authors": [
                "Tee Zhuo"
            ],
            "summary": "Also in today's newsletter, US interest rate decision and Musk's pay package voided ...",
            "banner_image": "https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fd1e00ek4ebabms.cloudfront.net%2Fproduction%2F4f54f454-8500-478d-a233-f3473179be84.png?source=next-article&fit=scale-down&quality=highest&width=700&dpr=1",
            "source": "Financial Times",
            "category_within_source": "Economy",
            "source_domain": "www.ft.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": -0.026459,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.031907",
                    "ticker_sentiment_score": "0.063678",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSCDF",
                    "relevance_score": "0.031907",
                    "ticker_sentiment_score": "-0.086823",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.031907",
                    "ticker_sentiment_score": "0.063678",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.031907",
                    "ticker_sentiment_score": "0.063678",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.031907",
                    "ticker_sentiment_score": "-0.020956",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.031907",
                    "ticker_sentiment_score": "-0.020956",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Big Earnings Afternoon: Microsoft, Alphabet, Starbucks & More",
            "url": "https://www.zacks.com/stock/news/2218328/big-earnings-afternoon-microsoft-alphabet-starbucks-more",
            "time_published": "20240130T231300",
            "authors": [
                "Mark Vickery"
            ],
            "summary": "Microsoft, Google-parent Alphabet, Mondelez and Skyworks all topped earnings expectations.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/af/1379.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999917"
                }
            ],
            "overall_sentiment_score": 0.165889,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.095138",
                    "ticker_sentiment_score": "0.244802",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.047654",
                    "ticker_sentiment_score": "0.053506",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDLZ",
                    "relevance_score": "0.095138",
                    "ticker_sentiment_score": "0.120758",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MA",
                    "relevance_score": "0.047654",
                    "ticker_sentiment_score": "0.007912",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SBUX",
                    "relevance_score": "0.095138",
                    "ticker_sentiment_score": "0.049059",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.095138",
                    "ticker_sentiment_score": "0.008421",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMD",
                    "relevance_score": "0.095138",
                    "ticker_sentiment_score": "0.037093",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SWKS",
                    "relevance_score": "0.095138",
                    "ticker_sentiment_score": "0.067943",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ADP",
                    "relevance_score": "0.095138",
                    "ticker_sentiment_score": "0.008421",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.095138",
                    "ticker_sentiment_score": "0.008421",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Futures: 3 AI Giants Fall On Earnings; Musk's $56 Bil Pay Deal Voided",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-tech-giants-microsoft-google-amd-earnings-elon-musk-56-billion-pay-plan/",
            "time_published": "20240130T221700",
            "authors": [
                "Investor's Business Daily",
                "ED CARSON"
            ],
            "summary": "Dow Jones Futures: Microsoft, Google, AMD Fall On Earnings. Elon Musk Loses $56 Billion Pay Plan Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/12/Stock-EyeAIgen-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999336"
                }
            ],
            "overall_sentiment_score": -0.089,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.410697",
                    "ticker_sentiment_score": "-0.09547",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.30021",
                    "ticker_sentiment_score": "-0.080922",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MPC",
                    "relevance_score": "0.061473",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.182967",
                    "ticker_sentiment_score": "-0.136553",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.182967",
                    "ticker_sentiment_score": "-0.138782",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ANET",
                    "relevance_score": "0.030759",
                    "ticker_sentiment_score": "-0.163082",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.21278",
                    "ticker_sentiment_score": "-0.153612",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.122581",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.061473",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMD",
                    "relevance_score": "0.271442",
                    "ticker_sentiment_score": "-0.085125",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.061473",
                    "ticker_sentiment_score": "-0.125027",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.092095",
                    "ticker_sentiment_score": "-0.236617",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Top Stock Reports for Apple, Visa & Novo Nordisk",
            "url": "https://www.zacks.com/research-daily/2217814/top-stock-reports-for-apple-visa-novo-nordisk",
            "time_published": "20240130T212900",
            "authors": [
                "Mark Vickery"
            ],
            "summary": "Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Visa Inc. (V) and Novo Nordisk A/S (NVO).",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/11/933.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.399676,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.211191",
                    "ticker_sentiment_score": "0.27401",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.312158",
                    "ticker_sentiment_score": "0.362133",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "V",
                    "relevance_score": "0.211191",
                    "ticker_sentiment_score": "0.479601",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Market Whales and Their Recent Bets on NVO Options - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/insights/options/24/01/36852887/market-whales-and-their-recent-bets-on-nvo-options",
            "time_published": "20240130T193112",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk. Looking at options history for Novo Nordisk NVO we detected 20 trades. If we consider the specifics of each trade, it is accurate to state that 55% of the investors opened trades with bullish expectations ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.137874,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MS",
                    "relevance_score": "0.102888",
                    "ticker_sentiment_score": "-0.163318",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.755492",
                    "ticker_sentiment_score": "0.330854",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Pfizer  ( PFE )  Q4 Earnings Top, Revenues Miss on COVID Sales Slump",
            "url": "https://www.zacks.com/stock/news/2218064/pfizer-pfe-q4-earnings-top-revenues-miss-on-covid-sales-slump",
            "time_published": "20240130T155300",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Pfizer (PFE) reports mixed fourth-quarter 2023 results. It re-affirms its 2024 sales and earnings guidance provided in December 2023.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.028847,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BHVN",
                    "relevance_score": "0.025734",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.051441",
                    "ticker_sentiment_score": "0.06656",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.077094",
                    "ticker_sentiment_score": "0.039643",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.348452",
                    "ticker_sentiment_score": "0.185884",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BNTX",
                    "relevance_score": "0.077094",
                    "ticker_sentiment_score": "-0.072658",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S - share repurchase programme",
            "url": "https://www.globenewswire.com/news-release/2024/01/30/2820203/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html",
            "time_published": "20240130T152800",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 30 January 2024 - On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.120468,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.121037",
                    "ticker_sentiment_score": "0.045024",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.121037",
                    "ticker_sentiment_score": "0.045024",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.77688",
                    "ticker_sentiment_score": "0.191353",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Wall Street Analysts See Novo Nordisk  ( NVO )  as a Buy: Should You Invest?",
            "url": "https://www.zacks.com/stock/news/2217885/wall-street-analysts-see-novo-nordisk-nvo-as-a-buy-should-you-invest",
            "time_published": "20240130T143006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Based on the average brokerage recommendation (ABR), Novo Nordisk (NVO) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
            "banner_image": "https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/NVO_01302024.png",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.938238"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.503496"
                }
            ],
            "overall_sentiment_score": 0.323525,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.351985",
                    "ticker_sentiment_score": "0.255314",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Drug, Biotech Stocks' Q4 Earnings Due on Jan 31: NVO, NVS & GSK",
            "url": "https://www.zacks.com/stock/news/2217797/drug-biotech-stocks-q4-earnings-due-on-jan-31-nvo-nvs-gsk",
            "time_published": "20240130T140900",
            "authors": [
                "Ahan Chakraborty"
            ],
            "summary": "Let's look at three biotech/drug companies, NVO, NVS and GSK, slated to release quarterly results on Jan 31.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/34/973.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.224479,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVS",
                    "relevance_score": "0.219809",
                    "ticker_sentiment_score": "0.103918",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GSK",
                    "relevance_score": "0.374714",
                    "ticker_sentiment_score": "0.159687",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.374714",
                    "ticker_sentiment_score": "0.176099",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.110973",
                    "ticker_sentiment_score": "0.255206",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Futures Fall Ahead Of Key Economic Data",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-key-economic-data-alphabet-amd-microsoft-to-report-earnings/",
            "time_published": "20240130T132300",
            "authors": [
                "Investor's Business Daily",
                "SCOTT LEHTONEN"
            ],
            "summary": "Dow Jones futures fell slightly Tuesday morning, as Wall Street prepared for key economic data, with the early release of two housing reports, consumer confidence numbers and job openings.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2017/04/stock-wallstreet-shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.111578,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DKNG",
                    "relevance_score": "0.142989",
                    "ticker_sentiment_score": "0.04644",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.071784",
                    "ticker_sentiment_score": "0.115734",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.142989",
                    "ticker_sentiment_score": "0.096854",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPOT",
                    "relevance_score": "0.107495",
                    "ticker_sentiment_score": "0.098818",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNOW",
                    "relevance_score": "0.142989",
                    "ticker_sentiment_score": "0.027056",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GM",
                    "relevance_score": "0.035929",
                    "ticker_sentiment_score": "0.222658",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.107495",
                    "ticker_sentiment_score": "0.078383",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.035929",
                    "ticker_sentiment_score": "0.034318",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.142989",
                    "ticker_sentiment_score": "0.05936",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.035929",
                    "ticker_sentiment_score": "0.222658",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.142989",
                    "ticker_sentiment_score": "0.111156",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.142989",
                    "ticker_sentiment_score": "0.096854",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PHM",
                    "relevance_score": "0.035929",
                    "ticker_sentiment_score": "0.222658",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMD",
                    "relevance_score": "0.071784",
                    "ticker_sentiment_score": "0.112764",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.142989",
                    "ticker_sentiment_score": "0.128408",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Will Novo Nordisk Be a $1 Trillion Company by 2030?",
            "url": "https://www.fool.com/investing/2024/01/30/will-novo-nordisk-be-a-1-trillion-company-by-2030/",
            "time_published": "20240130T121500",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Novo Nordisk's market cap has ballooned thanks to the overwhelming success of its Ozempic, Wegovy, and Rybelsus medications.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F762672%2Fdoctor-checking-blood-pressure.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.905476"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.289671,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.630923",
                    "ticker_sentiment_score": "0.426804",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.047749",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.047749",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.047749",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is a Surprise Coming for Novo Nordisk  ( NVO )  This Earnings Season?",
            "url": "https://www.zacks.com/stock/news/2217598/is-a-surprise-coming-for-novo-nordisk-nvo-this-earnings-season",
            "time_published": "20240130T110000",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.99237"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.451973,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.859898",
                    "ticker_sentiment_score": "0.576396",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Futures: Fed Meeting On Deck; AI Leader Surges Late",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-fed-meeting-on-deck-ai-stock-supermicro-surges-on-earnings-beat/",
            "time_published": "20240129T215400",
            "authors": [
                "Investor's Business Daily",
                "SCOTT LEHTONEN"
            ],
            "summary": "Dow Jones Futures: Fed Meeting On Deck. AI Stock Supermicro Surges On Earnings Beat Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/01/stock-FederalReserve-snow-11-shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                }
            ],
            "overall_sentiment_score": 0.191332,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "DKNG",
                    "relevance_score": "0.152018",
                    "ticker_sentiment_score": "0.003973",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.114318",
                    "ticker_sentiment_score": "0.257989",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.076358",
                    "ticker_sentiment_score": "0.221211",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.226301",
                    "ticker_sentiment_score": "0.147618",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPOT",
                    "relevance_score": "0.114318",
                    "ticker_sentiment_score": "0.087623",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNOW",
                    "relevance_score": "0.114318",
                    "ticker_sentiment_score": "0.042771",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.114318",
                    "ticker_sentiment_score": "0.093199",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SMCI",
                    "relevance_score": "0.114318",
                    "ticker_sentiment_score": "0.225418",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "EXPE",
                    "relevance_score": "0.114318",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.114318",
                    "ticker_sentiment_score": "0.072028",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.152018",
                    "ticker_sentiment_score": "0.163939",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.152018",
                    "ticker_sentiment_score": "0.036316",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SHAK",
                    "relevance_score": "0.076358",
                    "ticker_sentiment_score": "0.014542",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.076358",
                    "ticker_sentiment_score": "0.234483",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.152018",
                    "ticker_sentiment_score": "0.14465",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly Wants to Expand Access to Weight-Loss Treatments In Germany, In Talks With Government - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/24/01/36830456/eli-lilly-wants-to-expand-access-to-weight-loss-treatments-in-germany-in-talks-with-government",
            "time_published": "20240129T181423",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Eli Lilly And Co LLY is reportedly engaged in discussions with the German government to lift the ban on the public health system covering the costs of weight-loss treatments.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/mounjaro-medication-for-weight-loss_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.053268,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.59016",
                    "ticker_sentiment_score": "0.038645",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.258351",
                    "ticker_sentiment_score": "0.15576",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Stock Market Rises As Amazon and Microsoft Pull Ahead",
            "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-today-nearly-flat-as-amazon-microsoft-pull-ahead/",
            "time_published": "20240129T155800",
            "authors": [
                "Investor's Business Daily",
                "KIMBERLEY KOENIG"
            ],
            "summary": "Stock Market Today Nearly Flat As Amazon, Microsoft Pull Ahead Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/09/Stock-Amazon-hiring-company.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.769861"
                }
            ],
            "overall_sentiment_score": 0.166811,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.096283",
                    "ticker_sentiment_score": "0.023054",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.096283",
                    "ticker_sentiment_score": "0.039857",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.096283",
                    "ticker_sentiment_score": "0.2594",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.19117",
                    "ticker_sentiment_score": "0.11501",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.04823",
                    "ticker_sentiment_score": "0.044978",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FLYW",
                    "relevance_score": "0.096283",
                    "ticker_sentiment_score": "-0.046754",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WWD",
                    "relevance_score": "0.096283",
                    "ticker_sentiment_score": "-0.099949",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DLTR",
                    "relevance_score": "0.096283",
                    "ticker_sentiment_score": "0.118581",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.04823",
                    "ticker_sentiment_score": "-0.042991",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.19117",
                    "ticker_sentiment_score": "-0.076083",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SMCI",
                    "relevance_score": "0.096283",
                    "ticker_sentiment_score": "0.200771",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AAL",
                    "relevance_score": "0.096283",
                    "ticker_sentiment_score": "0.048777",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.04823",
                    "ticker_sentiment_score": "0.151982",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ZI",
                    "relevance_score": "0.096283",
                    "ticker_sentiment_score": "0.209291",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.19117",
                    "ticker_sentiment_score": "0.067106",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.096283",
                    "ticker_sentiment_score": "0.2594",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMD",
                    "relevance_score": "0.19117",
                    "ticker_sentiment_score": "-0.043193",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IRBT",
                    "relevance_score": "0.19117",
                    "ticker_sentiment_score": "-0.127305",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.143987",
                    "ticker_sentiment_score": "0.049363",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Leader In Weight Loss Drugs Nears Buy Point With Earnings Due This Week",
            "url": "https://www.investors.com/research/novo-nordisk-weight-loss-drug-leader-nears-buy-point-with-earnings-due/",
            "time_published": "20240129T150100",
            "authors": [
                "Investor's Business Daily",
                "VIDYA RAMAKRISHNAN"
            ],
            "summary": "IBD 50 stock Novo Nordisk ( NVO ) has formed a four-weeks-tight pattern with a buy point at 108.98. The health care leader is set to announce its fourth-quarter and full-year earnings on Wednesday. Novo Nordisk stock is today's selection for IBD 50 Stocks To Watch.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2018/01/Stock-NovoNordisk-1-company.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.989041"
                }
            ],
            "overall_sentiment_score": 0.260981,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "OMGA",
                    "relevance_score": "0.31482",
                    "ticker_sentiment_score": "0.139832",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.689185",
                    "ticker_sentiment_score": "0.322132",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "We're calling up a health care stock from our Bullpen watch list, starting a new position",
            "url": "https://www.cnbc.com/2024/01/29/were-calling-up-a-health-care-stock-from-our-bullpen-watch-list-starting-a-new-position.html",
            "time_published": "20240129T140341",
            "authors": [
                "Jim Cramer"
            ],
            "summary": "Now that expectations have cooled down, we think this pullback is one worth buying.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107250871-1685970222341-gettyimages-1258453480-Port_Trade_Growth_In_Lianyungang.jpeg?v=1698261998&w=600&h=300&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.96136"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.905476"
                }
            ],
            "overall_sentiment_score": 0.209243,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.074809",
                    "ticker_sentiment_score": "0.090625",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.037446",
                    "ticker_sentiment_score": "0.087033",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.221819",
                    "ticker_sentiment_score": "0.153796",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  to Report Q4 Earnings: What's in the Cards?",
            "url": "https://www.zacks.com/stock/news/2216966/novo-nordisk-nvo-to-report-q4-earnings-whats-in-the-cards",
            "time_published": "20240129T135900",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk's (NVO) sales in fourth-quarter 2023 are expected to have been driven by increased Diabetes and Obesity Care product sales despite pricing pressure in the United States.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999992"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.151538,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.236396",
                    "ticker_sentiment_score": "0.132165",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.501398",
                    "ticker_sentiment_score": "0.365304",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.236396",
                    "ticker_sentiment_score": "-0.001795",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Will New Drugs Drive Pfizer  ( PFE )  Sales in Q4 Earnings?",
            "url": "https://www.zacks.com/stock/news/2216911/will-new-drugs-drive-pfizer-pfe-sales-in-q4-earnings",
            "time_published": "20240129T132200",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Investor focus is likely to be on the sales numbers of Pfizer's (PFE) several newly launched drugs like Abrysvo, Velsipity, Penbraya as well as newly acquired products like Nurtec and Oxbryta on the fourth-quarter earnings call.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.187957,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BHVN",
                    "relevance_score": "0.051886",
                    "ticker_sentiment_score": "0.089543",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.103554",
                    "ticker_sentiment_score": "0.071798",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.154785",
                    "ticker_sentiment_score": "0.05123",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.3038",
                    "ticker_sentiment_score": "-0.042372",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BNTX",
                    "relevance_score": "0.154785",
                    "ticker_sentiment_score": "-0.056524",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Futures Await Huge Market News",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-microsoft-leads-huge-earnings-wave/",
            "time_published": "20240129T131000",
            "authors": [
                "ED CARSON",
                "Investor's Business Daily"
            ],
            "summary": "Dow Jones Futures: Microsoft Leads Huge Earnings Wave Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/Stock-BigWavePipe-08-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.890401"
                }
            ],
            "overall_sentiment_score": 0.128441,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.450828",
                    "ticker_sentiment_score": "0.05364",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.235442",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HUM",
                    "relevance_score": "0.079524",
                    "ticker_sentiment_score": "-0.178319",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.079524",
                    "ticker_sentiment_score": "0.004122",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.273224",
                    "ticker_sentiment_score": "0.063015",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.079524",
                    "ticker_sentiment_score": "-0.178319",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "INTC",
                    "relevance_score": "0.119038",
                    "ticker_sentiment_score": "-0.043251",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.235442",
                    "ticker_sentiment_score": "0.001774",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMD",
                    "relevance_score": "0.235442",
                    "ticker_sentiment_score": "0.029396",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.119038",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.158259",
                    "ticker_sentiment_score": "0.001322",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Futures Mixed Ahead Of Busy Week",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-ahead-of-busy-week-sofi-stock-surges-on-first-ever-profit/",
            "time_published": "20240129T130600",
            "authors": [
                "SCOTT LEHTONEN",
                "Investor's Business Daily"
            ],
            "summary": "Dow Jones Futures Fall Ahead Of Busy Week. SoFi Stock Surges On First Ever Profit Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2021/09/Stock-wallstreetflag-01-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.166003,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "DKNG",
                    "relevance_score": "0.107817",
                    "ticker_sentiment_score": "0.076704",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.107817",
                    "ticker_sentiment_score": "0.225161",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.143415",
                    "ticker_sentiment_score": "0.102174",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.143415",
                    "ticker_sentiment_score": "0.122362",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPOT",
                    "relevance_score": "0.143415",
                    "ticker_sentiment_score": "0.106252",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNOW",
                    "relevance_score": "0.143415",
                    "ticker_sentiment_score": "0.001274",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.072",
                    "ticker_sentiment_score": "0.127872",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.036037",
                    "ticker_sentiment_score": "0.116113",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.143415",
                    "ticker_sentiment_score": "0.073996",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.107817",
                    "ticker_sentiment_score": "0.107064",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MELI",
                    "relevance_score": "0.036037",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.143415",
                    "ticker_sentiment_score": "0.102174",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SOFI",
                    "relevance_score": "0.107817",
                    "ticker_sentiment_score": "0.066126",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.072",
                    "ticker_sentiment_score": "0.207777",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.072",
                    "ticker_sentiment_score": "-0.040665",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Major shareholder announcement",
            "url": "https://www.globenewswire.com/news-release/2024/01/29/2818771/0/en/Major-shareholder-announcement.html",
            "time_published": "20240129T121300",
            "authors": [
                "Novozymes A/S"
            ],
            "summary": "On January 29, 2024, following the satisfaction of all conditions precedent, the combination of Novozymes A/S ( \"Novozymes\" ) and Chr. Hansen Holding A/S ( \"Chr. Hansen\" ) by way of a statutory merger of the two companies ( the \"Combination\" ) , was successfully completed.",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/c466faee-a0aa-41be-87ca-4fdefb1cf50c",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.165366,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVZMY",
                    "relevance_score": "0.99525",
                    "ticker_sentiment_score": "0.297717",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.519739",
                    "ticker_sentiment_score": "0.158184",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "SoFi, iRobot, Tesla, Archer Daniels, McGrath RentCorp, ZoomInfo, and More Stock Market Movers",
            "url": "https://www.barrons.com/amp/articles/stock-market-movers-149f2d69",
            "time_published": "20240129T092400",
            "authors": [
                "Joe Woelfel"
            ],
            "summary": "Boeing, Evergrande, SoFi, Microsoft, Apple, and More Stock Market Movers ...",
            "banner_image": "https://images.barrons.com/im-780780/social",
            "source": "Barrons",
            "category_within_source": "n/a",
            "source_domain": "www.barrons.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.839681"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.95493"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.06188,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ALK",
                    "relevance_score": "0.123844",
                    "ticker_sentiment_score": "-0.00813",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UAL",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "-0.007007",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BE",
                    "relevance_score": "0.123844",
                    "ticker_sentiment_score": "0.019555",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ADM",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.061006",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FFIV",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.123844",
                    "ticker_sentiment_score": "0.08366",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.123844",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MA",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SBUX",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "QCOM",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMD",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IRBT",
                    "relevance_score": "0.123844",
                    "ticker_sentiment_score": "0.077742",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UPS",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EGRNQ",
                    "relevance_score": "0.123844",
                    "ticker_sentiment_score": "-0.157925",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NUE",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MO",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GM",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SMCI",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WSC",
                    "relevance_score": "0.123844",
                    "ticker_sentiment_score": "0.143711",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MGRC",
                    "relevance_score": "0.123844",
                    "ticker_sentiment_score": "0.143711",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ZI",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.195159",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SOFI",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.086015",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RCL",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.184834",
                    "ticker_sentiment_score": "-0.005884",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "2 Rising Biotechs That Could Become the Next Novo Nordisk",
            "url": "https://www.fool.com/investing/2024/01/29/2-rising-biotechs-that-could-become-the-next-novo/",
            "time_published": "20240129T075900",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "Each of these companies has a big market in its sights.",
            "banner_image": "https://g.foolcdn.com/editorial/images/762655/novo_nordisk_flag_with_logo_nvo.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                }
            ],
            "overall_sentiment_score": 0.192196,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.139804",
                    "ticker_sentiment_score": "0.027119",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.139804",
                    "ticker_sentiment_score": "0.077228",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.402761",
                    "ticker_sentiment_score": "0.303827",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Forget The Magnificent Seven. Focus On These Fab Five.",
            "url": "https://www.investors.com/news/sp-500-forget-magnificent-seven-focus-on-fab-five/",
            "time_published": "20240128T130000",
            "authors": [
                "Investor's Business Daily",
                "ED CARSON"
            ],
            "summary": "The Magnificent Seven stocks - S&P 500 giants Amazon.com ( AMZN ) , Apple ( AAPL ) , Google parent Alphabet ( GOOGL ) , Meta Platforms ( META ) , Microsoft ( MSFT ) , Nvidia ( NVDA ) and Tesla ( TSLA ) - have been grouped together since the start of the bull market in January 2023.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/11/Stock-AImachinelearning-01-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.181552,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.321927",
                    "ticker_sentiment_score": "0.294393",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HUM",
                    "relevance_score": "0.060161",
                    "ticker_sentiment_score": "-0.1661",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.149656",
                    "ticker_sentiment_score": "0.218425",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.526614",
                    "ticker_sentiment_score": "0.312372",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.265859",
                    "ticker_sentiment_score": "0.210761",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNPR",
                    "relevance_score": "0.060161",
                    "ticker_sentiment_score": "0.107001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.060161",
                    "ticker_sentiment_score": "0.100001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ADM",
                    "relevance_score": "0.060161",
                    "ticker_sentiment_score": "-0.1661",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "TSM",
                    "relevance_score": "0.090134",
                    "ticker_sentiment_score": "0.176881",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.40271",
                    "ticker_sentiment_score": "0.274766",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.321927",
                    "ticker_sentiment_score": "0.083558",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMD",
                    "relevance_score": "0.090134",
                    "ticker_sentiment_score": "-0.081834",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.149656",
                    "ticker_sentiment_score": "0.185532",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.294093",
                    "ticker_sentiment_score": "0.246411",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.060161",
                    "ticker_sentiment_score": "-0.1661",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "This week will make it clearer if the Fed will cut interest rates in March | Business",
            "url": "https://www.cnn.com/2024/01/28/business/stocks-week-ahead-economic-data-march-cut-fed/index.html",
            "time_published": "20240128T123000",
            "authors": [
                "Bryan Mena"
            ],
            "summary": "This week will make it clearer if the Fed will cut interest rates in March ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1845877607.jpg?c=16x9&q=w_800,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.999998"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.682689"
                }
            ],
            "overall_sentiment_score": 0.045759,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MDLZ",
                    "relevance_score": "0.023169",
                    "ticker_sentiment_score": "-0.035268",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.023169",
                    "ticker_sentiment_score": "-0.021795",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JBLU",
                    "relevance_score": "0.023169",
                    "ticker_sentiment_score": "-0.035268",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GM",
                    "relevance_score": "0.023169",
                    "ticker_sentiment_score": "-0.035268",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.023169",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HCA",
                    "relevance_score": "0.023169",
                    "ticker_sentiment_score": "-0.035268",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.023169",
                    "ticker_sentiment_score": "0.039643",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AWON",
                    "relevance_score": "0.023169",
                    "ticker_sentiment_score": "0.120569",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CLX",
                    "relevance_score": "0.023169",
                    "ticker_sentiment_score": "-0.021795",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.023169",
                    "ticker_sentiment_score": "-0.035268",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NMR",
                    "relevance_score": "0.023169",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DGX",
                    "relevance_score": "0.023169",
                    "ticker_sentiment_score": "-0.021795",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MA",
                    "relevance_score": "0.023169",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SBUX",
                    "relevance_score": "0.023169",
                    "ticker_sentiment_score": "-0.035268",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.023169",
                    "ticker_sentiment_score": "0.039643",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WBD",
                    "relevance_score": "0.023169",
                    "ticker_sentiment_score": "0.045126",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "X",
                    "relevance_score": "0.023169",
                    "ticker_sentiment_score": "-0.021795",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.046318",
                    "ticker_sentiment_score": "-0.030626",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CLF",
                    "relevance_score": "0.023169",
                    "ticker_sentiment_score": "-0.035268",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.023169",
                    "ticker_sentiment_score": "0.039643",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.023169",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "If You Invested $5,000 in Novo Nordisk in 2019, This Is How Much You Would Have Today",
            "url": "https://www.fool.com/investing/2024/01/27/if-you-invested-5000-in-novo-nordisk-in-2019/",
            "time_published": "20240127T160000",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "The answer may surprise you.",
            "banner_image": "https://media.ycharts.com/charts/67ec276a6508aaf6afdc910fd4bcc2bb.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.280356,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.065327",
                    "ticker_sentiment_score": "-0.01712",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.748842",
                    "ticker_sentiment_score": "0.459995",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Could Eli Lilly Be a Trillion-Dollar Company by 2030?",
            "url": "https://www.fool.com/investing/2024/01/27/could-eli-lilly-be-a-trillion-dollar-company-by-20/",
            "time_published": "20240127T132500",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Eli Lilly is the world's largest healthcare company by market cap, and the 10th most valuable business in the world.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F762341%2Fdoctor-showing-patient-a-chart.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.986714"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.503496"
                }
            ],
            "overall_sentiment_score": 0.305641,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.766317",
                    "ticker_sentiment_score": "0.468276",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.090304",
                    "ticker_sentiment_score": "0.097646",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Earnings Tsunami Looms For Market Rally; Seven Stocks To Watch",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-earnings-tsunami-looms-microsoft-apple-lead-7-stocks-to-watch/",
            "time_published": "20240126T214100",
            "authors": [
                "ED CARSON",
                "Investor's Business Daily"
            ],
            "summary": "Dow Jones Futures: Earnings Tsunami Looms. Microsoft, Apple Lead 7 Stocks To Watch Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/Stock-BigWavePipe-08-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.890401"
                }
            ],
            "overall_sentiment_score": 0.121082,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.443626",
                    "ticker_sentiment_score": "0.090942",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.210823",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HUM",
                    "relevance_score": "0.085173",
                    "ticker_sentiment_score": "-0.180785",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.085173",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.291842",
                    "ticker_sentiment_score": "0.108265",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.085173",
                    "ticker_sentiment_score": "-0.180785",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "INTC",
                    "relevance_score": "0.085173",
                    "ticker_sentiment_score": "-0.180785",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.25168",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMD",
                    "relevance_score": "0.25168",
                    "ticker_sentiment_score": "0.030817",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.127456",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.169378",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Merck, Johnson & Johnson CEOs agree to testify in Senate hearing on high drug prices",
            "url": "https://www.cnbc.com/2024/01/26/merck-jj-ceos-agree-to-testify-in-senate-hearing-on-drug-prices-.html",
            "time_published": "20240126T211709",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "The CEOs of Merck, Johnson & Johnson and Bristol Myers Squibb will testify at the hearing on drug prices, Sen. Bernie Sanders said.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107255764-1686668756779-gettyimages-1235403027-AFP_9NA2ZY.jpeg?v=1686668795&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.03827,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.085022",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.085022",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.085022",
                    "ticker_sentiment_score": "0.126295",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.085022",
                    "ticker_sentiment_score": "0.052216",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.085022",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk Options Trading: A Deep Dive into Market Sentiment - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/insights/options/24/01/36806316/novo-nordisk-options-trading-a-deep-dive-into-market-sentiment",
            "time_published": "20240126T180119",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk NVO revealed 10 unusual trades. Delving into the details, we found 60% of traders were bullish, while 40% showed bearish tendencies.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.157703,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MS",
                    "relevance_score": "0.096283",
                    "ticker_sentiment_score": "-0.244465",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.723718",
                    "ticker_sentiment_score": "0.321481",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Futures Lower Ahead Of Key Inflation Data",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-intel-plunges-on-earnings-cathie-wood-loads-up-as-tesla-dives/",
            "time_published": "20240126T131800",
            "authors": [
                "SCOTT LEHTONEN",
                "Investor's Business Daily"
            ],
            "summary": "Dow Jones Futures Fall As Intel Plunges On Earnings. Cathie Wood Loads Up As Tesla Dives Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2017/03/stock-wallstreet-031317-shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                }
            ],
            "overall_sentiment_score": 0.026473,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DKNG",
                    "relevance_score": "0.135602",
                    "ticker_sentiment_score": "0.12277",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MELI",
                    "relevance_score": "0.135602",
                    "ticker_sentiment_score": "0.11151",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.045396",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.224072",
                    "ticker_sentiment_score": "-0.170472",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "SPOT",
                    "relevance_score": "0.180124",
                    "ticker_sentiment_score": "0.121601",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNOW",
                    "relevance_score": "0.180124",
                    "ticker_sentiment_score": "-0.019372",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INTC",
                    "relevance_score": "0.135602",
                    "ticker_sentiment_score": "-0.250998",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.135602",
                    "ticker_sentiment_score": "0.144099",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WDC",
                    "relevance_score": "0.045396",
                    "ticker_sentiment_score": "-0.032952",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AXP",
                    "relevance_score": "0.090645",
                    "ticker_sentiment_score": "-0.356882",
                    "ticker_sentiment_label": "Bearish"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.045396",
                    "ticker_sentiment_score": "0.034912",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.180124",
                    "ticker_sentiment_score": "0.148327",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Zacks Industry Outlook Highlights Amphastar, Teva and Dr. Reddy's",
            "url": "https://www.zacks.com/stock/news/2216295/zacks-industry-outlook-highlights-amphastar-teva-and-dr-reddys",
            "time_published": "20240126T110000",
            "authors": [
                "Zacks Investment Research"
            ],
            "summary": "Amphastar, Teva and Dr. Reddy's have been highlighted in this Industry Outlook article.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/1019.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.682689"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.962106"
                }
            ],
            "overall_sentiment_score": 0.200217,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AMPH",
                    "relevance_score": "0.095517",
                    "ticker_sentiment_score": "0.030258",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.031907",
                    "ticker_sentiment_score": "0.010404",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Human Insulin Drugs Market In Brazil 2023-2028: Market Analysis, Drivers, Restraints, Opportunities, and Threats ... - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/human-insulin-drugs-market-in-brazil-2023-2028-market-analysis-drivers-restraints-opportunities-and-threats---17000--technavio-reports-302044119.html",
            "time_published": "20240126T023500",
            "authors": [],
            "summary": "Human Insulin Drugs Market In Brazil 2023-2028: Market Analysis, Drivers, Restraints, Opportunities, and Threats ... PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.26948,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVS",
                    "relevance_score": "0.054607",
                    "ticker_sentiment_score": "0.129809",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.054607",
                    "ticker_sentiment_score": "0.129809",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MNKD",
                    "relevance_score": "0.054607",
                    "ticker_sentiment_score": "0.129809",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.108958",
                    "ticker_sentiment_score": "0.098774",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BDX",
                    "relevance_score": "0.054607",
                    "ticker_sentiment_score": "0.129809",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.108958",
                    "ticker_sentiment_score": "0.098774",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "What are the Major Stock Market Risks for 2024?",
            "url": "https://www.zacks.com/commentary/2216190/what-are-the-major-stock-market-risks-for-2024",
            "time_published": "20240125T231000",
            "authors": [
                "John Blank"
            ],
            "summary": "After Davos is over, let's prognosticate from the cheap seats.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default38.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.955357"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                }
            ],
            "overall_sentiment_score": -0.056994,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.325208",
                    "ticker_sentiment_score": "0.232846",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.325208",
                    "ticker_sentiment_score": "0.232846",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly's Famed Obesity And Diabetes Drug, Mounjaro, Comes To UK Patients, Wins Regulatory Clearance For Prefilled Injection Pen - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/24/01/36790349/eli-lillys-famed-obesity-and-diabetes-drug-mounjaro-comes-to-uk-patients-wins-regulatory-clearanc",
            "time_published": "20240125T211159",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "The Medicines and Healthcare products Regulatory Agency ( MHRA ) has approved, Thursday, a four-dose version of the diabetes and weight management medicine Mounjaro ( tirzepatide ) . Eli Lilly And Co's LLY Mounjaro will be branded as Mounjaro KwikPen in the U.K.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/mounjaro-medication-for-weight-loss_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.181265,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.47672",
                    "ticker_sentiment_score": "0.132125",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.250386",
                    "ticker_sentiment_score": "0.064744",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Generic Drug Stocks to Watch Amid Improving Market Prospects",
            "url": "https://www.zacks.com/commentary/2215536/3-generic-drug-stocks-to-watch-amid-improving-market-prospects",
            "time_published": "20240125T153500",
            "authors": [
                "Sundeep Ganoria"
            ],
            "summary": "With the ease in inflationary pressure, the Zacks Medical - Generic Drugs industry is expected to benefit from declining costs. New product launches provide some respite to AMPH, RDY and TEVA.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.682689"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.990999"
                }
            ],
            "overall_sentiment_score": 0.206971,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AMPH",
                    "relevance_score": "0.064276",
                    "ticker_sentiment_score": "0.033366",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.032164",
                    "ticker_sentiment_score": "0.010417",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "What You Need to Know Ahead of Bristol-Myers  ( BMY )  Q4 Earnings",
            "url": "https://www.zacks.com/stock/news/2215936/what-you-need-to-know-ahead-of-bristol-myers-bmy-q4-earnings",
            "time_published": "20240125T153200",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Investors are likely to focus on Opdivos demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) reports Q4 results.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fa/45962.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999985"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.267049,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KRTX",
                    "relevance_score": "0.04076",
                    "ticker_sentiment_score": "0.178352",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "RYZB",
                    "relevance_score": "0.04076",
                    "ticker_sentiment_score": "0.178352",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MRTX",
                    "relevance_score": "0.04076",
                    "ticker_sentiment_score": "0.081645",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GSK",
                    "relevance_score": "0.121856",
                    "ticker_sentiment_score": "0.061363",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.161982",
                    "ticker_sentiment_score": "0.096548",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.279471",
                    "ticker_sentiment_score": "0.266256",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Alexandria  ( ARE )  to Post Q4 Earnings: What's in the Cards?",
            "url": "https://www.zacks.com/stock/news/2215820/alexandria-are-to-post-q4-earnings-whats-in-the-cards",
            "time_published": "20240125T145600",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "While Alexandria's (ARE) Q4 earnings are likely to have benefited from the healthy demand for its high-quality life science and lab office properties, high-interest expenses and economic uncertainty raise concern.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/46/176.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.904684"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.244822,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VICI",
                    "relevance_score": "0.122894",
                    "ticker_sentiment_score": "0.086819",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AGTEF",
                    "relevance_score": "0.082111",
                    "ticker_sentiment_score": "0.188848",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ARE",
                    "relevance_score": "0.122894",
                    "ticker_sentiment_score": "0.114414",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.122894",
                    "ticker_sentiment_score": "0.083375",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WELL",
                    "relevance_score": "0.163354",
                    "ticker_sentiment_score": "0.082832",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRGX",
                    "relevance_score": "0.082111",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pharma Stock Roundup: JNJ Reports Q4 Earnings, SNY Inks M&A Deal With INBX",
            "url": "https://www.zacks.com/stock/news/2215726/pharma-stock-roundup-jnj-reports-q4-earnings-sny-inks-ma-deal-with-inbx",
            "time_published": "20240125T142600",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sanofi (SNY) is set to acquire Inhibrx's (INBX) rare disease pipeline candidate, INBRX-101.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.9545"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.162707,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "INBX",
                    "relevance_score": "0.451494",
                    "ticker_sentiment_score": "0.26579",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.059785",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMAM",
                    "relevance_score": "0.059785",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.119235",
                    "ticker_sentiment_score": "-0.067585",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.119235",
                    "ticker_sentiment_score": "-0.07664",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.400417",
                    "ticker_sentiment_score": "0.232315",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Futures Higher Ahead Of GDP, Jobless Claims; Tesla Dives",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-gdp-jobless-claims-tesla-dives-on-earnings-musk-warning/",
            "time_published": "20240125T132208",
            "authors": [
                "SCOTT LEHTONEN",
                "Investor's Business Daily"
            ],
            "summary": "Dow Jones Futures Fall Ahead of GDP, Jobless Claims. Tesla Dives On Earnings, Musk Warning Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/07/Stock-Tesla-RedSilo-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.998932"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.142123,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DKNG",
                    "relevance_score": "0.112709",
                    "ticker_sentiment_score": "0.144311",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.037681",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPOT",
                    "relevance_score": "0.149889",
                    "ticker_sentiment_score": "0.114109",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNOW",
                    "relevance_score": "0.149889",
                    "ticker_sentiment_score": "0.080085",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.112709",
                    "ticker_sentiment_score": "0.130491",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LVS",
                    "relevance_score": "0.112709",
                    "ticker_sentiment_score": "0.034088",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAL",
                    "relevance_score": "0.112709",
                    "ticker_sentiment_score": "0.034088",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.037681",
                    "ticker_sentiment_score": "0.108946",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LUV",
                    "relevance_score": "0.075279",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.149889",
                    "ticker_sentiment_score": "0.088261",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MELI",
                    "relevance_score": "0.186738",
                    "ticker_sentiment_score": "0.127755",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.223179",
                    "ticker_sentiment_score": "-0.095741",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NOW",
                    "relevance_score": "0.075279",
                    "ticker_sentiment_score": "0.031255",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LRCX",
                    "relevance_score": "0.112709",
                    "ticker_sentiment_score": "0.034088",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AXP",
                    "relevance_score": "0.112709",
                    "ticker_sentiment_score": "0.206348",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Is Vanguard International Dividend Appreciation ETF  ( VIGI )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2215496/is-vanguard-international-dividend-appreciation-etf-vigi-a-strong-etf-right-now",
            "time_published": "20240125T112007",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default302.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999996"
                }
            ],
            "overall_sentiment_score": 0.264732,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.062761",
                    "ticker_sentiment_score": "0.263457",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVS",
                    "relevance_score": "0.062761",
                    "ticker_sentiment_score": "0.074019",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SAP",
                    "relevance_score": "0.125134",
                    "ticker_sentiment_score": "0.085209",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.062761",
                    "ticker_sentiment_score": "0.074019",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Top 10 blockbuster drugs that will become off-patent in 2024",
            "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/top-10-blockbuster-drugs-that-will-become-off-patent-in-2024/3375195/",
            "time_published": "20240125T105440",
            "authors": [
                "Sushmita Panda"
            ],
            "summary": "Drug patent, Drug patent 2024, Novo Nordisk, AstraZeneca, healthcare news, pharma news, - Pharma News The Financial Express ...",
            "banner_image": "https://www.financialexpress.com/wp-content/uploads/2024/01/medicine-2449619_1280-1.jpg",
            "source": "The Financial Express",
            "category_within_source": "n/a",
            "source_domain": "www.financialexpress.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.148238,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.13459",
                    "ticker_sentiment_score": "0.076126",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EXEL",
                    "relevance_score": "0.045054",
                    "ticker_sentiment_score": "0.060819",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.089965",
                    "ticker_sentiment_score": "0.064792",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Drug-Eluting Balloons Global Market is Expected to Expand at a Healthy Growth Rate of ~8% by 2028, Predicts DelveInsight",
            "url": "https://www.prnewswire.com/news-releases/drug-eluting-balloons-global-market-is-expected-to-expand-at-a-healthy-growth-rate-of-8-by-2028-predicts-delveinsight-302042856.html",
            "time_published": "20240124T220100",
            "authors": [
                "LLP",
                "DelveInsight Business Research"
            ],
            "summary": "Drug-Eluting Balloons Global Market is Expected to Expand at a Healthy Growth Rate of ~8% by 2028, Predicts ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.170441,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "PGEN",
                    "relevance_score": "0.025985",
                    "ticker_sentiment_score": "0.033663",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GBLX",
                    "relevance_score": "0.025985",
                    "ticker_sentiment_score": "0.033663",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.025985",
                    "ticker_sentiment_score": "0.033663",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IONS",
                    "relevance_score": "0.025985",
                    "ticker_sentiment_score": "0.033663",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.025985",
                    "ticker_sentiment_score": "0.033663",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PHG",
                    "relevance_score": "0.025985",
                    "ticker_sentiment_score": "0.077292",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MESO",
                    "relevance_score": "0.025985",
                    "ticker_sentiment_score": "0.033663",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ATHXQ",
                    "relevance_score": "0.025985",
                    "ticker_sentiment_score": "0.033663",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SRDX",
                    "relevance_score": "0.051943",
                    "ticker_sentiment_score": "0.104731",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EWTX",
                    "relevance_score": "0.025985",
                    "ticker_sentiment_score": "0.033663",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LSTA",
                    "relevance_score": "0.025985",
                    "ticker_sentiment_score": "0.032293",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.025985",
                    "ticker_sentiment_score": "0.077292",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BCDA",
                    "relevance_score": "0.025985",
                    "ticker_sentiment_score": "0.033663",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TNYA",
                    "relevance_score": "0.025985",
                    "ticker_sentiment_score": "0.033663",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BSX",
                    "relevance_score": "0.051943",
                    "ticker_sentiment_score": "0.048943",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SANA",
                    "relevance_score": "0.025985",
                    "ticker_sentiment_score": "0.033663",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRDL",
                    "relevance_score": "0.025985",
                    "ticker_sentiment_score": "0.033663",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SCPH",
                    "relevance_score": "0.025985",
                    "ticker_sentiment_score": "0.033663",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.025985",
                    "ticker_sentiment_score": "0.033663",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PBIGF",
                    "relevance_score": "0.025985",
                    "ticker_sentiment_score": "0.033663",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WINT",
                    "relevance_score": "0.025985",
                    "ticker_sentiment_score": "0.033663",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LXRX",
                    "relevance_score": "0.025985",
                    "ticker_sentiment_score": "0.033663",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CYTK",
                    "relevance_score": "0.025985",
                    "ticker_sentiment_score": "0.033663",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ITCI",
                    "relevance_score": "0.025985",
                    "ticker_sentiment_score": "0.033663",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.025985",
                    "ticker_sentiment_score": "0.033663",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TRUMF",
                    "relevance_score": "0.025985",
                    "ticker_sentiment_score": "0.077292",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSBHF",
                    "relevance_score": "0.025985",
                    "ticker_sentiment_score": "-0.084826",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FUJIF",
                    "relevance_score": "0.025985",
                    "ticker_sentiment_score": "0.033663",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.025985",
                    "ticker_sentiment_score": "0.033663",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EVO",
                    "relevance_score": "0.025985",
                    "ticker_sentiment_score": "0.033663",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Weight Loss Drug's Ozempic Counterfeit: Rising Reports Over Patient Safety Related Fake Drugs - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/24/01/36765784/weight-loss-drugs-ozempic-counterfeit-rising-reports-over-patient-safety-related-fake-drugs",
            "time_published": "20240124T192152",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Three individuals sought medical attention for dangerously low blood sugar in the U.S. in the previous year, having taken suspected fake versions of Novo Nordisk A/S's NVO diabetes medication, Ozempic ( semaglutide ) , according to the American Association of Poison Control Centers ( AAPCC ) .",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/OZempic-Insulin.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.316647,
            "overall_sentiment_label": "Somewhat-Bearish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.204072",
                    "ticker_sentiment_score": "-0.163204",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.56217",
                    "ticker_sentiment_score": "-0.381676",
                    "ticker_sentiment_label": "Bearish"
                }
            ]
        },
        {
            "title": "Jasper Therapeutics  ( JSPR )  Surges 110% in a Month: Here's Why",
            "url": "https://www.zacks.com/stock/news/2215186/jasper-therapeutics-jspr-surges-110-in-a-month-heres-why",
            "time_published": "20240124T171400",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Jasper Therapeutics (JSPR) surges after it provides business updates that highlight the company's progress with its pipeline. Multiple data readouts are expected throughout this year.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972193"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.054607,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "JSPR",
                    "relevance_score": "0.343619",
                    "ticker_sentiment_score": "0.157513",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CTMX",
                    "relevance_score": "0.249361",
                    "ticker_sentiment_score": "-0.020937",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SRPT",
                    "relevance_score": "0.101154",
                    "ticker_sentiment_score": "0.043569",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.200688",
                    "ticker_sentiment_score": "0.12085",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Stock Of The Day Lilly Is In A Buy Zone. And It's Not Related To Obesity.",
            "url": "https://www.investors.com/research/ibd-stock-of-the-day/eli-lilly-stock-rallies-into-buy-zone-on-surprising-results-in-treating-deafness/",
            "time_published": "20240124T171200",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "Eli Lilly Stock Rallies Into Buy Zone On Surprising Results In Treating Deafness Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/SOTD-1-24-2024LLY.png",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.962106"
                }
            ],
            "overall_sentiment_score": 0.053361,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.55533",
                    "ticker_sentiment_score": "0.145116",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AKUS",
                    "relevance_score": "0.151539",
                    "ticker_sentiment_score": "0.063005",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.151539",
                    "ticker_sentiment_score": "-0.049141",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.101367",
                    "ticker_sentiment_score": "-0.043919",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novartis  ( NVS )  to Report Q4 Earnings: Is a Beat in Store?",
            "url": "https://www.zacks.com/stock/news/2215142/novartis-nvs-to-report-q4-earnings-is-a-beat-in-store",
            "time_published": "20240124T163900",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novartis' (NVS) key drugs, Entresto, Kisqali and Pluvicto, are likely to have fueled its top and bottom-line numbers in the fourth quarter.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b7/2350.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999999"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.255301,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GSK",
                    "relevance_score": "0.1437",
                    "ticker_sentiment_score": "0.066641",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.190793",
                    "ticker_sentiment_score": "0.108368",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVS",
                    "relevance_score": "0.282777",
                    "ticker_sentiment_score": "0.262345",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Tech Futures Rally As Netflix Surges",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-as-netflix-surges-on-earnings-tesla-earnings-next/",
            "time_published": "20240124T131500",
            "authors": [
                "Investor's Business Daily",
                "SCOTT LEHTONEN"
            ],
            "summary": "Dow Jones Futures Rise As Netflix Surges On Earnings. Tesla Earnings Next Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2022/06/Stock-elonmusk-14-shutt.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.714479"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.157042,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "DKNG",
                    "relevance_score": "0.172713",
                    "ticker_sentiment_score": "0.175184",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.08687",
                    "ticker_sentiment_score": "0.035937",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MELI",
                    "relevance_score": "0.214937",
                    "ticker_sentiment_score": "0.195819",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.043499",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.08687",
                    "ticker_sentiment_score": "0.053432",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPOT",
                    "relevance_score": "0.214937",
                    "ticker_sentiment_score": "0.096366",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNOW",
                    "relevance_score": "0.172713",
                    "ticker_sentiment_score": "0.04812",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.172713",
                    "ticker_sentiment_score": "0.106914",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AXP",
                    "relevance_score": "0.172713",
                    "ticker_sentiment_score": "0.219604",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.043499",
                    "ticker_sentiment_score": "0.114787",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.172713",
                    "ticker_sentiment_score": "0.111839",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Team Novo Nordisk announce exciting collaboration with Ekoï for 2024",
            "url": "https://www.benzinga.com/pressreleases/24/01/n36753290/team-novo-nordisk-announce-exciting-collaboration-with-eko-for-2024",
            "time_published": "20240124T100000",
            "authors": [
                "PRNewswire"
            ],
            "summary": "Team Novo Nordisk athletes will race in Ekoï helmets and eyewear for the coming season.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.301862,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.692877",
                    "ticker_sentiment_score": "0.535072",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Airfinity launches world's first obesity data and analytics platform",
            "url": "https://www.benzinga.com/pressreleases/24/01/g36753281/airfinity-launches-worlds-first-obesity-data-and-analytics-platform",
            "time_published": "20240124T095709",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "London, England, Jan. 24, 2024 ( GLOBE NEWSWIRE ) -- Today, Airfinity is launching the world's first data and analytics platform dedicated to the breakthrough obesity treatments market.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.227109,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.105604",
                    "ticker_sentiment_score": "0.028772",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Inhibrx  ( INBX )  Up 6% on Sale of Rare Disease Drug to Sanofi",
            "url": "https://www.zacks.com/stock/news/2214518/inhibrx-inbx-up-6-on-sale-of-rare-disease-drug-to-sanofi",
            "time_published": "20240123T193000",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Sanofi (SNY) will acquire Inhibrx (INBX) for nearly $2.2 billion. Post-acquisition, it will retain the rare disease drug and spin out all other pipeline programs into a newly-traded public company.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.890401"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.139567,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "INBX",
                    "relevance_score": "0.716023",
                    "ticker_sentiment_score": "0.337321",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CTMX",
                    "relevance_score": "0.279015",
                    "ticker_sentiment_score": "-0.022981",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.169676",
                    "ticker_sentiment_score": "0.119393",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.567965",
                    "ticker_sentiment_score": "0.248232",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "J&J's  ( JNJ )  Q4 Earnings Beat, Darzalex, Stelara Drive Sales",
            "url": "https://www.zacks.com/stock/news/2214342/jjs-jnj-q4-earnings-beat-darzalex-stelara-drive-sales",
            "time_published": "20240123T160300",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sales of several key drugs like Darzalex, Stelara and Tremfya beat estimates.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                }
            ],
            "overall_sentiment_score": 0.19171,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.06623",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.06623",
                    "ticker_sentiment_score": "0.067094",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.099202",
                    "ticker_sentiment_score": "0.041704",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.099202",
                    "ticker_sentiment_score": "0.059246",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Futures Mixed After Earnings Reports",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-big-earnings-reports-magnificent-seven-stock-netflix-to-report-next/",
            "time_published": "20240123T131200",
            "authors": [
                "Investor's Business Daily",
                "SCOTT LEHTONEN"
            ],
            "summary": "Dow Jones Futures Fall On Big Earnings Reports. Magnificent Seven Stock Netflix To Report Next Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2017/04/stock-wallstreet-shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                }
            ],
            "overall_sentiment_score": 0.161722,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "DKNG",
                    "relevance_score": "0.170576",
                    "ticker_sentiment_score": "0.215034",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.170576",
                    "ticker_sentiment_score": "0.08804",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.042953",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UAL",
                    "relevance_score": "0.085782",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPOT",
                    "relevance_score": "0.212301",
                    "ticker_sentiment_score": "0.165004",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VZ",
                    "relevance_score": "0.128363",
                    "ticker_sentiment_score": "0.0644",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.170576",
                    "ticker_sentiment_score": "0.224647",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.085782",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AWON",
                    "relevance_score": "0.042953",
                    "ticker_sentiment_score": "0.044623",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.042953",
                    "ticker_sentiment_score": "0.118591",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.170576",
                    "ticker_sentiment_score": "0.096618",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MELI",
                    "relevance_score": "0.212301",
                    "ticker_sentiment_score": "0.251407",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HAL",
                    "relevance_score": "0.128363",
                    "ticker_sentiment_score": "0.031178",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.042953",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PG",
                    "relevance_score": "0.128363",
                    "ticker_sentiment_score": "0.0644",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AXP",
                    "relevance_score": "0.170576",
                    "ticker_sentiment_score": "0.166315",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ISRG",
                    "relevance_score": "0.128363",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.170576",
                    "ticker_sentiment_score": "0.150137",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GE",
                    "relevance_score": "0.128363",
                    "ticker_sentiment_score": "0.031178",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "5 Momentum Stocks to Buy Ahead of Earnings Results",
            "url": "https://www.zacks.com/stock/news/2213962/5-momentum-stocks-to-buy-ahead-of-earnings-results",
            "time_published": "20240123T122600",
            "authors": [
                "Nalak Das"
            ],
            "summary": "We have narrowed our search to five momentum stocks that are poised to beat on earnings results next week. These are: BEN, NVO, CPA, CRS, JHG.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/1948.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.980922"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.241548,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JHG",
                    "relevance_score": "0.28305",
                    "ticker_sentiment_score": "0.205119",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BEN",
                    "relevance_score": "0.143843",
                    "ticker_sentiment_score": "0.116387",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CPA",
                    "relevance_score": "0.214304",
                    "ticker_sentiment_score": "0.191928",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CRS",
                    "relevance_score": "0.28305",
                    "ticker_sentiment_score": "0.274264",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.214304",
                    "ticker_sentiment_score": "0.211512",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "2 Monster Stocks to Buy Without Any Hesitation",
            "url": "https://www.fool.com/investing/2024/01/23/2-monster-stocks-to-buy-without-any-hesitation/",
            "time_published": "20240123T110000",
            "authors": [
                "Adria Cimino"
            ],
            "summary": "These stocks both could deliver great rewards over time.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F762141%2Fgettyimages-468679176.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.99246"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.321362,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.551295",
                    "ticker_sentiment_score": "0.204225",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.060388",
                    "ticker_sentiment_score": "0.065101",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.504646",
                    "ticker_sentiment_score": "0.53287",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.120431",
                    "ticker_sentiment_score": "0.013032",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Jim Cramer Says Eli Lilly Could Replace Tesla In 'Magnificent Seven' List: 'To Ignore...Is To Reject The Facts' - Apple  ( NASDAQ:AAPL ) , Amazon.com  ( NASDAQ:AMZN ) ",
            "url": "https://www.benzinga.com/markets/equities/24/01/36729974/jim-cramer-says-eli-lilly-could-replace-tesla-in-magnificent-seven-list-to-ignore-is-to-reject-t",
            "time_published": "20240123T030212",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "Jim Cramer, the host of CNBC's \"Mad Money,\" has hinted at the possibility of Tesla Inc TSLA being replaced by Eli Lilly and Co LLY in the \"Magnificent Seven\" list of mega-cap stocks.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Jim-Cramer-Photo-by-s-bukley-on-Shutters_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.132447,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.18602",
                    "ticker_sentiment_score": "0.24853",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.18602",
                    "ticker_sentiment_score": "0.24853",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.18602",
                    "ticker_sentiment_score": "0.24853",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.18602",
                    "ticker_sentiment_score": "0.24853",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.18602",
                    "ticker_sentiment_score": "0.24853",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.589793",
                    "ticker_sentiment_score": "0.050007",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GM",
                    "relevance_score": "0.18602",
                    "ticker_sentiment_score": "-0.151246",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.18602",
                    "ticker_sentiment_score": "0.254895",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.589793",
                    "ticker_sentiment_score": "0.144922",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HTZ",
                    "relevance_score": "0.18602",
                    "ticker_sentiment_score": "-0.151246",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  Stock Dips While Market Gains: Key Facts",
            "url": "https://www.zacks.com/stock/news/2213778/novo-nordisk-nvo-stock-dips-while-market-gains-key-facts",
            "time_published": "20240122T225020",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) reachead $105.49 at the closing of the latest trading day, reflecting a -1.37% change compared to its last close.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default67.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.95493"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.269115,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.488777",
                    "ticker_sentiment_score": "0.369631",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer",
            "url": "https://www.prnewswire.com/news-releases/non-alcoholic-fatty-liver-disease-market-to-observe-impressive-growth-by-2032-evaluates-delveinsight--key-companies---medicinova-eli-lilly-and-company-astrazeneca-madrigal-pharmaceuticals-biomarin-pharmaceutical-glaxosmithk-302040349.html",
            "time_published": "20240122T220100",
            "authors": [
                "DelveInsight Business Research",
                "LLP"
            ],
            "summary": "Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.071985,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ETNB",
                    "relevance_score": "0.043381",
                    "ticker_sentiment_score": "0.059524",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GALT",
                    "relevance_score": "0.065032",
                    "ticker_sentiment_score": "0.043043",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INHD",
                    "relevance_score": "0.043381",
                    "ticker_sentiment_score": "0.059524",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.065032",
                    "ticker_sentiment_score": "0.043043",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALGS",
                    "relevance_score": "0.043381",
                    "ticker_sentiment_score": "0.059524",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALT",
                    "relevance_score": "0.043381",
                    "ticker_sentiment_score": "0.059524",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IONS",
                    "relevance_score": "0.065032",
                    "ticker_sentiment_score": "0.043043",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TERN",
                    "relevance_score": "0.065032",
                    "ticker_sentiment_score": "0.043043",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LPCN",
                    "relevance_score": "0.065032",
                    "ticker_sentiment_score": "0.043043",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.086634",
                    "ticker_sentiment_score": "0.066999",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HEPA",
                    "relevance_score": "0.065032",
                    "ticker_sentiment_score": "0.079121",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.065032",
                    "ticker_sentiment_score": "0.043043",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMRN",
                    "relevance_score": "0.021699",
                    "ticker_sentiment_score": "0.088332",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.065032",
                    "ticker_sentiment_score": "0.079121",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GLMD",
                    "relevance_score": "0.065032",
                    "ticker_sentiment_score": "0.043043",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SGMT",
                    "relevance_score": "0.021699",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GSK",
                    "relevance_score": "0.043381",
                    "ticker_sentiment_score": "0.059524",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CMMB",
                    "relevance_score": "0.065032",
                    "ticker_sentiment_score": "0.043043",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BGNE",
                    "relevance_score": "0.021699",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ORMP",
                    "relevance_score": "0.021699",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HSTO",
                    "relevance_score": "0.043381",
                    "ticker_sentiment_score": "0.059524",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALNY",
                    "relevance_score": "0.065032",
                    "ticker_sentiment_score": "0.043043",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MNOV",
                    "relevance_score": "0.043381",
                    "ticker_sentiment_score": "0.065823",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.043381",
                    "ticker_sentiment_score": "0.059524",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MTCR",
                    "relevance_score": "0.021699",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.086634",
                    "ticker_sentiment_score": "0.066999",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVA",
                    "relevance_score": "0.086634",
                    "ticker_sentiment_score": "0.066999",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ENTA",
                    "relevance_score": "0.021699",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AKRO",
                    "relevance_score": "0.086634",
                    "ticker_sentiment_score": "0.066999",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSBHF",
                    "relevance_score": "0.021699",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GILD",
                    "relevance_score": "0.043381",
                    "ticker_sentiment_score": "0.059524",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "AstraZeneca's  ( AZN )  Imfinzi Combo Meets Liver Cancer Study Goal",
            "url": "https://www.zacks.com/stock/news/2213719/astrazenecas-azn-imfinzi-combo-meets-liver-cancer-study-goal",
            "time_published": "20240122T194200",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Data from a late-stage shows that AstraZeneca's (AZN) cancer combination therapy reduces the risk of disease progression or death in certain liver cancer patients by 23%.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972193"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.043259,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CTMX",
                    "relevance_score": "0.234458",
                    "ticker_sentiment_score": "-0.018104",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.488217",
                    "ticker_sentiment_score": "0.130886",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SRPT",
                    "relevance_score": "0.09495",
                    "ticker_sentiment_score": "0.040773",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.18856",
                    "ticker_sentiment_score": "0.113845",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why WW International Stock Bounced 6% Higher Today",
            "url": "https://www.fool.com/investing/2024/01/22/why-weight-watchers-stock-bounced-6-higher-today/",
            "time_published": "20240122T192000",
            "authors": [
                "Rich Smith"
            ],
            "summary": "Morgan Stanley points out that there's still hope for the company formerly known as Weight Watchers.",
            "banner_image": "https://g.foolcdn.com/editorial/images/762189/man-stands-on-a-weight-scale-with-a-flexible-ruler-in-the-foreground.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.744043"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.111959,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WW",
                    "relevance_score": "0.709186",
                    "ticker_sentiment_score": "-0.218853",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.327366",
                    "ticker_sentiment_score": "-0.041329",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.084127",
                    "ticker_sentiment_score": "-0.19066",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "European Drug Regulator To Consider Expanded Use Of Novo Nordisk's Wegovy Weight-Loss Drug - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/24/01/36722609/european-drug-regulator-to-consider-expanded-use-of-novo-nordisks-wegovy-weight-loss-drug",
            "time_published": "20240122T190745",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "The European Medicines Agency ( EMA ) is set to discuss extending the application of Novo Nordisk A/S's NVO weight loss drug, Wegovy ( semaglutide ) , to include the reduction of stroke and heart attack risks.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Wegovy_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.002437,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "JPM",
                    "relevance_score": "0.156461",
                    "ticker_sentiment_score": "0.002678",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.67628",
                    "ticker_sentiment_score": "-0.030614",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Edgewise  ( EWTX )  Rallies 35% on Issue of New Common Stock",
            "url": "https://www.zacks.com/stock/news/2213712/edgewise-ewtx-rallies-35-on-issue-of-new-common-stock",
            "time_published": "20240122T190600",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Edgewise (EWTX) will issue secondary shares to raise $240 million in gross proceeds. The capital will be used to fund key initiatives, including the potential commercial launch of lead pipeline drugs.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972193"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.149,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CTMX",
                    "relevance_score": "0.265089",
                    "ticker_sentiment_score": "-0.021985",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SRPT",
                    "relevance_score": "0.107736",
                    "ticker_sentiment_score": "0.042241",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EWTX",
                    "relevance_score": "0.315493",
                    "ticker_sentiment_score": "0.201876",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.213517",
                    "ticker_sentiment_score": "0.123528",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Highlights From the 2024 JPMorgan Health Care Conference",
            "url": "https://www.fool.com/investing/2024/01/22/highlights-from-the-2024-jpmorgan-health-care-conf/",
            "time_published": "20240122T183900",
            "authors": [
                "Motley Fool Staff"
            ],
            "summary": "Weight loss drugs are taking center spotlight, but other developing treatments could change how we live.",
            "banner_image": "https://g.foolcdn.com/editorial/images/762063/mfm_0120.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.744043"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.116608,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.039532",
                    "ticker_sentiment_score": "0.033798",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.009887",
                    "ticker_sentiment_score": "-0.122802",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.019772",
                    "ticker_sentiment_score": "0.081833",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.009887",
                    "ticker_sentiment_score": "-0.122802",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.019772",
                    "ticker_sentiment_score": "0.091155",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BNTX",
                    "relevance_score": "0.029654",
                    "ticker_sentiment_score": "0.09583",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVCR",
                    "relevance_score": "0.019772",
                    "ticker_sentiment_score": "0.0243",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GPCR",
                    "relevance_score": "0.009887",
                    "ticker_sentiment_score": "0.082574",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.019772",
                    "ticker_sentiment_score": "0.081056",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ESALF",
                    "relevance_score": "0.009887",
                    "ticker_sentiment_score": "0.057158",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GE",
                    "relevance_score": "0.019772",
                    "ticker_sentiment_score": "0.036967",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.009887",
                    "ticker_sentiment_score": "0.057158",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.009887",
                    "ticker_sentiment_score": "0.08523",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "JNJ: Johnson & Johnson  ( JNJ ) : Analyzing Signals Before Quarterly Earnings",
            "url": "https://stocknews.com/news/jnj-nvs-nvo-snphy-amam-johnson-johnson-jnj-analyzing-signals-before-quarterly-earnings/",
            "time_published": "20240122T181128",
            "authors": [
                "StockNews.com Staff"
            ],
            "summary": "Boasting a market cap of $389.21 billion, leading pharma giant Johnson & Johnson ( JNJ ) is all set to lift the curtains on its fourth-quarter results ( ended December 2023 ) on January 23, 2024. Thus, this article sheds light on the fundamentals of JNJ to determine the stock's worthiness as an ...",
            "banner_image": "https://stocknews.com/wp-content/uploads/2023/06/Anushka-Mukherjee_Headshot-2.jpg",
            "source": "Stocknews.com",
            "category_within_source": "n/a",
            "source_domain": "stocknews.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.623304"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.87644"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.240609,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVS",
                    "relevance_score": "0.080593",
                    "ticker_sentiment_score": "0.113018",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNPHF",
                    "relevance_score": "0.040348",
                    "ticker_sentiment_score": "0.10791",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMAM",
                    "relevance_score": "0.080593",
                    "ticker_sentiment_score": "-0.124994",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.080593",
                    "ticker_sentiment_score": "0.113018",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.55206",
                    "ticker_sentiment_score": "0.312855",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Will the Individual MA Unit Aid Humana's  ( HUM )  Q4 Earnings?",
            "url": "https://www.zacks.com/stock/news/2213681/will-the-individual-ma-unit-aid-humanas-hum-q4-earnings",
            "time_published": "20240122T173600",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Humana's (HUM) Q4 results are likely to gain from growing premiums and an expanding customer base within its individual Medicare Advantage and Medicaid units, partly offset by higher marketing spend.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/55/1345.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.99998"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.257244,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "HUM",
                    "relevance_score": "0.471156",
                    "ticker_sentiment_score": "0.282046",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.091162",
                    "ticker_sentiment_score": "0.096622",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SGRY",
                    "relevance_score": "0.13637",
                    "ticker_sentiment_score": "0.126359",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.091162",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/insights/news/24/01/36720411/heres-how-much-you-would-have-made-owning-novo-nordisk-stock-in-the-last-10-years",
            "time_published": "20240122T173039",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Novo Nordisk NVO has outperformed the market over the past 10 years by 8.36% on an annualized basis producing an average annual return of 18.8%. Currently, Novo Nordisk has a market capitalization of $473.95 billion.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.160819,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.980595",
                    "ticker_sentiment_score": "0.386944",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S - share repurchase programme",
            "url": "https://www.globenewswire.com/news-release/2024/01/22/2812915/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html",
            "time_published": "20240122T120100",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 22 January 2024 - On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.122936,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.045242",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.045242",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.781591",
                    "ticker_sentiment_score": "0.195779",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Got $1,000? 3 Growth Stocks to Buy That Could Double Your Money",
            "url": "https://www.fool.com/investing/2024/01/22/got-1000-3-growth-stocks-to-buy-that-could-double/",
            "time_published": "20240122T104700",
            "authors": [
                "Justin Pope"
            ],
            "summary": "Healthcare is nearly a fifth of America's economy. Ride these high-flying healthcare stocks to monster gains.",
            "banner_image": "https://media.ycharts.com/charts/4bc5ce180ba5a010c3cf9919ef5bb208.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.998932"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.339046,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "HIMS",
                    "relevance_score": "0.104002",
                    "ticker_sentiment_score": "0.090383",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.206245",
                    "ticker_sentiment_score": "0.208971",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.206245",
                    "ticker_sentiment_score": "0.132559",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "2024: Five big global trends affecting lives and buisnesses - ETCFO",
            "url": "https://cfo.economictimes.indiatimes.com/news/economy/2024-five-big-global-trends-affecting-lives-and-buisnesses/107050372",
            "time_published": "20240122T101540",
            "authors": [
                "ETCFO",
                "Robin Banerjee"
            ],
            "summary": "In yet another article on 2024 trends, Robin Banerjee, a seasoned financial expert deep dives into global megatrends that would redefine, as he eloquently puts it, \"mankind's domain - the earth.\" ...",
            "banner_image": "https://cfo.economictimes.indiatimes.com/Themes/Release/images/responsive/etcfo-default.jpg",
            "source": "Economic Times",
            "category_within_source": "Top Stories",
            "source_domain": "cfo.economictimes.indiatimes.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                }
            ],
            "overall_sentiment_score": 0.082532,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.023885",
                    "ticker_sentiment_score": "0.048926",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Little-Known Biotech Company Shows How Hard It Is To Ride The Ozempic Wave",
            "url": "https://www.forbes.com/sites/johnkang/2024/01/21/little-known-biotech-company-shows-how-hard-it-is-to-ride-the-ozempic-wave/",
            "time_published": "20240122T030041",
            "authors": [
                "John Kang"
            ],
            "summary": "Shares of Korea-listed Caregen surged on hope its diabetes-weight loss supplement could give the little-known biotech company an Ozempic-like boost. But then the stock crashed.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65a8fe6352659d2a5930c678/0x0.jpg?format=jpg&crop=1920,1080,x0,y0,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.961735"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.858979"
                }
            ],
            "overall_sentiment_score": 0.085989,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.096283",
                    "ticker_sentiment_score": "0.080917",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.024126",
                    "ticker_sentiment_score": "0.187772",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.024126",
                    "ticker_sentiment_score": "0.187772",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Prediction: This Will Be the First Trillion-Dollar Healthcare Stock",
            "url": "https://www.fool.com/investing/2024/01/21/prediction-this-will-be-the-first-trillion-dollar/",
            "time_published": "20240121T160200",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "This company is currently firing on all cylinders.",
            "banner_image": "https://g.foolcdn.com/editorial/images/761056/doctor-with-patient-talking.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.267579,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.637818",
                    "ticker_sentiment_score": "0.397667",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.220809",
                    "ticker_sentiment_score": "0.191225",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.220809",
                    "ticker_sentiment_score": "0.213931",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.166551",
                    "ticker_sentiment_score": "0.132619",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Can TikTok Do for Peloton What It Did for Novo Nordisk and Ozempic?",
            "url": "https://www.fool.com/investing/2024/01/21/can-tiktok-do-for-peloton-what-it-did-for-novo-nor/",
            "time_published": "20240121T065900",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Peloton has been struggling to generate growth in recent periods. Can TikTok help turn that around?",
            "banner_image": "https://g.foolcdn.com/editorial/images/761249/team-of-traders-working-in-an-office.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.538269"
                }
            ],
            "overall_sentiment_score": 0.126909,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.053629",
                    "ticker_sentiment_score": "0.090002",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PTON",
                    "relevance_score": "0.107016",
                    "ticker_sentiment_score": "-0.11217",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here's What Investors Should Expect From Eli Lilly Stock in 2024",
            "url": "https://www.fool.com/investing/2024/01/20/heres-what-investors-should-expect-from-eli-lilly/",
            "time_published": "20240120T212900",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "More headlines on the horizon.",
            "banner_image": "https://g.foolcdn.com/editorial/images/761474/investors-watch-a-presentation-around-a-table.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.243767,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.544246",
                    "ticker_sentiment_score": "0.335515",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.066047",
                    "ticker_sentiment_score": "0.110251",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 High-Flying Stocks That Could Soar Even More in 2024",
            "url": "https://www.fool.com/investing/2024/01/20/3-high-flying-stocks-that-could-soar-even-more-in/",
            "time_published": "20240120T115000",
            "authors": [
                "David Jagielski",
                "Keith Speights",
                "and Prosper Junior Bakiny"
            ],
            "summary": "These big winners could keep the momentum going.",
            "banner_image": "https://g.foolcdn.com/editorial/images/761822/dna-on-monitor-scientists.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.87644"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.284698,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.260652",
                    "ticker_sentiment_score": "0.195213",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.044222",
                    "ticker_sentiment_score": "0.26179",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.044222",
                    "ticker_sentiment_score": "0.056817",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.30211",
                    "ticker_sentiment_score": "0.160317",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.044222",
                    "ticker_sentiment_score": "-0.005924",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "TransCode  ( RNAZ )  Down 50% on Issue of New Common Stock",
            "url": "https://www.zacks.com/stock/news/2213010/transcode-rnaz-down-50-on-issue-of-new-common-stock",
            "time_published": "20240119T180900",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "TransCode Therapeutics (RNAZ) will issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $7.5 million in gross proceeds from this issue.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972193"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.972756"
                }
            ],
            "overall_sentiment_score": 0.066624,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CTMX",
                    "relevance_score": "0.291644",
                    "ticker_sentiment_score": "-0.023738",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RNAZ",
                    "relevance_score": "0.34648",
                    "ticker_sentiment_score": "0.176745",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SRPT",
                    "relevance_score": "0.11894",
                    "ticker_sentiment_score": "0.043817",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.235252",
                    "ticker_sentiment_score": "0.133405",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "ADC Therapeutics  ( ADCT )  Rises 43% in a Month: Here's Why",
            "url": "https://www.zacks.com/stock/news/2213007/adc-therapeutics-adct-rises-43-in-a-month-heres-why",
            "time_published": "20240119T180500",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "ADC Therapeutics (ADCT) surges after it provides business updates that highlight the company's progress with its pipeline. Multiple data readouts are expected throughout this year.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972193"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Blockchain",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.115308,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ADCT",
                    "relevance_score": "0.523044",
                    "ticker_sentiment_score": "0.26941",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CTMX",
                    "relevance_score": "0.253514",
                    "ticker_sentiment_score": "-0.021218",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SRPT",
                    "relevance_score": "0.102888",
                    "ticker_sentiment_score": "0.043781",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.204072",
                    "ticker_sentiment_score": "0.122408",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:DLT",
                    "relevance_score": "0.051551",
                    "ticker_sentiment_score": "0.026922",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Best Growth Stocks to Buy for January 19th",
            "url": "https://www.zacks.com/commentary/2211318/best-growth-stocks-to-buy-for-january-19th",
            "time_published": "20240119T140400",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "ARCO, NVO and ENS made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 19, 2024.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ce/43337.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.173113,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ARCO",
                    "relevance_score": "0.764552",
                    "ticker_sentiment_score": "0.240241",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ENS",
                    "relevance_score": "0.388879",
                    "ticker_sentiment_score": "0.098693",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDNDF",
                    "relevance_score": "0.13459",
                    "ticker_sentiment_score": "0.061929",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.764552",
                    "ticker_sentiment_score": "0.188138",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Weightloss Drugs Ozempic And Wegovy's Success Sets Novo Nordisk's Owner To Utilize Dividend Windfall For Strategic Investments - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/24/01/36694255/weightloss-drugs-ozempic-and-wegovys-success-sets-novo-nordisks-owner-to-utilize-dividend-windfal",
            "time_published": "20240119T133007",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "In a recent interview, Kasim Kutay, Chief Executive Officer of Novo Holdings, announced the company's ambitious plans for further acquisitions and investments, particularly in Asia. As the main owner of Novo Nordisk A/S NVO, Novo Holdings, holding 77% of the votes, is gearing up for an active ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Wegovy.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.212408,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.644033",
                    "ticker_sentiment_score": "0.206861",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Futures Higher Ahead Of Inflation Reading",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-inflation-survey-nvidia-stock-jumps-to-record-highs/",
            "time_published": "20240119T132000",
            "authors": [
                "Investor's Business Daily",
                "SCOTT LEHTONEN"
            ],
            "summary": "Dow Jones Futures Rise Ahead Of Key Inflation Survey. Nvidia Stock Jumps To Record High Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2017/03/stock-wallstreet-031317-shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.149051,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DKNG",
                    "relevance_score": "0.168785",
                    "ticker_sentiment_score": "0.19166",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.210092",
                    "ticker_sentiment_score": "0.059294",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPOT",
                    "relevance_score": "0.210092",
                    "ticker_sentiment_score": "0.163677",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ALLY",
                    "relevance_score": "0.084871",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.168785",
                    "ticker_sentiment_score": "0.177965",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SLB",
                    "relevance_score": "0.127007",
                    "ticker_sentiment_score": "0.049738",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.042496",
                    "ticker_sentiment_score": "0.118454",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.168785",
                    "ticker_sentiment_score": "0.139559",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MELI",
                    "relevance_score": "0.210092",
                    "ticker_sentiment_score": "0.169643",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "STT",
                    "relevance_score": "0.127007",
                    "ticker_sentiment_score": "0.049738",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.042496",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RF",
                    "relevance_score": "0.127007",
                    "ticker_sentiment_score": "0.049738",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CMA",
                    "relevance_score": "0.127007",
                    "ticker_sentiment_score": "0.049738",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AXP",
                    "relevance_score": "0.168785",
                    "ticker_sentiment_score": "0.182147",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.168785",
                    "ticker_sentiment_score": "0.151911",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "The daily business briefing: January 19, 2024",
            "url": "https://theweek.com/business/the-daily-business-briefing-january-19-2024",
            "time_published": "20240119T130156",
            "authors": [
                "Harold Maass",
                "The Week US"
            ],
            "summary": "1. Macy's to cut 2,350 jobs in streamlining effort 2. Congress averts a government shutdown 3. Drugmakers hiked prices in first 2 weeks of 2024 4. Stock futures rise after Thursday's Apple-fueled tech gains 5. iRobot shares drop after report of EU opposition to acquisition by Amazon",
            "banner_image": "https://cdn.mos.cms.futurecdn.net/jsHTFozzBqDFrXPJLdtBcV-415-80.jpg",
            "source": "The Week News",
            "category_within_source": "n/a",
            "source_domain": "theweek.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.055417,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.032691",
                    "ticker_sentiment_score": "0.24442",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.032691",
                    "ticker_sentiment_score": "0.13585",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.032691",
                    "ticker_sentiment_score": "0.013238",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NYT",
                    "relevance_score": "0.032691",
                    "ticker_sentiment_score": "0.006789",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NKE",
                    "relevance_score": "0.032691",
                    "ticker_sentiment_score": "0.020481",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.032691",
                    "ticker_sentiment_score": "0.044177",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "M",
                    "relevance_score": "0.162364",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOX",
                    "relevance_score": "0.032691",
                    "ticker_sentiment_score": "0.059981",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FRNWF",
                    "relevance_score": "0.032691",
                    "ticker_sentiment_score": "0.05524",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WBD",
                    "relevance_score": "0.065327",
                    "ticker_sentiment_score": "0.001009",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IRBT",
                    "relevance_score": "0.032691",
                    "ticker_sentiment_score": "0.023315",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.097854",
                    "ticker_sentiment_score": "-0.062961",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.032691",
                    "ticker_sentiment_score": "-0.035826",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "10 things you need to know today: January 19, 2024",
            "url": "https://theweek.com/digest/round-up/10-things-you-need-to-know-today-january-19-2024",
            "time_published": "20240119T121342",
            "authors": [
                "The Week US",
                "Harold Maass"
            ],
            "summary": "1. Congress averts a government shutdown 2. DOJ report finds 'cascading failures' during Texas school shooting 3. Netanyahu opposes Palestinian state in postwar Gaza 4. Defamation trial judge shuts down Trump lawyer 5. Biden says strikes against Houthis will continue",
            "banner_image": "https://cdn.mos.cms.futurecdn.net/hrKWLNBNHdWJjoXumRuHhh-415-80.jpg",
            "source": "The Week News",
            "category_within_source": "n/a",
            "source_domain": "theweek.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": -0.101223,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "FRNWF",
                    "relevance_score": "0.020686",
                    "ticker_sentiment_score": "0.051465",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LMT",
                    "relevance_score": "0.020686",
                    "ticker_sentiment_score": "-0.016863",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.020686",
                    "ticker_sentiment_score": "0.013243",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NYT",
                    "relevance_score": "0.020686",
                    "ticker_sentiment_score": "-0.012762",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WBD",
                    "relevance_score": "0.020686",
                    "ticker_sentiment_score": "-0.016863",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOX",
                    "relevance_score": "0.020686",
                    "ticker_sentiment_score": "0.055923",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.020686",
                    "ticker_sentiment_score": "-0.016863",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Eli Lilly Stock Tumbled on Thursday",
            "url": "https://www.fool.com/investing/2024/01/18/why-eli-lilly-stock-tumbled-on-thursday/",
            "time_published": "20240118T233601",
            "authors": [
                "Eric Volkman"
            ],
            "summary": "Investors were a bit concerned about an industrywide move.",
            "banner_image": "https://g.foolcdn.com/editorial/images/761845/medical-professionals-conferring-in-a-hospial-corridor.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.109739,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.428632",
                    "ticker_sentiment_score": "0.07204",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.149656",
                    "ticker_sentiment_score": "0.16529",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Alpha-1 Antitrypsin Deficiency Market to Register Incremental Growth by 2032, Assesses DelveInsight | Key Companies - Kamada Pharmaceuticals, Arrowhead Pharmaceuticals, Takeda, Mereo BioPharma, AstraZeneca, Inhibrx, Novo Nordisk",
            "url": "https://www.prnewswire.com/news-releases/alpha-1-antitrypsin-deficiency-market-to-register-incremental-growth-by-2032-assesses-delveinsight--key-companies---kamada-pharmaceuticals-arrowhead-pharmaceuticals-takeda-mereo-biopharma-astrazeneca-inhibrx-novo-nordisk-302038155.html",
            "time_published": "20240118T220100",
            "authors": [
                "LLP",
                "DelveInsight Business Research"
            ],
            "summary": "Alpha-1 Antitrypsin Deficiency Market to Register Incremental Growth by 2032, Assesses DelveInsight | Key ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.111042,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ARWR",
                    "relevance_score": "0.095044",
                    "ticker_sentiment_score": "0.027938",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.047607",
                    "ticker_sentiment_score": "0.031954",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.023814",
                    "ticker_sentiment_score": "0.037329",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CNTA",
                    "relevance_score": "0.023814",
                    "ticker_sentiment_score": "-0.018133",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WVE",
                    "relevance_score": "0.023814",
                    "ticker_sentiment_score": "-0.018133",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALNY",
                    "relevance_score": "0.047607",
                    "ticker_sentiment_score": "-0.02087",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.071357",
                    "ticker_sentiment_score": "0.032536",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GRFS",
                    "relevance_score": "0.023814",
                    "ticker_sentiment_score": "0.164769",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "INBX",
                    "relevance_score": "0.023814",
                    "ticker_sentiment_score": "0.037329",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MREO",
                    "relevance_score": "0.071357",
                    "ticker_sentiment_score": "0.040684",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KMDA",
                    "relevance_score": "0.023814",
                    "ticker_sentiment_score": "-0.020993",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "List Price Of Ozempic And Other Drugs Reportedly Rise: Here's What That Means For Consumers",
            "url": "https://www.forbes.com/sites/ariannajohnson/2024/01/18/list-price-of-ozempic-and-other-drugs-reportedly-rise-heres-what-that-means-for-consumers/",
            "time_published": "20240118T194930",
            "authors": [
                "Arianna Johnson"
            ],
            "summary": "Almost 800 medications-including Ozempic and Mounjaro-had a median list price increase of 4.5% this month, according to a Wall Street Journal report, meaning copays may increase for consumers.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/651ed914b753a9b834db1a57/0x0.jpg?format=jpg&crop=3317,1864,x0,y171,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.682689"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.061908,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.113329",
                    "ticker_sentiment_score": "0.068214",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GILD",
                    "relevance_score": "0.056808",
                    "ticker_sentiment_score": "0.046999",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.113329",
                    "ticker_sentiment_score": "0.052573",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.056808",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.113329",
                    "ticker_sentiment_score": "0.052573",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "MAIA Soars 20% on Interim Results From Lung Cancer Study",
            "url": "https://www.zacks.com/stock/news/2212386/maia-soars-20-on-interim-results-from-lung-cancer-study",
            "time_published": "20240118T180600",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "MAIA Biotechnology (MAIA) reports updated results from a mid-stage study. Patients treated with its lead drug achieved disease control rates that were well-sustained compared with previous scans.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.890401"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.004825,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.18343",
                    "ticker_sentiment_score": "0.131918",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTMX",
                    "relevance_score": "0.300946",
                    "ticker_sentiment_score": "-0.024438",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novartis'  ( NVS )  Strong Portfolio, Pipeline to Fuel Growth in 2024",
            "url": "https://www.zacks.com/stock/news/2212312/novartis-nvs-strong-portfolio-pipeline-to-fuel-growth-in-2024",
            "time_published": "20240118T171100",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novartis (NVS) is poised to outperform in 2024, backed by a diverse portfolio and a deep pipeline.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default174.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.838487"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.322222,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ALC",
                    "relevance_score": "0.108222",
                    "ticker_sentiment_score": "0.289381",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BLCO",
                    "relevance_score": "0.054236",
                    "ticker_sentiment_score": "0.128775",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CYTK",
                    "relevance_score": "0.16171",
                    "ticker_sentiment_score": "0.171706",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.108222",
                    "ticker_sentiment_score": "0.067357",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.16171",
                    "ticker_sentiment_score": "0.131658",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KDNY",
                    "relevance_score": "0.054236",
                    "ticker_sentiment_score": "0.088771",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  Upgraded to Strong Buy: What Does It Mean for the Stock?",
            "url": "https://www.zacks.com/stock/news/2212339/novo-nordisk-nvo-upgraded-to-strong-buy-what-does-it-mean-for-the-stock",
            "time_published": "20240118T170006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default241.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.997845"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.658903"
                }
            ],
            "overall_sentiment_score": 0.318166,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.360752",
                    "ticker_sentiment_score": "0.3527",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Why Novo Nordisk  ( NVO )  is a Top Momentum Stock for the Long-Term",
            "url": "https://www.zacks.com/stock/news/2212144/why-novo-nordisk-nvo-is-a-top-momentum-stock-for-the-long-term",
            "time_published": "20240118T145007",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default148.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                }
            ],
            "overall_sentiment_score": 0.43255,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.59016",
                    "ticker_sentiment_score": "0.385625",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "AWON",
                    "relevance_score": "0.130926",
                    "ticker_sentiment_score": "0.017953",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Novo Nordisk Stock a Buy Now?",
            "url": "https://www.fool.com/investing/2024/01/18/is-novo-nordisk-stock-a-buy-now/",
            "time_published": "20240118T143000",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "The biotech is on a roll, and that won't end soon.",
            "banner_image": "https://g.foolcdn.com/editorial/images/760716/doctor-with-patient-talking.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                }
            ],
            "overall_sentiment_score": 0.331692,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.061949",
                    "ticker_sentiment_score": "0.081064",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.061949",
                    "ticker_sentiment_score": "0.081064",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.56296",
                    "ticker_sentiment_score": "0.386015",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.061949",
                    "ticker_sentiment_score": "0.081064",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "2024 Will Be a Good Year for the Pharma Industry: The Kiplinger Letter",
            "url": "https://www.kiplinger.com/business/a-good-year-for-the-pharma-industry-the-kiplinger-letter",
            "time_published": "20240118T133015",
            "authors": [
                "Matthew Housiaux"
            ],
            "summary": "2024: The Pharma Industry's Good Year Kiplinger's Personal Finance ...",
            "banner_image": "https://cdn.mos.cms.futurecdn.net/UjiFXv5gKrsiSW4baf7dkN-415-80.jpg",
            "source": "Kiplinger",
            "category_within_source": "n/a",
            "source_domain": "www.kiplinger.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.237549,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.19661",
                    "ticker_sentiment_score": "-0.0803",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.19661",
                    "ticker_sentiment_score": "0.059379",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.291182",
                    "ticker_sentiment_score": "0.032821",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.099066",
                    "ticker_sentiment_score": "0.066677",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.19661",
                    "ticker_sentiment_score": "-0.0803",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.099066",
                    "ticker_sentiment_score": "0.066677",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Tech Futures Rally Ahead Of Jobless Claims",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-jobless-claims-nvidia-stock-set-to-hit-more-record-highs/",
            "time_published": "20240118T132000",
            "authors": [
                "SCOTT LEHTONEN",
                "Investor's Business Daily"
            ],
            "summary": "Dow Jones Futures Fall Ahead Of Jobless Claims. Nvidia Set To Hit More Record Highs Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2017/03/stock-wallstreet-031317-shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.744043"
                }
            ],
            "overall_sentiment_score": 0.047556,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AA",
                    "relevance_score": "0.12165",
                    "ticker_sentiment_score": "0.057898",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.16171",
                    "ticker_sentiment_score": "0.129355",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.081276",
                    "ticker_sentiment_score": "0.062072",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPOT",
                    "relevance_score": "0.201356",
                    "ticker_sentiment_score": "0.114075",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.16171",
                    "ticker_sentiment_score": "0.170372",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.040691",
                    "ticker_sentiment_score": "0.117875",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.16171",
                    "ticker_sentiment_score": "0.135664",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MELI",
                    "relevance_score": "0.201356",
                    "ticker_sentiment_score": "0.091275",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.040691",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AXP",
                    "relevance_score": "0.16171",
                    "ticker_sentiment_score": "0.118043",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FAST",
                    "relevance_score": "0.12165",
                    "ticker_sentiment_score": "0.057898",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.16171",
                    "ticker_sentiment_score": "0.111091",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KEY",
                    "relevance_score": "0.12165",
                    "ticker_sentiment_score": "0.057898",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Tech Futures Rise On Chip Giant's Forecast",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-techs-lead-on-taiwan-semiconductor-forecast/",
            "time_published": "20240118T132000",
            "authors": [
                "Investor's Business Daily",
                "ED CARSON"
            ],
            "summary": "Dow Jones Futures Fall But Techs Rebound On Taiwan Semiconductor Forecast Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2021/04/Stock-taiwansemiconductor-04-company.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.967321"
                }
            ],
            "overall_sentiment_score": 0.016949,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AMAT",
                    "relevance_score": "0.129516",
                    "ticker_sentiment_score": "-0.025483",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "APP",
                    "relevance_score": "0.064973",
                    "ticker_sentiment_score": "0.093101",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CELH",
                    "relevance_score": "0.129516",
                    "ticker_sentiment_score": "0.042005",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.064973",
                    "ticker_sentiment_score": "0.109136",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GTLB",
                    "relevance_score": "0.097325",
                    "ticker_sentiment_score": "0.07269",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.129516",
                    "ticker_sentiment_score": "0.042005",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DDOG",
                    "relevance_score": "0.224606",
                    "ticker_sentiment_score": "-0.0571",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AXON",
                    "relevance_score": "0.129516",
                    "ticker_sentiment_score": "0.042005",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EXPE",
                    "relevance_score": "0.064973",
                    "ticker_sentiment_score": "0.093101",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.032513",
                    "ticker_sentiment_score": "0.024312",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "URI",
                    "relevance_score": "0.161494",
                    "ticker_sentiment_score": "0.038352",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.064973",
                    "ticker_sentiment_score": "-0.128215",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.193207",
                    "ticker_sentiment_score": "-0.032431",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DV",
                    "relevance_score": "0.129516",
                    "ticker_sentiment_score": "0.010691",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GDDY",
                    "relevance_score": "0.064973",
                    "ticker_sentiment_score": "0.093101",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.161494",
                    "ticker_sentiment_score": "-0.151683",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "QCOM",
                    "relevance_score": "0.097325",
                    "ticker_sentiment_score": "-0.026005",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LRCX",
                    "relevance_score": "0.129516",
                    "ticker_sentiment_score": "-0.025483",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIRK",
                    "relevance_score": "0.129516",
                    "ticker_sentiment_score": "-0.039665",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HUM",
                    "relevance_score": "0.097325",
                    "ticker_sentiment_score": "-0.064882",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.129516",
                    "ticker_sentiment_score": "-0.025483",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IBKR",
                    "relevance_score": "0.097325",
                    "ticker_sentiment_score": "0.011737",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPOT",
                    "relevance_score": "0.161494",
                    "ticker_sentiment_score": "0.008036",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RCL",
                    "relevance_score": "0.097325",
                    "ticker_sentiment_score": "0.037855",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ARM",
                    "relevance_score": "0.097325",
                    "ticker_sentiment_score": "0.011737",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Hartford Multifactor Developed Markets  ( ex-US )  ETF  ( RODM )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2211874/is-hartford-multifactor-developed-markets-ex-us-etf-rodm-a-strong-etf-right-now",
            "time_published": "20240118T112006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default67.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.200337,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.056943",
                    "ticker_sentiment_score": "0.055018",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "4 Fidelity Mutual Funds to Buy as the Market Ebbs and Flows",
            "url": "https://www.zacks.com/stock/news/2211852/4-fidelity-mutual-funds-to-buy-as-the-market-ebbs-and-flows",
            "time_published": "20240118T103600",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Invest in Fidelity mutual funds like FPHAX, FCAKX, FDTIX and FDSCX for high returns alongside risk reduction in the current environment.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3b/649.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999897"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.311928,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.090645",
                    "ticker_sentiment_score": "0.135128",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "THNOF",
                    "relevance_score": "0.045396",
                    "ticker_sentiment_score": "0.247153",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.090645",
                    "ticker_sentiment_score": "0.135128",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.045396",
                    "ticker_sentiment_score": "0.114293",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BSX",
                    "relevance_score": "0.045396",
                    "ticker_sentiment_score": "0.126219",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.045396",
                    "ticker_sentiment_score": "0.114293",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CMC",
                    "relevance_score": "0.045396",
                    "ticker_sentiment_score": "0.099407",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "AstraZeneca, Roche, peers sign renewable power purchase deal for China plants",
            "url": "https://www.scmp.com/business/article/3248900/astrazeneca-novartis-rival-drug-makers-buy-renewable-energy-envision-manufacturing-plants-china",
            "time_published": "20240118T074256",
            "authors": [
                "Yujie Xue"
            ],
            "summary": "AstraZeneca, Novartis and some their global peers have agreed to buy renewable power for their manufacturing facilities in mainland China under a three-year supply deal with Envision Energy.",
            "banner_image": "https://cdn.i-scmp.com/sites/default/files/styles/wide_landscape/public/d8/video/thumbnail/2023/08/15/clean_1.jpg?itok=wLzNM2TO",
            "source": "South China Morning Post",
            "category_within_source": "Business",
            "source_domain": "www.scmp.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.139409,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.122581",
                    "ticker_sentiment_score": "0.106725",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.061473",
                    "ticker_sentiment_score": "0.054001",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Futures: Nasdaq Holds Key Level; Watch These 17 Stocks",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-nasdaq-holds-support-taiwan-semi-earnings-due/",
            "time_published": "20240117T222400",
            "authors": [
                "ED CARSON",
                "Investor's Business Daily"
            ],
            "summary": "Dow Jones Futures: Nasdaq Holds Support, Watch These 17 Stocks. Taiwan Semi Earnings Due Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/08/stock-bounce-back-01-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                }
            ],
            "overall_sentiment_score": 0.040976,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AMAT",
                    "relevance_score": "0.103628",
                    "ticker_sentiment_score": "-0.023142",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "APP",
                    "relevance_score": "0.069194",
                    "ticker_sentiment_score": "0.093338",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CELH",
                    "relevance_score": "0.137868",
                    "ticker_sentiment_score": "0.043361",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.103628",
                    "ticker_sentiment_score": "-0.023142",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.069194",
                    "ticker_sentiment_score": "0.087308",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GTLB",
                    "relevance_score": "0.103628",
                    "ticker_sentiment_score": "0.073966",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IBKR",
                    "relevance_score": "0.103628",
                    "ticker_sentiment_score": "0.011963",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPOT",
                    "relevance_score": "0.171851",
                    "ticker_sentiment_score": "0.008382",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.137868",
                    "ticker_sentiment_score": "0.043361",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DDOG",
                    "relevance_score": "0.238802",
                    "ticker_sentiment_score": "-0.059982",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AXON",
                    "relevance_score": "0.137868",
                    "ticker_sentiment_score": "0.043361",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EXPE",
                    "relevance_score": "0.069194",
                    "ticker_sentiment_score": "0.093338",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.03463",
                    "ticker_sentiment_score": "0.024469",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "URI",
                    "relevance_score": "0.171851",
                    "ticker_sentiment_score": "0.039991",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.205516",
                    "ticker_sentiment_score": "-0.034005",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DV",
                    "relevance_score": "0.137868",
                    "ticker_sentiment_score": "0.011047",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GDDY",
                    "relevance_score": "0.069194",
                    "ticker_sentiment_score": "0.093338",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.171851",
                    "ticker_sentiment_score": "-0.059297",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "QCOM",
                    "relevance_score": "0.103628",
                    "ticker_sentiment_score": "-0.023142",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LRCX",
                    "relevance_score": "0.103628",
                    "ticker_sentiment_score": "-0.023142",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RCL",
                    "relevance_score": "0.103628",
                    "ticker_sentiment_score": "0.038512",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ARM",
                    "relevance_score": "0.103628",
                    "ticker_sentiment_score": "0.011963",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIRK",
                    "relevance_score": "0.171851",
                    "ticker_sentiment_score": "-0.033081",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Beta-thalassemia Market to Witness Upsurge in Growth During the Study Period  ( 2019-2032 ) , Evaluates DelveInsight | Leading Companies - Vertex Pharmaceuticals, CRISPR Therapeutics, Agios Pharmaceuticals, Celgene, Forma Therapeutics",
            "url": "https://www.prnewswire.com/news-releases/beta-thalassemia-market-to-witness-upsurge-in-growth-during-the-study-period-20192032-evaluates-delveinsight--leading-companies---vertex-pharmaceuticals-crispr-therapeutics-agios-pharmaceuticals-celgene-forma-therapeutics-302034997.html",
            "time_published": "20240117T220100",
            "authors": [
                "LLP",
                "DelveInsight Business Research"
            ],
            "summary": "Beta-thalassemia Market to Witness Upsurge in Growth During the Study Period ( 2019-2032 ) , Evaluates DelveInsight ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.178567,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BEAM",
                    "relevance_score": "0.027257",
                    "ticker_sentiment_score": "0.038951",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AGIO",
                    "relevance_score": "0.054483",
                    "ticker_sentiment_score": "0.093789",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GMDA",
                    "relevance_score": "0.027257",
                    "ticker_sentiment_score": "0.043538",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SLN",
                    "relevance_score": "0.054483",
                    "ticker_sentiment_score": "0.044844",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.027257",
                    "ticker_sentiment_score": "0.096627",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FULC",
                    "relevance_score": "0.027257",
                    "ticker_sentiment_score": "0.038951",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.027257",
                    "ticker_sentiment_score": "0.096627",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IONS",
                    "relevance_score": "0.027257",
                    "ticker_sentiment_score": "0.043538",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EDIT",
                    "relevance_score": "0.081645",
                    "ticker_sentiment_score": "0.095821",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IRON",
                    "relevance_score": "0.027257",
                    "ticker_sentiment_score": "0.038951",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "What to consider before starting the new weight loss medications",
            "url": "https://www.cnn.com/2024/01/17/health/weight-loss-medication-what-best-wellness/index.html",
            "time_published": "20240117T210200",
            "authors": [
                "Katia Hetter"
            ],
            "summary": "As prescriptions for popular weight loss drugs have soared, the class of medications known as GLP-1 agonists is changing the way people think about how to lose weight. Initially developed to treat type 2 diabetes, medications like semaglutide and tirzepatide have also been shown to be effective ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/240116085159-01-wegovy-cartridges-file.jpg?q=w_1110,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": -0.007265,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.057698",
                    "ticker_sentiment_score": "0.055025",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CVS",
                    "relevance_score": "0.028868",
                    "ticker_sentiment_score": "-0.20879",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "GETY",
                    "relevance_score": "0.028868",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.028868",
                    "ticker_sentiment_score": "0.048583",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The weight loss drug market may soon get more crowded. Here are the companies trying to enter the booming space",
            "url": "https://www.cnbc.com/2024/01/17/weight-loss-drugs-boehringer-ingelheim-terns-viking-may-join-market.html",
            "time_published": "20240117T204055",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "Wall Street has been focused on Novo Nordisk, Eli Lilly and other large drugmakers hoping to join the weight loss drug market, such as Pfizer, Roche and Amgen.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107310827-1696353063160-gettyimages-1692436769-64393_48_ms_1933.jpeg?v=1705518338&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.083518,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.125898",
                    "ticker_sentiment_score": "-0.123814",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.042122",
                    "ticker_sentiment_score": "-0.193871",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.125898",
                    "ticker_sentiment_score": "-0.003645",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.042122",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GPCR",
                    "relevance_score": "0.084127",
                    "ticker_sentiment_score": "-0.169389",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "TERN",
                    "relevance_score": "0.125898",
                    "ticker_sentiment_score": "-0.079646",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AWON",
                    "relevance_score": "0.042122",
                    "ticker_sentiment_score": "-0.049155",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.042122",
                    "ticker_sentiment_score": "0.139137",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.042122",
                    "ticker_sentiment_score": "-0.193871",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.084127",
                    "ticker_sentiment_score": "-0.004144",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Check Out What Whales Are Doing With NVO - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/markets/options/24/01/36664263/check-out-what-whales-are-doing-with-nvo",
            "time_published": "20240117T171613",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk. Looking at options history for Novo Nordisk NVO we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 62% of the investors opened trades with bullish expectations ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.225126,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.705377",
                    "ticker_sentiment_score": "0.329658",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Allakos  ( ALLK )  Plummets 60% on Ending Development of Lead Drug",
            "url": "https://www.zacks.com/stock/news/2211650/allakos-allk-plummets-60-on-ending-development-of-lead-drug",
            "time_published": "20240117T171000",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Allakos (ALLK) decides to stop developing its lead drug after top-line data from two mid-stage studies did not achieve their primary endpoints.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972193"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.04806,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CTMX",
                    "relevance_score": "0.295867",
                    "ticker_sentiment_score": "-0.024026",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALLK",
                    "relevance_score": "0.596532",
                    "ticker_sentiment_score": "0.046136",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SRPT",
                    "relevance_score": "0.120733",
                    "ticker_sentiment_score": "0.04636",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.238718",
                    "ticker_sentiment_score": "0.138524",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "How to Find Strong Medical Stocks Slated for Positive Earnings Surprises",
            "url": "https://www.zacks.com/stock/news/2211330/how-to-find-strong-medical-stocks-slated-for-positive-earnings-surprises",
            "time_published": "20240117T135006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default102.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999992"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.367973,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.387875",
                    "ticker_sentiment_score": "0.423278",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.264658",
                    "ticker_sentiment_score": "0.277114",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Regeneron and Petco Health and Wellness have been highlighted as Zacks Bull and Bear of the Day",
            "url": "https://www.zacks.com/stock/news/2211296/regeneron-and-petco-health-and-wellness-have-been-highlighted-as-zacks-bull-and-bear-of-the-day",
            "time_published": "20240117T131800",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Chicago, IL - January 17, 2024 - Zacks Equity Research shares Regeneron Pharmaceuticals ( REGN Quick QuoteREGN - ) as the Bull of the Day and Petco Health and Wellness ( WOOF Quick QuoteWOOF - ) as the Bear of the Day.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/702.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.682689"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999499"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.682689"
                }
            ],
            "overall_sentiment_score": 0.129375,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LNVGF",
                    "relevance_score": "0.060236",
                    "ticker_sentiment_score": "0.115003",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.149842",
                    "ticker_sentiment_score": "0.080993",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.12013",
                    "ticker_sentiment_score": "0.113842",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DELL",
                    "relevance_score": "0.149842",
                    "ticker_sentiment_score": "0.056864",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.060236",
                    "ticker_sentiment_score": "0.051019",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WOOF",
                    "relevance_score": "0.208593",
                    "ticker_sentiment_score": "-0.003416",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Futures Drop Ahead Of Retail Sales",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-retail-sales-tesla-stock-slides-on-more-price-cuts/",
            "time_published": "20240117T131700",
            "authors": [
                "Investor's Business Daily",
                "SCOTT LEHTONEN"
            ],
            "summary": "Dow Jones futures sank along with other major indexes early Wednesday, as markets continued to slide after failing to gain their footing on Tuesday. Meanwhile, Tesla stock struggled below critical benchmarks after the company lowered prices on its Model Y electric vehicles in Germany.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/10/stock-wall-street-flags-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                }
            ],
            "overall_sentiment_score": 0.059572,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.17179",
                    "ticker_sentiment_score": "0.162926",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MELI",
                    "relevance_score": "0.2138",
                    "ticker_sentiment_score": "0.213082",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.043264",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IBKR",
                    "relevance_score": "0.129284",
                    "ticker_sentiment_score": "0.072138",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.295867",
                    "ticker_sentiment_score": "-0.173677",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "SPOT",
                    "relevance_score": "0.2138",
                    "ticker_sentiment_score": "0.144712",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.17179",
                    "ticker_sentiment_score": "0.174547",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CAT",
                    "relevance_score": "0.17179",
                    "ticker_sentiment_score": "0.081006",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SCHW",
                    "relevance_score": "0.129284",
                    "ticker_sentiment_score": "0.072138",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.043264",
                    "ticker_sentiment_score": "0.010972",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.17179",
                    "ticker_sentiment_score": "0.144019",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.17179",
                    "ticker_sentiment_score": "0.185633",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "The Ozempic Plateau",
            "url": "https://www.theatlantic.com/health/archive/2024/01/why-you-will-stop-losing-weight-ozempic/677148/",
            "time_published": "20240117T130000",
            "authors": [
                "Sarah Zhang"
            ],
            "summary": "Why You Will Stop Losing Weight on Ozempic The Atlantic ...",
            "banner_image": "https://cdn.theatlantic.com/thumbor/ebFJC3QOM1yV4wObOlaNxLDGU1w=/0x0:2000x1125/960x540/media/img/mt/2024/01/OzempicsEdge_1/original.png",
            "source": "The Atlantic",
            "category_within_source": "n/a",
            "source_domain": "www.theatlantic.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.002417,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.028524",
                    "ticker_sentiment_score": "-0.018944",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:USD",
                    "relevance_score": "0.028524",
                    "ticker_sentiment_score": "-0.102407",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Bull of the Day: Regeneron Pharmaceuticals  ( REGN ) ",
            "url": "https://www.zacks.com/commentary/2211051/bull-of-the-day-regeneron-pharmaceuticals-regn",
            "time_published": "20240117T093000",
            "authors": [
                "Ethan Feller"
            ],
            "summary": "The Biotechnology company enjoys a litany of bullish catalysts on the horizon ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default21.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.839681"
                }
            ],
            "overall_sentiment_score": 0.242725,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.20698",
                    "ticker_sentiment_score": "0.072522",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.20698",
                    "ticker_sentiment_score": "0.231906",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.20698",
                    "ticker_sentiment_score": "0.072522",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  Dips More Than Broader Market: What You Should Know",
            "url": "https://www.zacks.com/stock/news/2211093/novo-nordisk-nvo-dips-more-than-broader-market-what-you-should-know",
            "time_published": "20240116T225018",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "In the closing of the recent trading day, Novo Nordisk (NVO) stood at $106.35, denoting a -0.76% change from the preceding trading day.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default254.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.891286"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.200266,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.511256",
                    "ticker_sentiment_score": "0.209269",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Adaptimmune  ( ADAP )  Surges More Than 80% in a Month: Here's Why",
            "url": "https://www.zacks.com/stock/news/2210881/adaptimmune-adap-surges-more-than-80-in-a-month-heres-why",
            "time_published": "20240116T161700",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Adaptimmune (ADAP) surges on the completion of the rolling submission, with the FDA seeking approval for its most advanced pipeline candidate as the first engineered cell therapy for solid tumors.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972193"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.137053,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CTMX",
                    "relevance_score": "0.293038",
                    "ticker_sentiment_score": "0.069295",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ADAP",
                    "relevance_score": "0.236396",
                    "ticker_sentiment_score": "0.030949",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SRPT",
                    "relevance_score": "0.119532",
                    "ticker_sentiment_score": "0.043907",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.059935",
                    "ticker_sentiment_score": "0.1",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.236396",
                    "ticker_sentiment_score": "0.133925",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Best Growth Stocks to Buy for January 16th",
            "url": "https://www.zacks.com/commentary/2210722/best-growth-stocks-to-buy-for-january-16th",
            "time_published": "20240116T144200",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "NVO, AIZ and PAX made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 16, 2024.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.459462"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.090366,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AIZ",
                    "relevance_score": "0.678102",
                    "ticker_sentiment_score": "0.093539",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.678102",
                    "ticker_sentiment_score": "0.273399",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PAX",
                    "relevance_score": "0.678102",
                    "ticker_sentiment_score": "-0.255183",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Is it a Good Idea to Buy Fusion Pharmaceuticals  ( FUSN )  Stock Now?",
            "url": "https://www.zacks.com/stock/news/2210622/is-it-a-good-idea-to-buy-fusion-pharmaceuticals-fusn-stock-now",
            "time_published": "20240116T132200",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Here, we discuss some reasons why investing in Fusion Pharmaceuticals (FUSN) stock now may turn out to be a prudent move.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.123707,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.186738",
                    "ticker_sentiment_score": "0.107147",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.276909",
                    "ticker_sentiment_score": "-0.002043",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FUSN",
                    "relevance_score": "0.762438",
                    "ticker_sentiment_score": "0.284194",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "4 Pharma Stocks to Buy, According to an Analyst. Novo Nordisk Isn't One.",
            "url": "https://www.barrons.com/articles/pharma-stocks-novo-nordisk-astrazeneca-gsk-buy-2e92c0c0",
            "time_published": "20240116T124300",
            "authors": [
                "Adam Clark"
            ],
            "summary": "The European pharmaceutical sector looks set for a good year on strong cash flows and attractive valuations, according to UBS analysts. They picked out four stocks that could particularly benefit but left out weight-loss drug pioneer and market darling Novo Nordisk, and struck a bearish note on ...",
            "banner_image": "https://images.barrons.com/im-272936/social",
            "source": "Barrons",
            "category_within_source": "n/a",
            "source_domain": "www.barrons.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.405553,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.622414",
                    "ticker_sentiment_score": "0.566585",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.622414",
                    "ticker_sentiment_score": "0.566585",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Sell AstraZeneca, says UBS, which upgrades European rivals including GSK",
            "url": "https://www.marketwatch.com/story/sell-astrazeneca-says-ubs-which-upgrades-european-rivals-including-gsk-ddb55ad7",
            "time_published": "20240116T103400",
            "authors": [
                "Steve Goldstein"
            ],
            "summary": "UBS analysts shook up their ratings of European drugmakers, including making a double-downgrade of AstraZeneca and a double-upgrade of U.K. rival GSK.",
            "banner_image": "https://images.mktw.net/im-254778/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.046178,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.740604",
                    "ticker_sentiment_score": "-0.140164",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.501398",
                    "ticker_sentiment_score": "0.300471",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.348103",
                    "ticker_sentiment_score": "0.155892",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Futures Fall; Elon Musk Makes This Tesla Threat",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-boeing-apple-in-focus-elon-musk-makes-this-tesla-threat/",
            "time_published": "20240115T234000",
            "authors": [
                "Investor's Business Daily",
                "ED CARSON"
            ],
            "summary": "Futures Fall. Elon Musk Makes This Tesla Threat Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2022/05/Stock-elonmusk-grumpy-01-shutt.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.016993,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.349803",
                    "ticker_sentiment_score": "0.12775",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MELI",
                    "relevance_score": "0.165788",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.246444",
                    "ticker_sentiment_score": "0.21025",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.138464",
                    "ticker_sentiment_score": "-0.018659",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.349803",
                    "ticker_sentiment_score": "-0.165023",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.138464",
                    "ticker_sentiment_score": "0.072576",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.055621",
                    "ticker_sentiment_score": "0.13589",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.027828",
                    "ticker_sentiment_score": "-0.054775",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DAL",
                    "relevance_score": "0.055621",
                    "ticker_sentiment_score": "0.053346",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.138464",
                    "ticker_sentiment_score": "-0.093256",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Heart Failure Treatment Drug Market to Accelerate Immensely by 2032, Predicts DelveInsight",
            "url": "https://www.prnewswire.com/news-releases/heart-failure-treatment-drug-market-to-accelerate-immensely-by-2032-predicts-delveinsight-302034593.html",
            "time_published": "20240115T220500",
            "authors": [
                "DelveInsight Business Research",
                "LLP"
            ],
            "summary": "The dynamics of the heart failure market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, and incremental healthcare spending across the world.",
            "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.165054,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BCDA",
                    "relevance_score": "0.046861",
                    "ticker_sentiment_score": "0.08891",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PGEN",
                    "relevance_score": "0.023441",
                    "ticker_sentiment_score": "0.03228",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TNYA",
                    "relevance_score": "0.023441",
                    "ticker_sentiment_score": "0.03228",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.046861",
                    "ticker_sentiment_score": "0.08891",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SANA",
                    "relevance_score": "0.023441",
                    "ticker_sentiment_score": "0.03228",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRDL",
                    "relevance_score": "0.023441",
                    "ticker_sentiment_score": "0.03228",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IONS",
                    "relevance_score": "0.023441",
                    "ticker_sentiment_score": "0.03228",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.023441",
                    "ticker_sentiment_score": "0.03228",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SCPH",
                    "relevance_score": "0.046861",
                    "ticker_sentiment_score": "0.08891",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.093561",
                    "ticker_sentiment_score": "0.092837",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MESO",
                    "relevance_score": "0.046861",
                    "ticker_sentiment_score": "0.08891",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PBIGF",
                    "relevance_score": "0.023441",
                    "ticker_sentiment_score": "0.03228",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WINT",
                    "relevance_score": "0.070242",
                    "ticker_sentiment_score": "0.050911",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LXRX",
                    "relevance_score": "0.046861",
                    "ticker_sentiment_score": "0.08891",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CYTK",
                    "relevance_score": "0.046861",
                    "ticker_sentiment_score": "0.08891",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ITCI",
                    "relevance_score": "0.046861",
                    "ticker_sentiment_score": "0.08891",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ATHXQ",
                    "relevance_score": "0.023441",
                    "ticker_sentiment_score": "0.03228",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.046861",
                    "ticker_sentiment_score": "0.08891",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EWTX",
                    "relevance_score": "0.023441",
                    "ticker_sentiment_score": "0.03228",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FUJIF",
                    "relevance_score": "0.023441",
                    "ticker_sentiment_score": "0.03228",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.023441",
                    "ticker_sentiment_score": "0.03228",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TENX",
                    "relevance_score": "0.023441",
                    "ticker_sentiment_score": "0.113992",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EVO",
                    "relevance_score": "0.023441",
                    "ticker_sentiment_score": "0.03228",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Centene  ( CNC )  Sells Circle Health to Boost Managed Care Business",
            "url": "https://www.zacks.com/stock/news/2210400/centene-cnc-sells-circle-health-to-boost-managed-care-business",
            "time_published": "20240115T182100",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Centene (CNC) concludes the divestiture of Circle Health to expand its core Managed Care business. Additionally, its plan members will enjoy continued access to Kroger's pharmacy network in 2024.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/2354.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.682689"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.291833,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CNC",
                    "relevance_score": "0.546745",
                    "ticker_sentiment_score": "0.473877",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "AMPH",
                    "relevance_score": "0.261117",
                    "ticker_sentiment_score": "0.100771",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.197413",
                    "ticker_sentiment_score": "0.053358",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KR",
                    "relevance_score": "0.323078",
                    "ticker_sentiment_score": "0.287993",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Here is Why Growth Investors Should Buy Novo Nordisk  ( NVO )  Now",
            "url": "https://www.zacks.com/stock/news/2210387/here-is-why-growth-investors-should-buy-novo-nordisk-nvo-now",
            "time_published": "20240115T174505",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) is well positioned to outperform the market, as it exhibits above-average growth in financials.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default245.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.983783"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.459462"
                }
            ],
            "overall_sentiment_score": 0.444776,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.56415",
                    "ticker_sentiment_score": "0.493743",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Iovance  ( IOVA )  Surges More Than 150% in 3 Months: Here's Why",
            "url": "https://www.zacks.com/stock/news/2210369/iovance-iova-surges-more-than-150-in-3-months-heres-why",
            "time_published": "20240115T172700",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Iovance's (IOVA) surges on the anticipated FDA approval for its lead pipeline drug as the first individualized, one-time cell therapy for certain patients with melanoma.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972193"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.093496,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CTMX",
                    "relevance_score": "0.21193",
                    "ticker_sentiment_score": "0.053496",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IOVA",
                    "relevance_score": "0.170275",
                    "ticker_sentiment_score": "0.024084",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SRPT",
                    "relevance_score": "0.085629",
                    "ticker_sentiment_score": "0.042008",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.170275",
                    "ticker_sentiment_score": "0.107254",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  Is Up 2.45% in One Week: What You Should Know",
            "url": "https://www.zacks.com/stock/news/2210353/novo-nordisk-nvo-is-up-245-in-one-week-what-you-should-know",
            "time_published": "20240115T170003",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Does Novo Nordisk (NVO) have what it takes to be a top stock pick for momentum investors? Let's find out.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default267.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.980922"
                }
            ],
            "overall_sentiment_score": 0.301335,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.59404",
                    "ticker_sentiment_score": "0.399017",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "AWON",
                    "relevance_score": "0.06623",
                    "ticker_sentiment_score": "0.053577",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio",
            "url": "https://www.zacks.com/stock/news/2210191/why-this-1-growth-stock-could-be-a-great-addition-to-your-portfolio",
            "time_published": "20240115T144507",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default290.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.928139"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.435714,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.369319",
                    "ticker_sentiment_score": "0.414896",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "AWON",
                    "relevance_score": "0.076602",
                    "ticker_sentiment_score": "0.01469",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Merck  ( MRK )  Keytruda Ok'd by FDA for Expanded Cervical Cancer Use",
            "url": "https://www.zacks.com/stock/news/2210152/merck-mrk-keytruda-okd-by-fda-for-expanded-cervical-cancer-use",
            "time_published": "20240115T143000",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "FDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on data from the phase KEYNOTE-A18 study.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.838487"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.116433,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "FUSN",
                    "relevance_score": "0.316439",
                    "ticker_sentiment_score": "0.023179",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.064973",
                    "ticker_sentiment_score": "0.009134",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.129516",
                    "ticker_sentiment_score": "0.052545",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.193207",
                    "ticker_sentiment_score": "0.045776",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "I'm Passing on Pfizer Stock in 2024. Here's Why.",
            "url": "https://www.fool.com/investing/2024/01/15/im-passing-on-pfizer-stock-in-2024-heres-why/",
            "time_published": "20240115T122500",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Pfizer's best days might be behind it as demand for its COVID-19 products hits a wall.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F760744%2Fcovid-19-vaccine-booster-shot-injection.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999355"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.111002,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.056943",
                    "ticker_sentiment_score": "0.077004",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.746902",
                    "ticker_sentiment_score": "0.229002",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "These 2 Top Healthcare Stocks Declared Dividend Raises in 2023",
            "url": "https://www.fool.com/investing/2024/01/15/these-2-top-healthcare-stocks-declared-dividend-ra/",
            "time_published": "20240115T114600",
            "authors": [
                "Eric Volkman"
            ],
            "summary": "For different reasons, both Eli Lilly and UnitedHealth are doing well enough to enact substantial dividend raises.",
            "banner_image": "https://g.foolcdn.com/editorial/images/760775/medical-professionals-conferring-in-a-hospial-corridor.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.200385,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.290262",
                    "ticker_sentiment_score": "0.153969",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.059341",
                    "ticker_sentiment_score": "0.132101",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.234119",
                    "ticker_sentiment_score": "0.150481",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and AstraZeneca",
            "url": "https://www.zacks.com/stock/news/2209905/the-zacks-analyst-blog-highlights-eli-lilly-novo-nordisk-amgen-and-astrazeneca",
            "time_published": "20240115T105000",
            "authors": [
                "Zacks Investment Research"
            ],
            "summary": "Eli Lilly, Novo Nordisk, Amgen and AstraZeneca are included in this Analyst Blog.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e5/1416.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.094253,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.261117",
                    "ticker_sentiment_score": "0.085906",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.261117",
                    "ticker_sentiment_score": "0.040358",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.210274",
                    "ticker_sentiment_score": "0.07059",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.053153",
                    "ticker_sentiment_score": "0.149079",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.261117",
                    "ticker_sentiment_score": "0.241559",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S - share repurchase programme",
            "url": "https://www.globenewswire.com/news-release/2024/01/15/2809046/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html",
            "time_published": "20240115T104300",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 15 January 2024 - On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.143899,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.045242",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.045242",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.781591",
                    "ticker_sentiment_score": "0.230049",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Futures Fall: Market Rally Stellar; Four Stocks In Buy Zones",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-stellar-market-rally/",
            "time_published": "20240114T231900",
            "authors": [
                "Investor's Business Daily",
                "ED CARSON"
            ],
            "summary": "Futures Fall: Market Rally Stellar. Four Stocks In Buy Zones Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2018/07/stock-bull-charge-02-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.053334,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.404312",
                    "ticker_sentiment_score": "0.14192",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MELI",
                    "relevance_score": "0.193465",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.28664",
                    "ticker_sentiment_score": "0.236438",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.097457",
                    "ticker_sentiment_score": "0.090714",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.224903",
                    "ticker_sentiment_score": "-0.156739",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.16171",
                    "ticker_sentiment_score": "0.079619",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.065061",
                    "ticker_sentiment_score": "0.136213",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.032558",
                    "ticker_sentiment_score": "-0.056152",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DAL",
                    "relevance_score": "0.065061",
                    "ticker_sentiment_score": "0.054082",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.065061",
                    "ticker_sentiment_score": "-0.086608",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Move Over, Novo Nordisk -- This Is the Pharmaceutical Company I am Most Bullish On in 2024",
            "url": "https://www.fool.com/investing/2024/01/14/move-over-novo-nordisk-this-is-the-pharmaceutical/",
            "time_published": "20240114T114500",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Novo Nordisk may dominate the weight management space, but pharma giant Eli Lilly is quickly gaining steam.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F760470%2Fbreast-cancer-awareness-doctor.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.210943,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.436009",
                    "ticker_sentiment_score": "0.40443",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.436009",
                    "ticker_sentiment_score": "0.315391",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "After Surging 53% in 2023, This Pharmaceutical Stock Might Be About to Crash. Here's Why I'm Probably Wrong",
            "url": "https://www.fool.com/investing/2024/01/13/after-surging-53-in-2023-this-pharmaceutical-stock/",
            "time_published": "20240113T153000",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "The rise of Ozempic and Wegovy helped Novo Nordisk stock surge over 50% last year.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F760592%2Fblood-pressure-doctor-senior-citizen.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                }
            ],
            "overall_sentiment_score": 0.200507,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.245835",
                    "ticker_sentiment_score": "0.111819",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.584467",
                    "ticker_sentiment_score": "0.200302",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "3 Unstoppable Stocks to Buy in 2024",
            "url": "https://www.fool.com/investing/2024/01/13/3-unstoppable-stocks-to-buy-in-2024/",
            "time_published": "20240113T124800",
            "authors": [
                "Keith Speights",
                "David Jagielski",
                "and Prosper Junior Bakiny"
            ],
            "summary": "These stocks appear to be on a clear path to continued growth.",
            "banner_image": "https://g.foolcdn.com/editorial/images/761021/scientists-in-a-lab-smiling.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.25543,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.266343",
                    "ticker_sentiment_score": "0.049266",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.349945",
                    "ticker_sentiment_score": "0.133208",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MORN",
                    "relevance_score": "0.045224",
                    "ticker_sentiment_score": "0.143626",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.308614",
                    "ticker_sentiment_score": "0.308668",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FOREX:DKK",
                    "relevance_score": "0.045224",
                    "ticker_sentiment_score": "0.270178",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FOREX:NOK",
                    "relevance_score": "0.045224",
                    "ticker_sentiment_score": "0.270178",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Why Novo Nordisk Stock Soared 53% in 2023  ( Hint: It Wasn't Just Ozempic ) ",
            "url": "https://www.fool.com/investing/2024/01/13/novo-nordisk-stock-soared-2023-ozempic/",
            "time_published": "20240113T104800",
            "authors": [
                "Keith Speights"
            ],
            "summary": "Last year was one for the history books for the Danish drugmaker.",
            "banner_image": "https://g.foolcdn.com/editorial/images/760984/ozempic.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.317721,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.650131",
                    "ticker_sentiment_score": "0.444422",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Market Making All The Right Moves; 4 Stocks In Buy Zones",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-rally-making-the-right-moves-nvidia-microsoft-lead-tesla-breaks-down/",
            "time_published": "20240112T221400",
            "authors": [
                "Investor's Business Daily",
                "ED CARSON"
            ],
            "summary": "Dow Jones Futures: Market Rally Making The Right Moves. Nvidia, Microsoft Lead, Tesla Breaks Down Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2018/07/stock-bull-charge-02-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.057794,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.355588",
                    "ticker_sentiment_score": "0.081902",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MELI",
                    "relevance_score": "0.182506",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.212248",
                    "ticker_sentiment_score": "0.143681",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.070598",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.241684",
                    "ticker_sentiment_score": "-0.1804",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.212248",
                    "ticker_sentiment_score": "0.119715",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.061315",
                    "ticker_sentiment_score": "0.126024",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.03068",
                    "ticker_sentiment_score": "-0.011302",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DAL",
                    "relevance_score": "0.061315",
                    "ticker_sentiment_score": "0.071779",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.061315",
                    "ticker_sentiment_score": "-0.086306",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "UnitedHealth Group  ( UNH )  Q4 Earnings Beat on Membership Growth",
            "url": "https://www.zacks.com/stock/news/2209723/unitedhealth-group-unh-q4-earnings-beat-on-membership-growth",
            "time_published": "20240112T193500",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "UnitedHealth Group's (UNH) Q4 results benefit on the back of double-digit revenue growth in its UnitedHealthcare and Optum segments. Management maintains its 2024 adjusted EPS target within $27.50-$28.00.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/1007.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.99989"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.199832,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ADMA",
                    "relevance_score": "0.128592",
                    "ticker_sentiment_score": "0.094716",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LNTH",
                    "relevance_score": "0.128592",
                    "ticker_sentiment_score": "0.10155",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.085936",
                    "ticker_sentiment_score": "0.09658",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.44717",
                    "ticker_sentiment_score": "0.218044",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Emergent  ( EBS )  Gets $235.8M DoD Contract for Anthrax Vaccine",
            "url": "https://www.zacks.com/stock/news/2209718/emergent-ebs-gets-2358m-dod-contract-for-anthrax-vaccine",
            "time_published": "20240112T192000",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Emergent (EBS) signs a deal with the U.S. Department of Defense to supply its anthrax vaccine initially for a five-year period, with an option to extend it for another five years.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972193"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.310843"
                }
            ],
            "overall_sentiment_score": 0.10424,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CTMX",
                    "relevance_score": "0.279653",
                    "ticker_sentiment_score": "-0.022969",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SRPT",
                    "relevance_score": "0.113866",
                    "ticker_sentiment_score": "0.045288",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.225425",
                    "ticker_sentiment_score": "0.13402",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EBS",
                    "relevance_score": "0.225425",
                    "ticker_sentiment_score": "0.147569",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Should You Invest in Novo Nordisk  ( NVO )  Based on Bullish Wall Street Views?",
            "url": "https://www.zacks.com/stock/news/2209492/should-you-invest-in-novo-nordisk-nvo-based-on-bullish-wall-street-views",
            "time_published": "20240112T143006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "The average brokerage recommendation (ABR) for Novo Nordisk (NVO) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
            "banner_image": "https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/NVO_01122024.png",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.938238"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.503496"
                }
            ],
            "overall_sentiment_score": 0.325489,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.362254",
                    "ticker_sentiment_score": "0.233886",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "$1000 Invested In This Stock 10 Years Ago Would Be Worth $5,600 Today - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/news/24/01/36610484/1000-invested-in-this-stock-10-years-ago-would-be-worth-5-600-today",
            "time_published": "20240112T140022",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Novo Nordisk NVO has outperformed the market over the past 10 years by 8.79% on an annualized basis producing an average annual return of 18.74%. Currently, Novo Nordisk has a market capitalization of $476.90 billion.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.160819,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.980595",
                    "ticker_sentiment_score": "0.386944",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Futures Lower Ahead Of Key Inflation Data",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-inflation-data-tesla-stock-dives-despite-cathie-wood-buys/",
            "time_published": "20240112T131700",
            "authors": [
                "SCOTT LEHTONEN",
                "Investor's Business Daily"
            ],
            "summary": "Dow Jones Futures Drop Ahead Of Inflation Data. Tesla Stock Dives Despite Cathie Wood Buys Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2021/09/Stock-wallstreetflag-01-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.682689"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.038073,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.144491",
                    "ticker_sentiment_score": "0.152901",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.03631",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.10863",
                    "ticker_sentiment_score": "0.209181",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.10863",
                    "ticker_sentiment_score": "0.209181",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.10863",
                    "ticker_sentiment_score": "0.209181",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.180056",
                    "ticker_sentiment_score": "0.148814",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.03631",
                    "ticker_sentiment_score": "0.010849",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.180056",
                    "ticker_sentiment_score": "0.125872",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DAL",
                    "relevance_score": "0.072545",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.10863",
                    "ticker_sentiment_score": "-0.15628",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "MELI",
                    "relevance_score": "0.144491",
                    "ticker_sentiment_score": "0.147904",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.250019",
                    "ticker_sentiment_score": "-0.123804",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.10863",
                    "ticker_sentiment_score": "0.209181",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CAT",
                    "relevance_score": "0.144491",
                    "ticker_sentiment_score": "0.111375",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.144491",
                    "ticker_sentiment_score": "0.141657",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "FDA Finds No Link Between Obesity Drugs and Suicidal Thoughts",
            "url": "https://www.zacks.com/stock/news/2209351/fda-finds-no-link-between-obesity-drugs-and-suicidal-thoughts",
            "time_published": "20240112T124700",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "The GLP-1 segment is an important class of drugs for multiple cardiometabolic diseases and is gaining significant popularity.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.101797,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.227007",
                    "ticker_sentiment_score": "0.104048",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.227007",
                    "ticker_sentiment_score": "0.056869",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.171282",
                    "ticker_sentiment_score": "0.110461",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.05749",
                    "ticker_sentiment_score": "0.149399",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.227007",
                    "ticker_sentiment_score": "0.250732",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Ozempic not linked to suicidal thoughts, FDA report finds",
            "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/ozempic-not-linked-to-suicidal-thoughts-fda-report-finds/3363168/",
            "time_published": "20240112T111249",
            "authors": [
                "Bloomberg"
            ],
            "summary": "US regulators found no link between weight-loss drugs like Novo Nordisk A/S's Ozempic and suicidal thoughts, a positive sign for the popular medications as similar reviews in Europe remain ongoing.",
            "banner_image": "https://www.financialexpress.com/wp-content/uploads/2024/01/pills-384846_1280.jpg",
            "source": "The Financial Express",
            "category_within_source": "n/a",
            "source_domain": "www.financialexpress.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.082165,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.121037",
                    "ticker_sentiment_score": "0.025567",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.121037",
                    "ticker_sentiment_score": "0.025567",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.121037",
                    "ticker_sentiment_score": "-0.009974",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "FDA Finds No Evidence Weight-Loss Drugs Cause Suicidal Thoughts - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/news/24/01/36602710/fda-finds-no-evidence-weight-loss-drugs-cause-suicidal-thoughts",
            "time_published": "20240111T215505",
            "authors": [
                "Erica Kollmann"
            ],
            "summary": "Following a preliminary review, the U.S. Food and Drug Administration found no evidence that weight-loss drugs cause suicidal thoughts.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/man-3011213-1280.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.117571,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.269776",
                    "ticker_sentiment_score": "-0.071299",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.269776",
                    "ticker_sentiment_score": "-0.081664",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Aclaris  ( ACRS )  Down 21% on Mixed Results From Eczema Study",
            "url": "https://www.zacks.com/stock/news/2209029/aclaris-acrs-down-21-on-mixed-results-from-eczema-study",
            "time_published": "20240111T164600",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Though data from a mid-stage study shows that treatment with Aclaris' (ACRS) JAK inhibitor met its primary endpoint, it also displays a greater-than-expected placebo effect.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972193"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.0,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CTMX",
                    "relevance_score": "0.23907",
                    "ticker_sentiment_score": "-0.020236",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ACRS",
                    "relevance_score": "0.144853",
                    "ticker_sentiment_score": "-0.044098",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SRPT",
                    "relevance_score": "0.096866",
                    "ticker_sentiment_score": "0.043075",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.19231",
                    "ticker_sentiment_score": "0.117024",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "C4  ( CCCC )  Up 6% on Restructuring Plan to Curb Cash Burn",
            "url": "https://www.zacks.com/stock/news/2209026/c4-cccc-up-6-on-restructuring-plan-to-curb-cash-burn",
            "time_published": "20240111T164400",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "The new restructuring plan will allow C4 Therapeutics (CCCC) to extend its cash runway into 2027. The company plans to reduce its workforce by nearly 30%.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.890401"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.089571,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "SRPT",
                    "relevance_score": "0.108222",
                    "ticker_sentiment_score": "0.056455",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.16171",
                    "ticker_sentiment_score": "0.119641",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.054236",
                    "ticker_sentiment_score": "0.052814",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CCCC",
                    "relevance_score": "0.413708",
                    "ticker_sentiment_score": "0.050021",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance - Amgen  ( NASDAQ:AMGN ) ",
            "url": "https://www.benzinga.com/general/biotech/24/01/36594746/large-drugmakers-show-enthusiasm-to-embrace-100b-obesity-market-despite-novo-and-lillys-dominance",
            "time_published": "20240111T164037",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Pharmaceutical companies, including Amgen Inc AMGN and Pfizer Inc PFE, are strategically positioning themselves to tap into the burgeoning obesity market. The pursuit involves developing innovative drugs or engaging in strategic acquisitions to compete with established players such as Novo ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/11/aapharma_0.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.164763,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BAYZF",
                    "relevance_score": "0.228073",
                    "ticker_sentiment_score": "0.084786",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.33628",
                    "ticker_sentiment_score": "0.252282",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.33628",
                    "ticker_sentiment_score": "0.252282",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ALT",
                    "relevance_score": "0.228073",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.531326",
                    "ticker_sentiment_score": "0.077283",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.43789",
                    "ticker_sentiment_score": "0.185632",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings",
            "url": "https://www.zacks.com/stock/news/2208771/want-better-returns-dont-ignore-these-2-medical-stocks-set-to-beat-earnings",
            "time_published": "20240111T135006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default65.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999996"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.351131,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.330876",
                    "ticker_sentiment_score": "0.345292",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.202366",
                    "ticker_sentiment_score": "0.282262",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Futures Rise Ahead Of Imminent CPI Inflation Report",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-cpi-inflation-report-nvidia-stock-set-to-hit-record-high/",
            "time_published": "20240111T132200",
            "authors": [
                "Investor's Business Daily",
                "SCOTT LEHTONEN"
            ],
            "summary": "Dow Jones futures were slightly higher in premarket trades Thursday, as Wall Street braced for a critical inflation report from the Labor Department. Among individual stocks, Nvidia stock rallied and set to hit another record high, while crypto stock Coinbase ( COIN ) jumped on SEC approval for ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2017/03/stock-wallstreet-031317-shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.682689"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.143159,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "KBH",
                    "relevance_score": "0.124809",
                    "ticker_sentiment_score": "-0.031077",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.165883",
                    "ticker_sentiment_score": "0.213819",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.206509",
                    "ticker_sentiment_score": "0.027872",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.041755",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.206509",
                    "ticker_sentiment_score": "0.210346",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CAT",
                    "relevance_score": "0.165883",
                    "ticker_sentiment_score": "0.230009",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.041755",
                    "ticker_sentiment_score": "0.200708",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.206509",
                    "ticker_sentiment_score": "0.139379",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.165883",
                    "ticker_sentiment_score": "0.158303",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "COIN",
                    "relevance_score": "0.124809",
                    "ticker_sentiment_score": "0.078085",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.124809",
                    "ticker_sentiment_score": "0.078085",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "P/E Ratio Insights for Novo Nordisk - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/news/24/01/36592569/pe-ratio-insights-for-novo-nordisk",
            "time_published": "20240111T131513",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "In the current session, the stock is trading at $108.78, after a 0.10% spike. Over the past month, Novo Nordisk Inc. NVO stock increased by 11.06%, and in the past year, by 59.68%.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                }
            ],
            "overall_sentiment_score": 0.209639,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.443626",
                    "ticker_sentiment_score": "0.190941",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "The Political Theater Of Importing Prescription Drugs From Canada",
            "url": "https://www.forbes.com/sites/johnlamattina/2024/01/11/the-political-theater-of-importing-prescription-drugs-from-canada/",
            "time_published": "20240111T125218",
            "authors": [
                "John LaMattina"
            ],
            "summary": "Florida Governor Ron DeSantis made news last week when his plan to import prescription drugs from Canada was temporarily endorsed by the FDA. Importing drugs from Canada has been under discussion for years, the hope being that these drugs could be acquired at cheaper Canadian prices than those ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/659f03a819c3b56e482accd8/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.097825,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.127456",
                    "ticker_sentiment_score": "0.116382",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Your tax dollars are getting spent on weight-loss drugs like Ozempic, and the total is adding up",
            "url": "https://www.businessinsider.com/ozempic-weight-loss-drugs-insurance-medicaid-taxpayer-dollars-2024-1",
            "time_published": "20240111T110900",
            "authors": [
                "Ayelet Sheffey",
                "Juliana Kaplan"
            ],
            "summary": "Weight loss drugs like Ozempic draining tax dollars - Business Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.004742,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.141935",
                    "ticker_sentiment_score": "0.071416",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Focal Segmental Glomerulosclerosis Market to Observe Impressive Growth by 2032, Predicts DelveInsight | Leading Companies - ACELYRIN, Genentech, ChemoCentryx, Travere Therapeutics, Boehringer Ingelheim, Chinook Therapeutics",
            "url": "https://www.prnewswire.com/news-releases/focal-segmental-glomerulosclerosis-market-to-observe-impressive-growth-by-2032-predicts-delveinsight--leading-companies---acelyrin-genentech-chemocentryx-travere-therapeutics-boehringer-ingelheim-chinook-therapeutics-302030785.html",
            "time_published": "20240110T220100",
            "authors": [
                "DelveInsight Business Research",
                "LLP"
            ],
            "summary": "Focal Segmental Glomerulosclerosis Market to Observe Impressive Growth by 2032, Predicts DelveInsight | Leading ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.106846,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ZVSA",
                    "relevance_score": "0.028321",
                    "ticker_sentiment_score": "0.038274",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALDX",
                    "relevance_score": "0.028321",
                    "ticker_sentiment_score": "0.086235",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TVTX",
                    "relevance_score": "0.084821",
                    "ticker_sentiment_score": "0.088295",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.056607",
                    "ticker_sentiment_score": "-0.017",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KDNY",
                    "relevance_score": "0.056607",
                    "ticker_sentiment_score": "0.085954",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.028321",
                    "ticker_sentiment_score": "0.038274",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DMAC",
                    "relevance_score": "0.028321",
                    "ticker_sentiment_score": "0.002769",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.028321",
                    "ticker_sentiment_score": "0.038274",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LXRX",
                    "relevance_score": "0.028321",
                    "ticker_sentiment_score": "0.002769",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SLRN",
                    "relevance_score": "0.028321",
                    "ticker_sentiment_score": "0.086235",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.028321",
                    "ticker_sentiment_score": "0.002769",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PROK",
                    "relevance_score": "0.056607",
                    "ticker_sentiment_score": "-0.017",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.028321",
                    "ticker_sentiment_score": "0.002769",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Analyst Assesses Cell-Programming Focused Ginkgo Bioworks' Positioning Amid Revenue Surge, Program Adjustments - Ginkgo Bioworks Holdings  ( NYSE:DNA ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36580897/analyst-assesses-cell-programming-focused-ginkgo-bioworks-positioning-amid-revenue-",
            "time_published": "20240110T192943",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Wednesday, Ginkgo Bioworks Holdings Inc DNA released preliminary FY23 sales of $250 million-$260 million, compared to the consensus of $258.65 million. Preliminary cell engineering and biosecurity revenue are expected to be within the disclosed guidance range of $145 million-$150 million and up ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/10/dna.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.222569,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "DNA",
                    "relevance_score": "0.355588",
                    "ticker_sentiment_score": "0.160827",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.241684",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.241684",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Looking At Novo Nordisk's Recent Unusual Options Activity - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/markets/options/24/01/36579939/looking-at-novo-nordisks-recent-unusual-options-activity",
            "time_published": "20240110T164603",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Deep-pocketed investors have adopted a bullish approach towards Novo Nordisk NVO, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.213998,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.697241",
                    "ticker_sentiment_score": "0.332341",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Futures Mixed As CPI Inflation Data Looms",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-goldman-sachs-downgraded-bitcoin-stock-coinbase-slides/",
            "time_published": "20240110T131400",
            "authors": [
                "SCOTT LEHTONEN",
                "Investor's Business Daily"
            ],
            "summary": "Dow Jones Futures Fall As Goldman Sachs Downgraded. Bitcoin Stock Coinbase Slides Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2017/08/WallStreetFinance2-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Blockchain",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.143114,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.138265",
                    "ticker_sentiment_score": "0.102157",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.206099",
                    "ticker_sentiment_score": "0.088336",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.138265",
                    "ticker_sentiment_score": "0.071156",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.069394",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRWD",
                    "relevance_score": "0.069394",
                    "ticker_sentiment_score": "0.188027",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.069394",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.069394",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.172342",
                    "ticker_sentiment_score": "0.184649",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SMCI",
                    "relevance_score": "0.069394",
                    "ticker_sentiment_score": "0.188027",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.138265",
                    "ticker_sentiment_score": "-0.161588",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.03473",
                    "ticker_sentiment_score": "0.115549",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.172342",
                    "ticker_sentiment_score": "0.120675",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COIN",
                    "relevance_score": "0.103927",
                    "ticker_sentiment_score": "-0.231723",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "PSMT",
                    "relevance_score": "0.103927",
                    "ticker_sentiment_score": "0.12371",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KBH",
                    "relevance_score": "0.103927",
                    "ticker_sentiment_score": "0.12371",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.138265",
                    "ticker_sentiment_score": "0.071156",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.172342",
                    "ticker_sentiment_score": "0.077385",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SGH",
                    "relevance_score": "0.103927",
                    "ticker_sentiment_score": "0.12371",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.069394",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAT",
                    "relevance_score": "0.138265",
                    "ticker_sentiment_score": "0.210256",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GCT",
                    "relevance_score": "0.069394",
                    "ticker_sentiment_score": "0.188027",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.138265",
                    "ticker_sentiment_score": "0.172429",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.103927",
                    "ticker_sentiment_score": "-0.231723",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Ginkgo Bioworks Provides Business Updates at J.P. Morgan Healthcare Conference",
            "url": "https://www.prnewswire.com/news-releases/ginkgo-bioworks-provides-business-updates-at-jp-morgan-healthcare-conference-302031259.html",
            "time_published": "20240110T123500",
            "authors": [
                "Ginkgo Bioworks"
            ],
            "summary": "Expects to meet 2023 new program and revenue guidance ranges Ended the year with nearly $950 million in cash and cash equivalents, a strong balance sheet providing multi-year runway as Ginkgo sees operational efficiencies in the business",
            "banner_image": "https://mma.prnewswire.com/media/1583909/Ginkgo_Logo_Lockup.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.990999"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.219116,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.027476",
                    "ticker_sentiment_score": "0.004673",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DNA",
                    "relevance_score": "0.190524",
                    "ticker_sentiment_score": "0.121595",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.082299",
                    "ticker_sentiment_score": "0.146189",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.05492",
                    "ticker_sentiment_score": "0.142845",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.027476",
                    "ticker_sentiment_score": "0.096738",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Bring On The Competition In Obesity Drugs: Novo Nordisk CEO Optimistic About Prolonged Patient Adherence to Obesity Drug Wegovy - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/24/01/36572555/bring-on-the-competition-in-obesity-drugs-novo-nordisk-ceo-optimistic-about-prolonged-patient-adh",
            "time_published": "20240110T114313",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Lars Fruergaard Jorgensen, CEO of Novo Nordisk A/S NVO, shared insights during the JPMorgan Healthcare conference, highlighting Wegovy's efficacy for weight loss, indicating that patients are likely to continue with Wegovy for more extended periods compared to older treatments commonly used.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/10/wegovy-company.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.266805,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.342487",
                    "ticker_sentiment_score": "0.044989",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.117486",
                    "ticker_sentiment_score": "0.002294",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.445569",
                    "ticker_sentiment_score": "0.124314",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Prothena  ( PRTA )  Surges 12.3%: Is This an Indication of Further Gains?",
            "url": "https://www.zacks.com/stock/news/2208019/prothena-prta-surges-123-is-this-an-indication-of-further-gains",
            "time_published": "20240110T103800",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default25.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.961735"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.145004,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.085324",
                    "ticker_sentiment_score": "0.075254",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PRTA",
                    "relevance_score": "0.407844",
                    "ticker_sentiment_score": "0.145586",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.085324",
                    "ticker_sentiment_score": "0.075254",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Wegovy: Uses, Dosage, Side Effects And Warnings",
            "url": "https://www.forbes.com/health/weight-loss/wegovy/",
            "time_published": "20240110T080600",
            "authors": [
                "Alyssa Northrop"
            ],
            "summary": "What Is Wegovy? Uses, Side Effects And Warnings - Forbes Health Forbes ...",
            "banner_image": "https://thumbor.forbes.com/thumbor/fit-in/x/https://www.forbes.com/health/wp-content/uploads/2023/09/Ro.png",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.012018,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.030485",
                    "ticker_sentiment_score": "0.030582",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ozempic's unconventional origins",
            "url": "https://www.ft.com/content/1107bca8-5e17-4a20-9d0b-a985574d454e",
            "time_published": "20240110T050000",
            "authors": [
                "Michela Tindera",
                "Hannah Kuchler"
            ],
            "summary": "What's next for Novo Nordisk?",
            "banner_image": "https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fwww.ft.com%2F__origami%2Fservice%2Fimage%2Fv2%2Fimages%2Fraw%2Fhttps%253A%252F%252Fnext-video-editor-images.s3.ap-northeast-1.amazonaws.com%252F917e8a38-6d52-41f9-adc5-93aa27987f5f%3Fsource%3Dnext-article%26fit%3Dscale-down%26quality%3Dhighest%26width%3D700%26dpr%3D1?source=next-opengraph&fit=scale-down&width=900",
            "source": "Financial Times",
            "category_within_source": "Companies",
            "source_domain": "www.ft.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.207203,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SPOT",
                    "relevance_score": "0.266828",
                    "ticker_sentiment_score": "0.195752",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.504646",
                    "ticker_sentiment_score": "0.293318",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  Ascends While Market Falls: Some Facts to Note",
            "url": "https://www.zacks.com/stock/news/2207800/novo-nordisk-nvo-ascends-while-market-falls-some-facts-to-note",
            "time_published": "20240109T225019",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "In the most recent trading session, Novo Nordisk (NVO) closed at $106.95, indicating a +0.52% shift from the previous trading day.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default306.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.839681"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.19869,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.554916",
                    "ticker_sentiment_score": "0.252176",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Is WisdomTree Global ex-U.S. Quality Dividend Growth ETF  ( DNL )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2207713/is-wisdomtree-global-ex-us-quality-dividend-growth-etf-dnl-a-strong-etf-right-now",
            "time_published": "20240109T215517",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default271.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999858"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.287399,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SSNLF",
                    "relevance_score": "0.059935",
                    "ticker_sentiment_score": "0.076999",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MORN",
                    "relevance_score": "0.059935",
                    "ticker_sentiment_score": "0.186255",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WT",
                    "relevance_score": "0.293038",
                    "ticker_sentiment_score": "0.287602",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.059935",
                    "ticker_sentiment_score": "0.076999",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSM",
                    "relevance_score": "0.059935",
                    "ticker_sentiment_score": "0.076999",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Moderna  ( MRNA )  Issues 2023 Preliminary Results, Stock Up 4%",
            "url": "https://www.zacks.com/stock/news/2207654/moderna-mrna-issues-2023-preliminary-results-stock-up-4",
            "time_published": "20240109T181500",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Moderna (MRNA) reports unaudited product sales of around $6.7 billion for 2023, meeting its previously issued guidance. Share price rises following the announcement.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.928139"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.061261,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.64962",
                    "ticker_sentiment_score": "0.15185",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.184598",
                    "ticker_sentiment_score": "0.119388",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTMX",
                    "relevance_score": "0.273807",
                    "ticker_sentiment_score": "-0.022647",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk's  ( NVO )  Phase III Diabetes Study Meets Primary Goal",
            "url": "https://www.zacks.com/stock/news/2207561/novo-nordisks-nvo-phase-iii-diabetes-study-meets-primary-goal",
            "time_published": "20240109T162600",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) reports positive top-line data from one of its late-stage studies under the COMBINE program evaluating once-weekly IcoSema in type II diabetes patients.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.986564"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.090054,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ADMA",
                    "relevance_score": "0.319488",
                    "ticker_sentiment_score": "0.163131",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ACAD",
                    "relevance_score": "0.231332",
                    "ticker_sentiment_score": "0.061906",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.362065",
                    "ticker_sentiment_score": "0.007722",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PBYI",
                    "relevance_score": "0.231332",
                    "ticker_sentiment_score": "0.162542",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons",
            "url": "https://www.globenewswire.com/news-release/2024/01/09/2806517/0/en/Novo-Nordisk-A-S-Trading-in-Novo-Nordisk-shares-by-board-members-executives-and-associated-persons.html",
            "time_published": "20240109T161500",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 9 January 2024 - This company announcement discloses the data of the transaction ( s ) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.100301,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.186738",
                    "ticker_sentiment_score": "0.058933",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.186738",
                    "ticker_sentiment_score": "0.058933",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.94121",
                    "ticker_sentiment_score": "0.177803",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Biotech ETFs Stage Solid Comeback at the Start of 2024",
            "url": "https://www.zacks.com/stock/news/2207551/biotech-etfs-stage-solid-comeback-at-the-start-of-2024",
            "time_published": "20240109T160500",
            "authors": [
                "Sweta Killa"
            ],
            "summary": "The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999999"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.147642,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.133346",
                    "ticker_sentiment_score": "0.162037",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.089129",
                    "ticker_sentiment_score": "0.084886",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KRTX",
                    "relevance_score": "0.089129",
                    "ticker_sentiment_score": "0.058856",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.089129",
                    "ticker_sentiment_score": "0.084886",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RYZB",
                    "relevance_score": "0.089129",
                    "ticker_sentiment_score": "0.058856",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.089129",
                    "ticker_sentiment_score": "0.058856",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.133346",
                    "ticker_sentiment_score": "0.06769",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.089129",
                    "ticker_sentiment_score": "0.058856",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GRCL",
                    "relevance_score": "0.089129",
                    "ticker_sentiment_score": "0.058856",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HARP",
                    "relevance_score": "0.089129",
                    "ticker_sentiment_score": "0.084886",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.133346",
                    "ticker_sentiment_score": "0.162037",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.133346",
                    "ticker_sentiment_score": "0.071668",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "OMGA",
                    "relevance_score": "0.089129",
                    "ticker_sentiment_score": "0.140918",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Simple Tricks That Every Investor Should Use  ( but Most Don't ) ",
            "url": "https://www.fool.com/investing/2024/01/09/3-simple-tricks-that-every-investor-should-use-but/",
            "time_published": "20240109T151500",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "Having a few tricks up your sleeve can increase your returns over time.",
            "banner_image": "https://media.ycharts.com/charts/48e06246cfdd0fa2187cc0683cfa221e.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                }
            ],
            "overall_sentiment_score": 0.233827,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.170576",
                    "ticker_sentiment_score": "-0.026863",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.128363",
                    "ticker_sentiment_score": "0.032509",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.085782",
                    "ticker_sentiment_score": "0.123385",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.170576",
                    "ticker_sentiment_score": "-0.026863",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Futures Lower As Netflix Slides On Downgrade",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-netflix-slides-on-downgrade-nvidia-set-to-hit-more-record-highs/",
            "time_published": "20240109T131200",
            "authors": [
                "Investor's Business Daily",
                "SCOTT LEHTONEN"
            ],
            "summary": "Dow Jones Futures Fall As Netflix Slides On Downgrade. Nvidia To Hit More Record Highs Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/10/stock-wall-street-flags-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.125108,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.212115",
                    "ticker_sentiment_score": "0.025517",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.246404",
                    "ticker_sentiment_score": "0.120353",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.142355",
                    "ticker_sentiment_score": "0.087329",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.142355",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.071463",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.071463",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.17741",
                    "ticker_sentiment_score": "0.19543",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NEOG",
                    "relevance_score": "0.107016",
                    "ticker_sentiment_score": "-0.03966",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.035768",
                    "ticker_sentiment_score": "0.115999",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.17741",
                    "ticker_sentiment_score": "0.125977",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.142355",
                    "ticker_sentiment_score": "0.087329",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AYI",
                    "relevance_score": "0.107016",
                    "ticker_sentiment_score": "-0.03966",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.212115",
                    "ticker_sentiment_score": "0.110013",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.071463",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "V",
                    "relevance_score": "0.142355",
                    "ticker_sentiment_score": "0.146672",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAT",
                    "relevance_score": "0.142355",
                    "ticker_sentiment_score": "0.219761",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.142355",
                    "ticker_sentiment_score": "0.140471",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Better Growth Investment: Ginkgo Bioworks vs. Shiba Inu",
            "url": "https://www.fool.com/investing/2024/01/09/better-growth-investment-ginkgo-bioworks-vs-shiba/",
            "time_published": "20240109T125700",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "Both of these investments need to prove that they can actually grow.",
            "banner_image": "https://g.foolcdn.com/editorial/images/759677/investor-sitting-with-laptop-and-dog.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Blockchain",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.210206,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.050572",
                    "ticker_sentiment_score": "0.076428",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DNA",
                    "relevance_score": "0.200273",
                    "ticker_sentiment_score": "0.185511",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.050572",
                    "ticker_sentiment_score": "0.076428",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.050572",
                    "ticker_sentiment_score": "0.076428",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:SHIB",
                    "relevance_score": "0.342939",
                    "ticker_sentiment_score": "0.190441",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Pfizer's Aggressive Stance In Obesity Drugs: CEO Albert Bourla Confirms Bold Bet Despite Prior Drug Hurdles - Pfizer  ( NYSE:PFE ) ",
            "url": "https://www.benzinga.com/general/biotech/24/01/36552329/pfizers-aggressive-stance-in-obesity-drugs-ceo-albert-bourla-confirms-bold-bet-despite-prior-drug",
            "time_published": "20240109T124231",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Monday, at the JP Morgan Healthcare Conference, Pfizer Inc PFE CEO Albert Bourla expressed that the company is determined to move forward in the burgeoning obesity market despite setbacks involving a terminated weight-loss drug candidate due to severe side effects.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/09/weight-loss-photo_by_vidmir_rais_via_pixabay.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.014279,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.213048",
                    "ticker_sentiment_score": "0.089198",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.107495",
                    "ticker_sentiment_score": "-0.00444",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.213048",
                    "ticker_sentiment_score": "0.089198",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.500753",
                    "ticker_sentiment_score": "0.056545",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk Foundation partners with CARB-X to fight drug-resistant infections",
            "url": "https://www.benzinga.com/pressreleases/24/01/n36551659/novo-nordisk-foundation-partners-with-carb-x-to-fight-drug-resistant-infections",
            "time_published": "20240109T110000",
            "authors": [
                "PRNewswire"
            ],
            "summary": "COPENHAGEN, Denmark, Jan. 9, 2024 /PRNewswire/ -- The Novo Nordisk Foundation is committing up to USD 25 million to support the early-stage development of innovative tools to prevent, diagnose and treat the most dangerous drug-resistant bacterial infections.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.228024,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.153891",
                    "ticker_sentiment_score": "0.198898",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Obesity drug challengers will struggle to break into plus-sized market",
            "url": "https://www.ft.com/content/184617f3-9a88-4d23-8e23-d1a08d5577dd",
            "time_published": "20240109T050017",
            "authors": [],
            "summary": "Weight loss treatments are tipped to rake in $80bn a year by 2030. Danish pioneer Novo Nordisk and rival Eli Lilly have made the running. But others are trying to find space in the field. Around a dozen companies are set to announce trial results for over 20 drugs this year.",
            "banner_image": "https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fd6c748xw2pzm8.cloudfront.net%2Fprod%2F880fa250-ae40-11ee-bb0e-3537ccd787f0-standard.png?source=next-article&fit=scale-down&quality=highest&width=700&dpr=1",
            "source": "Financial Times",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.ft.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.197503,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "C",
                    "relevance_score": "0.07913",
                    "ticker_sentiment_score": "0.266321",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.07913",
                    "ticker_sentiment_score": "0.097567",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "OMGA",
                    "relevance_score": "0.07913",
                    "ticker_sentiment_score": "0.211921",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.308891",
                    "ticker_sentiment_score": "0.222308",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Ozempic Users Might Experience Caloric Intake Rise Post-Discontinuation: Survey - Allurion Technologies  ( NYSE:ALUR ) , Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/news/24/01/36548855/ozempic-users-might-experience-caloric-intake-rise-post-discontinuation-survey",
            "time_published": "20240109T031455",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "Deutsche Bank has recently conducted a survey suggesting that patients using Novo Nordisk A/S NVO weight loss medication, Ozempic, may increase their caloric intake after discontinuing the treatment. What Happened: The survey involved 600 U.S. consumers.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Ozempic-and-other-drugs-for-weight-loss_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.121188,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ALUR",
                    "relevance_score": "0.25168",
                    "ticker_sentiment_score": "-0.212424",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.369685",
                    "ticker_sentiment_score": "0.051776",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "People may eat more calories after stopping weight loss drugs, according to Deutsche Bank survey",
            "url": "https://www.cnbc.com/2024/01/08/post-ozempic-patients-may-eat-more-calories-deutsche-bank-survey-finds.html",
            "time_published": "20240108T231814",
            "authors": [
                "Christina Cheddar Berk"
            ],
            "summary": "Ozempic and Wegovy have been cheered for helping people shed unwanted pounds, but the findings of a recent poll underscore the challenges patients face.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107259397-1687277605147-gettyimages-1408952743-l1001366_50b477ae-2102-40fb-b230-7433d4181724.jpeg?v=1704734611&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Investing",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.918141"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.071782,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MDLZ",
                    "relevance_score": "0.073098",
                    "ticker_sentiment_score": "0.140098",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALUR",
                    "relevance_score": "0.036587",
                    "ticker_sentiment_score": "0.021305",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.036587",
                    "ticker_sentiment_score": "0.147733",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.073098",
                    "ticker_sentiment_score": "0.005093",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KHC",
                    "relevance_score": "0.036587",
                    "ticker_sentiment_score": "0.139851",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UL",
                    "relevance_score": "0.073098",
                    "ticker_sentiment_score": "0.140098",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.073098",
                    "ticker_sentiment_score": "0.140098",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Wall Street Raises The Bar For These Four Stocks In 2024",
            "url": "https://www.investors.com/research/nvda-stock-wall-street-raises-the-bar-for-it-and-three-other-stocks-for-2024/",
            "time_published": "20240108T223000",
            "authors": [
                "VIDYA RAMAKRISHNAN",
                "Investor's Business Daily"
            ],
            "summary": "NVDA Stock: Wall Street Raises The Bar For It And Three Other Stocks For 2024 Separator Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2020/03/stock-Nvidia-AI-02-company.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999897"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999813"
                }
            ],
            "overall_sentiment_score": 0.396707,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MELI",
                    "relevance_score": "0.214304",
                    "ticker_sentiment_score": "0.273838",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.413425",
                    "ticker_sentiment_score": "0.566473",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "DECK",
                    "relevance_score": "0.28305",
                    "ticker_sentiment_score": "0.299456",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.28305",
                    "ticker_sentiment_score": "0.333814",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Futures: Magnificent Seven Stocks Lead Market Rally",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-magnificent-seven-stocks-rally-nvidia-breaks-out-past-buy-point/",
            "time_published": "20240108T215500",
            "authors": [
                "SCOTT LEHTONEN",
                "Investor's Business Daily"
            ],
            "summary": "Dow Jones Futures: Magnificent Seven Stocks Rally. Nvidia Breaks Out Past Buy Point Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/02/Stock-Chip-glows-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.208919,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "0.155184",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.076971",
                    "ticker_sentiment_score": "0.086006",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.153226",
                    "ticker_sentiment_score": "0.122934",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.228073",
                    "ticker_sentiment_score": "0.270391",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.076971",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.076971",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.076971",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.153226",
                    "ticker_sentiment_score": "0.202159",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.153226",
                    "ticker_sentiment_score": "0.123387",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.228073",
                    "ticker_sentiment_score": "0.154061",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.153226",
                    "ticker_sentiment_score": "0.113992",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.076971",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "V",
                    "relevance_score": "0.153226",
                    "ticker_sentiment_score": "0.155683",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CAT",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "0.220472",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.190868",
                    "ticker_sentiment_score": "0.251625",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "0.014102",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Nvidia dives deeper into AI drug development with Amgen, Recursion partnerships",
            "url": "https://www.marketwatch.com/story/nvidia-dives-deeper-into-ai-drug-development-with-amgen-recursion-partnerships-de481c8b",
            "time_published": "20240108T180000",
            "authors": [
                "Eleanor Laise"
            ],
            "summary": "Nvidia is doubling down on artificial-intelligence-powered drug discovery and development, announcing expanded partnerships with Amgen and Recursion Pharmaceuticals.",
            "banner_image": "https://images.mktw.net/im-608401/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.106715,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.545493",
                    "ticker_sentiment_score": "0.144731",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RXRX",
                    "relevance_score": "0.132004",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.26042",
                    "ticker_sentiment_score": "0.185456",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.132004",
                    "ticker_sentiment_score": "0.105235",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.132004",
                    "ticker_sentiment_score": "0.123084",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Wegovy and Ozempic Maker Novo Nordisk Shares Data From Phase 3 Diabetes Study Of Semaglutide/Insulin Containing Candidate - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/24/01/36536686/wegovy-and-ozempic-maker-novo-nordisk-shares-data-from-phase-3-diabetes-study-of-semaglutideinsul",
            "time_published": "20240108T161101",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Novo Nordisk A/S NVO announced topline results from the COMBINE 3 phase 3a trial of once-weekly IcoSema, a fixed-ratio combination of basal insulin icodec and semaglutide. Semaglutide is used in Novo Nordisk's blockbuster weight loss and diabetes drugs Wegvoy and Ozempic.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/08/ozempic.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.094053,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.339356",
                    "ticker_sentiment_score": "0.129526",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Merck  ( MRK )  Begins Pivotal Studies on Four Cancer Candidates",
            "url": "https://www.zacks.com/stock/news/2207014/merck-mrk-begins-pivotal-studies-on-four-cancer-candidates",
            "time_published": "20240108T151100",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Merck (MRK) begins global pivotal studies on bomedemstat, nemtabrutinib, MK-2870 and MK-5684.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/12/31139.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.928139"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.051921,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.267559",
                    "ticker_sentiment_score": "0.057317",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AQST",
                    "relevance_score": "0.391923",
                    "ticker_sentiment_score": "0.104365",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Could Novo Nordisk Stock Help You Retire a Millionaire?",
            "url": "https://www.fool.com/investing/2024/01/08/could-novo-nordisk-stock-help-you-retire-a-million/",
            "time_published": "20240108T144500",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "This company is steadily gaining in value, and its growth runway is quite long, too.",
            "banner_image": "https://g.foolcdn.com/editorial/images/760344/investor-ponders-a-screen.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.955357"
                }
            ],
            "overall_sentiment_score": 0.237262,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GLDAF",
                    "relevance_score": "0.055492",
                    "ticker_sentiment_score": "0.04202",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.373911",
                    "ticker_sentiment_score": "0.308675",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Two Biotechs Roughly Double After Snagging Splashy Takeover Deals",
            "url": "https://www.investors.com/news/technology/amam-stock-harp-stock-catapult-after-snagging-jnj-merck-buyouts/",
            "time_published": "20240108T141900",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "AMAM Stock, HARP Stock Catapult After Snagging J&J, Merck Buyouts Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2017/10/stock-JohnsonANDjohnson-02-shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.980922"
                }
            ],
            "overall_sentiment_score": 0.210915,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BSX",
                    "relevance_score": "0.529185",
                    "ticker_sentiment_score": "0.18163",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HARP",
                    "relevance_score": "0.334762",
                    "ticker_sentiment_score": "0.110142",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.114682",
                    "ticker_sentiment_score": "-0.131349",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AXNX",
                    "relevance_score": "0.436009",
                    "ticker_sentiment_score": "0.214449",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.114682",
                    "ticker_sentiment_score": "0.37702",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.227007",
                    "ticker_sentiment_score": "0.160288",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Is Beleaguered Big Pharma Merck Finally Staging A Comeback?",
            "url": "https://www.investors.com/news/technology/merck-stock-is-it-finally-time-for-this-2023-laggard-to-stage-a-comeback/",
            "time_published": "20240108T140005",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "Merck Stock: Is It Finally Time For This 2023 Laggard To Stage A Comeback? Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/05/Stock-merckhq-rahway-03-company.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.977154"
                }
            ],
            "overall_sentiment_score": -0.023982,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "SKXJF",
                    "relevance_score": "0.175433",
                    "ticker_sentiment_score": "-0.153983",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "DSKYF",
                    "relevance_score": "0.175433",
                    "ticker_sentiment_score": "-0.153983",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.058903",
                    "ticker_sentiment_score": "-0.117998",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.058903",
                    "ticker_sentiment_score": "0.337242",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Futures Mixed As Boeing Dives On Groundings",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-boeing-dives-on-groundings-coinbase-rallies-on-price-target-hike/",
            "time_published": "20240108T130900",
            "authors": [
                "SCOTT LEHTONEN",
                "Investor's Business Daily"
            ],
            "summary": "Dow Jones Futures Fall As Boeing Dives On Groundings. Coinbase Rallies On Price Hike Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2017/10/stock-WallStreet-03-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Blockchain",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.119998,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.141935",
                    "ticker_sentiment_score": "0.115667",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.245693",
                    "ticker_sentiment_score": "0.107766",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.141935",
                    "ticker_sentiment_score": "0.080304",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.071251",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.071251",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNOW",
                    "relevance_score": "0.071251",
                    "ticker_sentiment_score": "0.214688",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.071251",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.141935",
                    "ticker_sentiment_score": "0.225583",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AWON",
                    "relevance_score": "0.035661",
                    "ticker_sentiment_score": "0.128652",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.035661",
                    "ticker_sentiment_score": "0.115954",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.141935",
                    "ticker_sentiment_score": "0.054607",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COIN",
                    "relevance_score": "0.141935",
                    "ticker_sentiment_score": "-0.02624",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DAL",
                    "relevance_score": "0.071251",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.071251",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.106699",
                    "ticker_sentiment_score": "0.070375",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.245693",
                    "ticker_sentiment_score": "0.11348",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.071251",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "V",
                    "relevance_score": "0.141935",
                    "ticker_sentiment_score": "0.152618",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CAT",
                    "relevance_score": "0.17689",
                    "ticker_sentiment_score": "0.211943",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.106699",
                    "ticker_sentiment_score": "-0.085498",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "COMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema demonstrating non-inferior reduction in HbA1c versus daily basal-bolus treatment  ( insulin glargine U100 and insulin aspart )  in people with type 2 diabetes",
            "url": "https://www.globenewswire.com/news-release/2024/01/08/2805354/0/en/COMBINE-3-phase-3a-trial-successfully-completed-with-once-weekly-IcoSema-demonstrating-non-inferior-reduction-in-HbA1c-versus-daily-basal-bolus-treatment-insulin-glargine-U100-and-.html",
            "time_published": "20240108T124900",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "COMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema demonstrating non-inferior reduction in HbA versus daily basal-bolus treatment ( insulin glargine U100 and insulin aspart ) in people with type 2 diabetes",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.066229,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.051111",
                    "ticker_sentiment_score": "0.038",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.051111",
                    "ticker_sentiment_score": "0.038",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.25142",
                    "ticker_sentiment_score": "0.048613",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ginkgo Bioworks Announces Inaugural Members of New Biopharma Advisory Board - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/ginkgo-bioworks-announces-inaugural-members-of-new-biopharma-advisory-board-302027954.html",
            "time_published": "20240108T120000",
            "authors": [],
            "summary": "Ginkgo Bioworks Announces Inaugural Members of New Biopharma Advisory Board PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.224156,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SYBX",
                    "relevance_score": "0.032916",
                    "ticker_sentiment_score": "0.090614",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DNA",
                    "relevance_score": "0.289652",
                    "ticker_sentiment_score": "0.304048",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.032916",
                    "ticker_sentiment_score": "0.090614",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.032916",
                    "ticker_sentiment_score": "0.090614",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Insurance denials for popular new weight loss medications leave patients with risky choices",
            "url": "https://www.cnn.com/2024/01/08/health/weight-loss-drug-insurance-denials/index.html",
            "time_published": "20240108T114000",
            "authors": [
                "Brenda Goodman"
            ],
            "summary": "When she started taking the weight loss medication Wegovy in November 2021, Macarena Khoury had a BMI of 37, and she spent most of her day thinking about food. \"All the time. All day. Like, 'I'm hungry. I need to eat this.",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1255267455.jpg?c=16x9&q=h_144,w_256,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.038431,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.043618",
                    "ticker_sentiment_score": "0.007915",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.021817",
                    "ticker_sentiment_score": "-0.042892",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S - share repurchase programme",
            "url": "https://www.globenewswire.com/news-release/2024/01/08/2805196/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html",
            "time_published": "20240108T111100",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsværd, Denmark, 08 January 2024 - On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.122936,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.045242",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.045242",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.781591",
                    "ticker_sentiment_score": "0.195779",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Dewpoint Therapeutics Filed Multiple Patent Applications with the US Patent Office on Novel Composition of Matter for the Treatment of ALS",
            "url": "https://www.benzinga.com/pressreleases/24/01/g36526357/dewpoint-therapeutics-filed-multiple-patent-applications-with-the-us-patent-office-on-novel-compos",
            "time_published": "20240107T200000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "Patent applications reinforce Dewpoint's leadership in the discovery of condensate-modifying drugs ( c-mods ) to treat diseases of high unmet need New first-in-class composition of matter targeting TDP-43 condensates to correct complex ALS-associated neuronal dysfunction",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.130707,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.060388",
                    "ticker_sentiment_score": "0.020018",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Nvidia And Spotify Lead Five Stocks Near Buy Points",
            "url": "https://www.investors.com/news/nvidia-spotify-lead-five-stocks-near-buy-points/",
            "time_published": "20240106T161200",
            "authors": [
                "JED GRAHAM",
                "Investor's Business Daily"
            ],
            "summary": "Nvidia ( NVDA ) , one of the Magnificent Seven stocks, and digital audio streaming leader Spotify ( SPOT ) head this weekend's watchlist of stocks near buy points.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/05/Stock-nvidia-hq-04-company.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.818451"
                }
            ],
            "overall_sentiment_score": 0.141748,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "TGT",
                    "relevance_score": "0.060236",
                    "ticker_sentiment_score": "0.173176",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CELH",
                    "relevance_score": "0.32231",
                    "ticker_sentiment_score": "0.198665",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.294446",
                    "ticker_sentiment_score": "0.241706",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ULTA",
                    "relevance_score": "0.060236",
                    "ticker_sentiment_score": "0.173176",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.03014",
                    "ticker_sentiment_score": "0.070517",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SBUX",
                    "relevance_score": "0.03014",
                    "ticker_sentiment_score": "0.068427",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPOT",
                    "relevance_score": "0.34974",
                    "ticker_sentiment_score": "0.242228",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MNST",
                    "relevance_score": "0.090247",
                    "ticker_sentiment_score": "-0.130828",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.237551",
                    "ticker_sentiment_score": "0.119502",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.060236",
                    "ticker_sentiment_score": "0.041072",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PEP",
                    "relevance_score": "0.060236",
                    "ticker_sentiment_score": "0.073016",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "OMGA",
                    "relevance_score": "0.060236",
                    "ticker_sentiment_score": "-0.004022",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Investing Trends to Follow in 2024",
            "url": "https://www.fool.com/investing/2024/01/06/investing-trends-to-follow-in-2024/",
            "time_published": "20240106T130000",
            "authors": [
                "Motley Fool Staff"
            ],
            "summary": "We've also got Motley Fool co-founder Tom Gardner sharing an investing lesson from last year and a stock for this one.",
            "banner_image": "https://g.foolcdn.com/editorial/images/759866/mfm_29.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972476"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.084187,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.011873",
                    "ticker_sentiment_score": "0.082431",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TGT",
                    "relevance_score": "0.011873",
                    "ticker_sentiment_score": "0.019194",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.005937",
                    "ticker_sentiment_score": "0.103315",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.005937",
                    "ticker_sentiment_score": "-0.033259",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KO",
                    "relevance_score": "0.005937",
                    "ticker_sentiment_score": "0.013661",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDNDF",
                    "relevance_score": "0.005937",
                    "ticker_sentiment_score": "0.013661",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VZ",
                    "relevance_score": "0.005937",
                    "ticker_sentiment_score": "0.080034",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EPR",
                    "relevance_score": "0.017808",
                    "ticker_sentiment_score": "0.061109",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.005937",
                    "ticker_sentiment_score": "-0.033259",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.005937",
                    "ticker_sentiment_score": "0.013661",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.017808",
                    "ticker_sentiment_score": "0.026016",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMT",
                    "relevance_score": "0.017808",
                    "ticker_sentiment_score": "0.072931",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.029676",
                    "ticker_sentiment_score": "-0.029458",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.005937",
                    "ticker_sentiment_score": "0.013661",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DPZ",
                    "relevance_score": "0.005937",
                    "ticker_sentiment_score": "0.013661",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HSY",
                    "relevance_score": "0.005937",
                    "ticker_sentiment_score": "0.013661",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.005937",
                    "ticker_sentiment_score": "0.103315",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SHOP",
                    "relevance_score": "0.118296",
                    "ticker_sentiment_score": "0.031635",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "YUM",
                    "relevance_score": "0.005937",
                    "ticker_sentiment_score": "0.013661",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DMPZF",
                    "relevance_score": "0.005937",
                    "ticker_sentiment_score": "0.013661",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.005937",
                    "ticker_sentiment_score": "0.103315",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SBUX",
                    "relevance_score": "0.029676",
                    "ticker_sentiment_score": "0.080901",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BBBYQ",
                    "relevance_score": "0.005937",
                    "ticker_sentiment_score": "-0.019619",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Covid and Flu Cases Are Spiking. It Looks Serious.",
            "url": "https://www.barrons.com/amp/articles/covid-flu-spiking-variant-be52906f",
            "time_published": "20240106T073000",
            "authors": [
                "Josh Nathan-Kazis"
            ],
            "summary": "JN.1, a new Covid-19 variant taking hold in the U.S., is raising concerns of potential disruptions to U.S. hospitals. The arrival of a new Covid-19 variant just as the winter flu season takes hold in the U.S. is sending tens of thousands of Americans to emergency rooms, and raising concerns about ...",
            "banner_image": "https://images.barrons.com/im-58738368/social",
            "source": "Barrons",
            "category_within_source": "n/a",
            "source_domain": "www.barrons.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.650727"
                }
            ],
            "overall_sentiment_score": -0.120913,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BAC",
                    "relevance_score": "0.048425",
                    "ticker_sentiment_score": "0.080118",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.048425",
                    "ticker_sentiment_score": "-0.137",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ozempic's massive bills: Weight loss drugs will be billed to US taxpayers",
            "url": "https://www.business-standard.com/world-news/ozempic-s-massive-bills-weight-loss-drugs-will-be-billed-to-us-taxpayers-124010600081_1.html",
            "time_published": "20240106T022123",
            "authors": [
                "Bloomberg"
            ],
            "summary": "State health plans and Medicaid offices are seeing eye-popping bills for Novo Nordisk A/S's Ozempic, its sister drug Wegovy and similar medications known as GLP-1s. They're a breakthrough for treating two of the most complex chronic health conditions.",
            "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2024-01/06/full/1704507116-4251.png?im=Resize=(640,480)",
            "source": "Business Standard",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.business-standard.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": -0.036132,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CVS",
                    "relevance_score": "0.045655",
                    "ticker_sentiment_score": "0.005",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JEF",
                    "relevance_score": "0.022837",
                    "ticker_sentiment_score": "0.062761",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CMG",
                    "relevance_score": "0.022837",
                    "ticker_sentiment_score": "0.062761",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAVA",
                    "relevance_score": "0.022837",
                    "ticker_sentiment_score": "0.062761",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.113812",
                    "ticker_sentiment_score": "0.022134",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.022837",
                    "ticker_sentiment_score": "0.062761",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "JPMorgan Healthcare, CES Show, Bank Earnings, Inflation Data",
            "url": "https://www.investors.com/research/investing-action-plan/jpmorgan-healthcare-ces-show-bank-earnings-inflation-data-investing-action-plan/",
            "time_published": "20240105T222900",
            "authors": [
                "Investor's Business Daily",
                "IBD STAFF"
            ],
            "summary": "The big benchmarks launched the New Year by posting their first weekly slip since October. The Dow trimmed less than 1% while the Nasdaq lopped off 3%. Chips faltered, but solar stocks and auto retailers were the hardest hit industries. Big Pharma names had a good week, as Merck ( MRK ) led the ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2022/07/Stock-marketgrowth-03-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.890401"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.650727"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.891286"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.173993,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CELH",
                    "relevance_score": "0.123526",
                    "ticker_sentiment_score": "0.144722",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.123526",
                    "ticker_sentiment_score": "0.144722",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WDFC",
                    "relevance_score": "0.123526",
                    "ticker_sentiment_score": "0.013892",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.123526",
                    "ticker_sentiment_score": "0.021094",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WIT",
                    "relevance_score": "0.082535",
                    "ticker_sentiment_score": "0.064744",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.164188",
                    "ticker_sentiment_score": "0.1163",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPOT",
                    "relevance_score": "0.123526",
                    "ticker_sentiment_score": "0.144722",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.123526",
                    "ticker_sentiment_score": "0.021094",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.123526",
                    "ticker_sentiment_score": "0.144722",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BK",
                    "relevance_score": "0.082535",
                    "ticker_sentiment_score": "0.018562",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.082535",
                    "ticker_sentiment_score": "0.133922",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.082535",
                    "ticker_sentiment_score": "0.018562",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KBH",
                    "relevance_score": "0.164188",
                    "ticker_sentiment_score": "0.107238",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AYI",
                    "relevance_score": "0.123526",
                    "ticker_sentiment_score": "0.091327",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "QCOM",
                    "relevance_score": "0.082535",
                    "ticker_sentiment_score": "0.088799",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.164188",
                    "ticker_sentiment_score": "0.024866",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INTC",
                    "relevance_score": "0.164188",
                    "ticker_sentiment_score": "0.109444",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BBY",
                    "relevance_score": "0.082535",
                    "ticker_sentiment_score": "0.088799",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.082535",
                    "ticker_sentiment_score": "0.133922",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INFY",
                    "relevance_score": "0.082535",
                    "ticker_sentiment_score": "0.064744",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LRLCF",
                    "relevance_score": "0.041323",
                    "ticker_sentiment_score": "0.084607",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.082535",
                    "ticker_sentiment_score": "0.088799",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/markets/options/24/01/36517221/spotlight-on-novo-nordisk-analyzing-the-surge-in-options-activity",
            "time_published": "20240105T204555",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Deep-pocketed investors have adopted a bearish approach towards Novo Nordisk NVO, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.1779,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.716023",
                    "ticker_sentiment_score": "0.222027",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "People taking Wegovy and Ozempic have lower risk of suicidal thoughts vs. older drugs, study finds",
            "url": "https://apnews.com/article/semaglutide-wegovy-ozempic-suicide-thoughts-ee81ba196bb08776166d97ae5bcd4279",
            "time_published": "20240105T192500",
            "authors": [
                "JONEL ALECCIA"
            ],
            "summary": "People taking the popular diabetes and obesity drugs Ozempic and had a lower risk of suicidal thoughts than those taking other medications to treat the same conditions, a new federal study finds.",
            "banner_image": "https://dims.apnews.com/dims4/default/576715f/2147483647/strip/true/crop/3355x2235+0+1/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2Fd5%2F87%2F510a0f5ffd970d70c3c67baf5a71%2Fb9febcfdcdff4c24be7b80b70d597c3a",
            "source": "Associated Press",
            "category_within_source": "Markets",
            "source_domain": "apnews.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.104829,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "HHH",
                    "relevance_score": "0.089129",
                    "ticker_sentiment_score": "0.173257",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.17715",
                    "ticker_sentiment_score": "-0.144281",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "IBD Stock Of The Day: The Buying Opportunity In Weight Loss",
            "url": "https://www.investors.com/research/ibd-stock-of-the-day/novo-nordisk-stock-lingers-in-a-buy-zone-after-snagging-two-obesity-deals/",
            "time_published": "20240105T180100",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "Novo Nordisk Stock Lingers In Buy Zone After Snagging Two Obesity Deals Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/SOTD-1-4-2024NVO.png",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999365"
                }
            ],
            "overall_sentiment_score": 0.130124,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.404098",
                    "ticker_sentiment_score": "0.232614",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.350564",
                    "ticker_sentiment_score": "0.141762",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.120431",
                    "ticker_sentiment_score": "0.032569",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.120431",
                    "ticker_sentiment_score": "0.032569",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "OMGA",
                    "relevance_score": "0.120431",
                    "ticker_sentiment_score": "0.106572",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.120431",
                    "ticker_sentiment_score": "0.032569",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.060388",
                    "ticker_sentiment_score": "0.337437",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Omega  ( OMGA )  Up 95% on Obesity Drug Deal With Novo Nordisk",
            "url": "https://www.zacks.com/stock/news/2206517/omega-omga-up-95-on-obesity-drug-deal-with-novo-nordisk",
            "time_published": "20240105T175500",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Using Omega's (OMGA) proprietary technology platform, Novo Nordisk (NVO) intends to develop a novel therapeutic for obesity, which will enhance the body's metabolism activity to burn excess fats.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/34/973.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.249163,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.171282",
                    "ticker_sentiment_score": "0.181114",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.171282",
                    "ticker_sentiment_score": "0.135412",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "OMGA",
                    "relevance_score": "0.334762",
                    "ticker_sentiment_score": "0.156185",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.436009",
                    "ticker_sentiment_score": "0.356733",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Stock Market Skids To Start 2024: Weekly Review",
            "url": "https://www.investors.com/news/stock-market-skids-to-start-2024-as-tesla-apple-stumble-mobileye-crashes-weekly-review/",
            "time_published": "20240105T172600",
            "authors": [
                "IBD STAFF",
                "Investor's Business Daily"
            ],
            "summary": "Stock Market Skids To Start 2024 As Tesla, Apple Stumble, Mobileye Crashes: Weekly Review Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2021/03/Stock-BullBearMarket-88-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Blockchain",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999186"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.918141"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.004903,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MARA",
                    "relevance_score": "0.122425",
                    "ticker_sentiment_score": "0.031073",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XPEV",
                    "relevance_score": "0.061394",
                    "ticker_sentiment_score": "0.043033",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.182736",
                    "ticker_sentiment_score": "-0.254609",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "ADI",
                    "relevance_score": "0.061394",
                    "ticker_sentiment_score": "-0.10812",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GM",
                    "relevance_score": "0.061394",
                    "ticker_sentiment_score": "0.097219",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.122425",
                    "ticker_sentiment_score": "-0.020511",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NXPI",
                    "relevance_score": "0.061394",
                    "ticker_sentiment_score": "-0.10812",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAG",
                    "relevance_score": "0.061394",
                    "ticker_sentiment_score": "-0.048948",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AWON",
                    "relevance_score": "0.03072",
                    "ticker_sentiment_score": "0.092757",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LW",
                    "relevance_score": "0.091977",
                    "ticker_sentiment_score": "-0.053265",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TXN",
                    "relevance_score": "0.061394",
                    "ticker_sentiment_score": "-0.10812",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "STM",
                    "relevance_score": "0.061394",
                    "ticker_sentiment_score": "-0.10812",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COIN",
                    "relevance_score": "0.122425",
                    "ticker_sentiment_score": "0.031073",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SMPL",
                    "relevance_score": "0.091977",
                    "ticker_sentiment_score": "-0.053265",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BCS",
                    "relevance_score": "0.03072",
                    "ticker_sentiment_score": "-0.282869",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.212514",
                    "ticker_sentiment_score": "0.010321",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NIO",
                    "relevance_score": "0.061394",
                    "ticker_sentiment_score": "0.043033",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.182736",
                    "ticker_sentiment_score": "-0.026343",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CPE",
                    "relevance_score": "0.091977",
                    "ticker_sentiment_score": "-0.085615",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LI",
                    "relevance_score": "0.122425",
                    "ticker_sentiment_score": "-0.019092",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "OMGA",
                    "relevance_score": "0.061394",
                    "ticker_sentiment_score": "0.036136",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.122425",
                    "ticker_sentiment_score": "0.031073",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk's Ozempic And Wegovy Helps Lose Weight, Not One's Mind: US Study Find No Increased Suicidal Thoughts Risk - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/24/01/36509636/novo-nordisks-ozempic-and-wegovy-helps-lose-weight-not-ones-mind-us-study-find-no-increased-suici",
            "time_published": "20240105T154115",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "On Friday, a comprehensive U.S. study revealed that the use of Novo Nordisk A/S's NVO drugs Ozempic and Wegovy, widely prescribed for type 2 diabetes and obesity, respectively, is not associated with an increased risk of suicidal thoughts.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/05/ozempic.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.240928,
            "overall_sentiment_label": "Somewhat-Bearish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.423843",
                    "ticker_sentiment_score": "0.102776",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Lilly  ( LLY )  Starts Website to Help Access Tirzepatide Drugs",
            "url": "https://www.zacks.com/stock/news/2206369/lilly-lly-starts-website-to-help-access-tirzepatide-drugs",
            "time_published": "20240105T153600",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Eli Lilly's (LLY) digital pharmacy is expected to provide patients easy access to its FDA-approved tirzepatide medicines, Mounjaro and Zepbound.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/702.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.203265,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.510838",
                    "ticker_sentiment_score": "0.022707",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LFMD",
                    "relevance_score": "0.204647",
                    "ticker_sentiment_score": "0.052019",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HIMS",
                    "relevance_score": "0.270523",
                    "ticker_sentiment_score": "0.064996",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.068896",
                    "ticker_sentiment_score": "0.207108",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.137278",
                    "ticker_sentiment_score": "0.300003",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  Up on $1.1B Research Deals With 2 Biotechs",
            "url": "https://www.zacks.com/stock/news/2206370/novo-nordisk-nvo-up-on-11b-research-deals-with-2-biotechs",
            "time_published": "20240105T153500",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) gains 4% after signing $1.1 billion research collaboration agreements with two biotech companies to develop novel treatment approaches for cardiometabolic diseases.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.228746,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.164749",
                    "ticker_sentiment_score": "0.15357",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.244928",
                    "ticker_sentiment_score": "0.091398",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "OMGA",
                    "relevance_score": "0.322549",
                    "ticker_sentiment_score": "0.162148",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.467318",
                    "ticker_sentiment_score": "0.323723",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Pharma Stock Roundup: LLY's New Digital Pharmacy, NVO & ABBV's Fresh R&D Deals",
            "url": "https://www.zacks.com/stock/news/2206363/pharma-stock-roundup-llys-new-digital-pharmacy-nvo-abbvs-fresh-rd-deals",
            "time_published": "20240105T152500",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "Eli Lilly (LLY) launches a new direct-to-consumer website to provide easy access to its medicines. Novo Nordisk (NVO) announces two research collaborations to develop novel treatments for cardiometabolic diseases.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/88/898.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.143344,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.295867",
                    "ticker_sentiment_score": "0.076649",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.295867",
                    "ticker_sentiment_score": "0.240803",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.199859",
                    "ticker_sentiment_score": "0.154026",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.295867",
                    "ticker_sentiment_score": "0.125188",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.050465",
                    "ticker_sentiment_score": "-0.119302",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "This Top 10% Stock Is Playing A Game Of Whiplash",
            "url": "https://www.investors.com/news/technology/kymr-stock-whiplash-shares-surge-then-topple-after-275-million-offering/",
            "time_published": "20240105T151600",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "KYMR Stock Whiplash: Shares Surge, Then Topple After $275 Million Offering Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/Stock-kymera-01-shutt.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.998962"
                }
            ],
            "overall_sentiment_score": -0.024361,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "KYMR",
                    "relevance_score": "0.524949",
                    "ticker_sentiment_score": "0.247639",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.16171",
                    "ticker_sentiment_score": "-0.143216",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DSSMY",
                    "relevance_score": "0.16171",
                    "ticker_sentiment_score": "0.092165",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.081276",
                    "ticker_sentiment_score": "-0.145926",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.081276",
                    "ticker_sentiment_score": "0.345837",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.16171",
                    "ticker_sentiment_score": "-0.143216",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "'s 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet - Adicet Bio  ( NASDAQ:ACET ) ",
            "url": "https://www.benzinga.com/exclusives/24/01/36510864/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet",
            "time_published": "20240105T150843",
            "authors": [
                "Chris Katje"
            ],
            "summary": "Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention. Investors are constantly on the hunt for undervalued, under-followed and emerging stocks.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/BZ-Stock-Whisper-Index-Logo-6.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.227204,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MARA",
                    "relevance_score": "0.184363",
                    "ticker_sentiment_score": "0.262761",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SIDU",
                    "relevance_score": "0.184363",
                    "ticker_sentiment_score": "0.079324",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MOBX",
                    "relevance_score": "0.244109",
                    "ticker_sentiment_score": "0.25355",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "OMGA",
                    "relevance_score": "0.123526",
                    "ticker_sentiment_score": "0.158579",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.184363",
                    "ticker_sentiment_score": "0.200775",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ACET",
                    "relevance_score": "0.184363",
                    "ticker_sentiment_score": "0.081358",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.465901",
                    "ticker_sentiment_score": "0.496873",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Here's Why You Should Retain Alexandria  ( ARE )  Stock for Now",
            "url": "https://www.zacks.com/stock/news/2206335/heres-why-you-should-retain-alexandria-are-stock-for-now",
            "time_published": "20240105T145500",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Alexandria (ARE) is likely to benefit from the solid demand for top-quality life-science assets in key markets. However, a vast development outlay amid high interest rates is concerning.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/8e/695.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.366525,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "STAG",
                    "relevance_score": "0.131403",
                    "ticker_sentiment_score": "0.101388",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ARE",
                    "relevance_score": "0.043979",
                    "ticker_sentiment_score": "0.144563",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.043979",
                    "ticker_sentiment_score": "0.142724",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MCO",
                    "relevance_score": "0.043979",
                    "ticker_sentiment_score": "0.264848",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.043979",
                    "ticker_sentiment_score": "0.264848",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AGTEF",
                    "relevance_score": "0.087824",
                    "ticker_sentiment_score": "0.126134",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PK",
                    "relevance_score": "0.174587",
                    "ticker_sentiment_score": "0.124554",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "REXR",
                    "relevance_score": "0.131403",
                    "ticker_sentiment_score": "0.101388",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRGX",
                    "relevance_score": "0.043979",
                    "ticker_sentiment_score": "0.142724",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ozempic And Wegovy Not Linked To Uptick In Suicidal Thoughts, Study Finds",
            "url": "https://www.forbes.com/sites/roberthart/2024/01/05/ozempic-and-wegovy-not-linked-to-uptick-in-suicidal-thoughts-study-finds/",
            "time_published": "20240105T141511",
            "authors": [
                "Robert Hart"
            ],
            "summary": "Weight loss and diabetes drugs Wegovy and Ozempic are not linked to an increase in suicidal thoughts, according to research published in Nature Medicine Friday, an encouraging finding for consumers as health agencies in Europe and the U.S. probe the potential side effects of the wildly popular ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/654e47843345c024866cae6c/0x0.jpg?format=jpg&crop=5200,2927,x0,y269,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.145338,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NYT",
                    "relevance_score": "0.04872",
                    "ticker_sentiment_score": "-0.125982",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WBD",
                    "relevance_score": "0.04872",
                    "ticker_sentiment_score": "-0.226206",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.04872",
                    "ticker_sentiment_score": "-0.14795",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.04872",
                    "ticker_sentiment_score": "0.013005",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "It's Been An Abysmal Two Years. But Biotech Is Looking Up.",
            "url": "https://www.investors.com/news/technology/biotech-stocks-pharma-heat-up-in-2024-as-buyouts-obesity-ai-drive-excitement/",
            "time_published": "20240105T140000",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "Biotech Stocks, Pharma Heat Up In 2024 As Buyouts, Obesity And AI Drive Excitement Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/A1-010824-biotech-Gash.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.12567,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.035679",
                    "ticker_sentiment_score": "0.069333",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NBIX",
                    "relevance_score": "0.02379",
                    "ticker_sentiment_score": "0.14181",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KRTX",
                    "relevance_score": "0.035679",
                    "ticker_sentiment_score": "0.037838",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IONS",
                    "relevance_score": "0.02379",
                    "ticker_sentiment_score": "0.084592",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RYZB",
                    "relevance_score": "0.02379",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.02379",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ARWR",
                    "relevance_score": "0.02379",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALEC",
                    "relevance_score": "0.09495",
                    "ticker_sentiment_score": "0.150269",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.153696",
                    "ticker_sentiment_score": "0.053027",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VERV",
                    "relevance_score": "0.02379",
                    "ticker_sentiment_score": "0.006781",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "OMGA",
                    "relevance_score": "0.02379",
                    "ticker_sentiment_score": "0.079056",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NTLA",
                    "relevance_score": "0.02379",
                    "ticker_sentiment_score": "-0.008781",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BHVN",
                    "relevance_score": "0.02379",
                    "ticker_sentiment_score": "-0.001871",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.02379",
                    "ticker_sentiment_score": "0.067127",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.035679",
                    "ticker_sentiment_score": "0.017905",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CPRX",
                    "relevance_score": "0.02379",
                    "ticker_sentiment_score": "0.14181",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BEAM",
                    "relevance_score": "0.02379",
                    "ticker_sentiment_score": "0.057997",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.02379",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GRCL",
                    "relevance_score": "0.02379",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CLNN",
                    "relevance_score": "0.02379",
                    "ticker_sentiment_score": "-0.020246",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GPCR",
                    "relevance_score": "0.035679",
                    "ticker_sentiment_score": "0.08972",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMPH",
                    "relevance_score": "0.02379",
                    "ticker_sentiment_score": "0.14181",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ARGX",
                    "relevance_score": "0.011896",
                    "ticker_sentiment_score": "-0.115274",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.02379",
                    "ticker_sentiment_score": "0.067127",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.02379",
                    "ticker_sentiment_score": "-0.042606",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ESALF",
                    "relevance_score": "0.035679",
                    "ticker_sentiment_score": "0.064761",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.059429",
                    "ticker_sentiment_score": "0.106048",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "GlycoEra AG Announces New Investor, Appoints Industry Veteran Greg Fralish as Chief Business Officer - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/glycoera-ag-announces-new-investor-appoints-industry-veteran-greg-fralish-as-chief-business-officer-302027158.html",
            "time_published": "20240105T130000",
            "authors": [],
            "summary": "GlycoEra AG Announces New Investor, Appoints Industry Veteran Greg Fralish as Chief Business Officer PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.247567,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "TSVT",
                    "relevance_score": "0.077593",
                    "ticker_sentiment_score": "0.068456",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JWCTF",
                    "relevance_score": "0.077593",
                    "ticker_sentiment_score": "0.068456",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BLUE",
                    "relevance_score": "0.077593",
                    "ticker_sentiment_score": "0.068456",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.077593",
                    "ticker_sentiment_score": "0.068456",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.077593",
                    "ticker_sentiment_score": "0.018317",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3  ( Foralumab )  with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation",
            "url": "https://www.globenewswire.com/news-release/2024/01/05/2804560/0/en/Tiziana-Life-Sciences-Files-New-Patent-Application-for-Combination-Therapy-of-anti-CD3-Foralumab-with-GLP-1-Receptor-Agonist-for-Additional-Reduction-of-Obesity-Associated-Inflamma.html",
            "time_published": "20240105T120000",
            "authors": [
                "Tiziana Life Sciences Plc"
            ],
            "summary": "Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist ...",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/991c340c-a083-4bcb-ad41-e7eea83f6f97",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.124132,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "TLSA",
                    "relevance_score": "0.163354",
                    "ticker_sentiment_score": "0.143621",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.04111",
                    "ticker_sentiment_score": "0.006997",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        }
    ]
}